WO1988004300A1 - Rna ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods - Google Patents
Rna ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods Download PDFInfo
- Publication number
- WO1988004300A1 WO1988004300A1 PCT/US1987/003161 US8703161W WO8804300A1 WO 1988004300 A1 WO1988004300 A1 WO 1988004300A1 US 8703161 W US8703161 W US 8703161W WO 8804300 A1 WO8804300 A1 WO 8804300A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- rna
- enzyme
- ivs
- endoribonuclease
- sequence
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
- C12N2310/111—Antisense spanning the whole gene, or a large part of it
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
- C12N2310/124—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes based on group I or II introns
- C12N2310/1241—Tetrahymena
Definitions
- the invention was made in part with government funds under Grant GM 28039 from the National Institutes of Health.
- compositions of RNA functioning as an RNA enzyme i.e. a ribozyme in several capacities: dephosphorylase (acid phosphatase and transphosphorylase), ribonucleotidyl transferase (polymerase activity) and sequence-specific endoribonuclease activities.
- dephosphorylase acid phosphatase and transphosphorylase
- ribonucleotidyl transferase polymerase activity
- sequence-specific endoribonuclease activities sequence-specific endoribonuclease activities.
- RNA can serve as an enzyme acting on other RNA molecules in vitro (ribozyme) as a: 1) dephosphorylating enzyme catalyzing the removal of 3' terminal phosphate of RNA in a sequence-specific manner, 2) RNA polymerase (nucleotidyl transferase) catalyzing the conversion of oligoribonucleotides to polyribonucleotides, 3) sequence specific endoribonuclease. (This latter activity is also referred to as RNA restriction endonuclease or endoribonuclease activity.)
- Figure 1 compares RNA self-splicing (A) to RNA endoribonuclease activity (B).
- Figure 2 shows products of cleavage of a variety of RNA substrates by the RNA endoribonuclease.
- Figure 3 compares different substrate activity of three variant forms of L-19 IVS ribozyme in 2.5M urea.
- Figure 4 shows the time course of oligonucleotide cleavage.
- Figure 5 shows the cleavage and reforming of oligoribonucleotide substrates by L-19 IVS RNA.
- Figure 6 shows the kinetics of conversion of pC 5 to larger and smaller oligonucleotides with L-19 IVS RNA.
- Figure 7 shows the enzyme-substrate intermediate of L-19 IVS RNA.
- Figure 8 is a model for enzymatic mechanism of L-19 IVS RNA acting as a ribonucleotidyl transferase.
- Figure 9 shows the competitive inhibition of pC 5 reaction by dC 5 .
- Figure 10 shows the relation of reactions catalyzed by the L-19 IVS RNA to self-splicing and related IVS RNA-mediated reactions.
- Figure 11 shows the dephosphorylation of oligo (cytidylic acid) 3-phosphate.
- Figure 12 shows the effect of pH on phosphotransfer and nucleotidyl transfer reactions.
- Figure 13 shows that the phosphorylation of L-19 IVS RNA ribozyme is reversible.
- Figure 14 shows the L-19 IVS RNA acts catalytically as a phosphotransferase.
- Figure 15 shows the single active site model for the activity of L-19 IVS RNA on phosphate diester and phosphate monoester substrates.
- Figure 16 shows the plasmid construction which produces the L-21 IVS RNA.
- Fig. 1 A model for the L-19 IVS RNA acting like an RNA restriction endonuclease by a mechanism that is an intermolecular version of the first step of pre-rRNA self-splicing. Thin letters and lines represent IVS sequences, boldface letters and thick lines represent exon sequences (above) or substrate RNA sequences (below), and the G in italics is a free guanosine nucleotide or nucleoside.
- Fig. 2 The L-19 IVS-beta RNA cleaves large RNA substrates with transfer of guanosine.
- M Mixture of 4 substrate RNAs as molecular weight markers.
- M Mixture of 4 substrate RNAs as molecular weight markers.
- IVS-beta RNA also becomes GTP-labeled during the incubation.
- c Nucleotide sequence of the cleavage product pAK105 (1) determined by the enzymatic method
- L-19 IVS RNA was synthesized by methods similar to those described previously (Zaug, A.J., and Cech, T.R., (1986) Science 231:470-475), except a different RNA polymerase-template system was used.
- Plasmid pT7-TTlA3 which contains a T7 RNA polymerase promoter, a 42 bp 5' exon, the entire 413 bp IVS, and an 82 bp 3' exon
- the transcripts were incubated further under self-splicing, cyclization, and site-specific hydrolysis conditions to produce L-19 IVS RNA (Zaug, A.J., et al. (1984) Science 224:574-578; Zaug, A.J. and Cech, T.R., (1986) Science 231:470-475).
- the 3'-terminal guanosine was then removed by periodate oxidation and beta-elimination (Winter, G., et al. (1978) Nucleic Acids Res. 5 , 3129-3139) to yield L-19 IVS-beta RNA.
- Substrate RNAs were produced by T7 RNA polymerase transcription of BamHI-cleaved pAK105 (Mount, S.M., et al. (1983) Cell 33,509-518), XmnI- or Seal-cleaved pT7-1 (purchased from U.S. Biochemical Corp.), and SnaBI-cleaved pDW27, which encodes Ml RNA (obtained from D. Wahl and N. Pace).
- BamHI-cleaved pAK105 Mount, S.M., et al. (1983) Cell 33,509-518
- XmnI- or Seal-cleaved pT7-1 purchased from U.S. Biochemical Corp.
- SnaBI-cleaved pDW27 which encodes Ml RNA (obtained from D. Wahl and N. Pace).
- Substrate RNAs were incubated with L-19 IVS-beta RNA in 5 mM MgCl 2 , 10 mM NaCl, 50 mM Tris-HCl, pH 7.5 at 50°C; in addition, GTP was present at the concentration indicated. Reactions were stopped by the addition of EDTA to a final concentration of 25 mM. Products were analyzed by electrophoresis in 4% polyacrylamide, 8 M urea gels and subjected to fluorography (a) or autoradiography (b).
- Fig. 3 Three different ribozymes can distinguish between sequences that differ by only one single-base change within the recognition element.
- a Synthesis of defined oligoribonucleotide substrates by the method of Lowary et al. (Lowary, P., et al. NATO ASI Series A, vol. 110, 69-76, 1986). DNA was transcribed with T7 RNA polymerase in the presence of [alpha- 32 P]ATP to produce oligoribonucleotides labeled with 32P in the positions indicated (*).
- b Proposed interactions between, the three oligoribonucleotide substrates (top strands, boldface letters) and the active sites of the matched ribozymes (bottom strands).
- Substrates were prepared by transcription of deoxyoligonucleotides synthesized on an Applied Biosystems DNA Synthesizer. The same promoter top strand was used in each transcription. The bottom strand, which contains promoter and template sequences, was varied to obtain the different RNA substrates.
- the DNA was transcribed with purified phage T7 RNA polymerase (Davanloo, P., et al. (1984) Proc. Nat'l. Acad. Sci. U.S.A. 81:2035-2039) as described (Lowary, P., et al. NATO ASI Series, vol. 110, as above).
- Variant ribozymes are described by Been and Cech (Been, M.D., et al. (1986) Cell, 47: 207-216).
- the 24C ribozyme was similarly prepared from transcripts of pBG/-3G: 24C.
- the variant ribozymes were not subjected to beta-elimination to remove their 3'-terminal G.
- Fig. 4 Kinetic analysis of the RNA endoribonuclease reaction.
- a The oligoribonucleotide substrate (2.5 uM) was incubated with wild-type L-19 IVS-beta RNA (0.2 uM) as in Fig. 3, except that urea was omitted.
- b Kinetics of cleavage of GGCCCUCUA 5 as a function of GTP concentration.
- RNA substrate concentration was kept constant at 2.5 uM.
- c Kinetics of cleavage as a function of RNA substrate concentration, with GTP concentration kept constant at 0.5 mM.
- Fig. 5 The L-19 IVS RNA catalyzes the cleavage and rejoining of oligoribonucleotide substrates; (A) 10 uM pC 5 and (B) 10 uM d-pC 5 , both with 1.6 uM L-19 IVS RNA; (C) 45 uM pC 5 in the absence of L-19 IVS RNA; (D) 45 uM pLVb with 1.6 uM L-19 IVS
- RNA RNA
- E 10 uM pC 5
- F 50 uM pC 5
- G 100 uM pC 5
- Oligonucleotides were 5'-end labeled by treatment with [gamma- 32 P]ATP and polynucleotide kinase; they were diluted with unlabeled oligonucleotide of the same- sequence to keep the amount of radioactivity per reaction constant.
- RNA was synthesized by transcription and splicing in vitro.
- Supercoiled pSPTTlAS DNA Price, J.V., et al.
- nucleoside triphosphates 0.5 mM each
- 6 mM MgCl 2 4 mM spermidine
- 10 mM dithiothreitol 4 mM tris-HCl
- pH 7.5 pH 7.5
- Nucleic acids were precipitated with three volumes of ethanol and redissolved in 50 mM CHES, pH 9.0; MgCl 2 was added to a final concentration of 20 mM, and the solution was incubated at 42°C for 1 hour to promote site-specific hydrolysis of the circular IVS RNA to give L-19 IVS RNA (Zaug, A.J., et al., Science 224, 574 (1984). The reaction was stopped by the addition of EDTA to 25 mM. The L-19 IVS RNA was purified by preparative gel electrophoresis and Sephadex G-50 chromatography.
- Labeled oligonucleotides were incubated with unlabeled L-19 IVS RNA at 42°C in 20 mM MgCl 2 , 50 mM tris, pH 7.5, for 0, 1, 2, 5, 10, 30, and 60 minutes. Reactions were stopped by the addition of EDTA to a final concentration of 25 mM. Products were analyzed by electrophoresis in a 20 percent polyacrylamide, 7M urea gel, autoradiograms of which are shown.
- IVS RNA IVS RNA. Products were separated by polyacrylamide gel electrophoresis. With the autoradiogram as a guide, the gel was cut into strips and the radioactivity in each RNA species was- determined by liquid scintillation counting. The amount of reaction at each time was taken as the radioactivity in pC 3 + pC 4 + pC + pC 7 +
- V o The initial velocity of product formation, V o , was determined from a semilogarithmic plot of the fraction of reaction as a function of time. V o was then plotted as a function of substrate concentration; the line is a least-squares fit to the Michaelis-Menten equation.
- Fig. 7 Formation and resolution of the covalent enzyme-substrate intermediate.
- A To form the covalent L-19 IVS RNA-substrate, intermediate, 8.5 nM 5 was treated with 0.16 uM L-19 IVS RNA under standard reaction conditions for 0 to 60 minutes.
- B (0.01 uM) was reacted with 0.16 uM L-19 IVS RNA. Cleavage occurred normally, but there was very little rejoining.
- C Labeled covalent intermediate was prepared as in (A) (60 minutes) and purified by electrophoresis in a 4 percent polyacrylamide, 8M urea gel. It was then incubated with
- Isolated covalent intermediate as in (C) was incubated under site-specific hydrolysis conditions (20 mM MgCl 2 ,
- Fig. 8 Model for the enzymatic mechanism of the L-19 IVS RNA.
- the RNA catalyzes cleavage and rejoining of oligo (C) by the pathway 1 - 2 - 3 - 4 - 1.
- the L-19 IVS RNA enzyme (1) is shown with the oligopyrimidine binding site (RRRRRR, six purines) near its 5' end and G 414 with a free 3'-hydroxyl group at its 3' end.
- RRRRRRRR oligopyrimidine binding site
- the complex folded core structure of the molecule (Davies, R.W., et al., (1982) Nature (London)
- the covalent intermediate is usually loaded with a single nucleotide, as shown; with substrates of longer chain length, an oligonucleotide can be attached to the 3' end of G 414 . If C 5 binds to the intermediate (3) in the manner shown in (4), transesterification can occur to give the new product
- the covalent intermediate (3) undergoes hydrolysis, releasing the nucleotide or oligonucleotide attached to its 3' end (in this case pC) and regenerating the enzyme (1).
- Fig. 9 Competitive inhibition of the pC 5 reaction by d-C 5 .
- Fig. 10 Relation of reactions catalyzed by the L-19 IVS RNA to self-splicing and the related IVS RNA-mediated reactions.
- Formation of the covalent enzyme-substrate intermediate (A) is analogous to IVS RNA autocyclization (B).
- Resolution of the enzyme-substrate intermediate (C) is analogous to. exon ligation (D) or the reversal of cyclization (Sullivan, F.X. and Cech, T.R. (1985) Cell 42:639).
- Hydrolysis of the enzyme-substrate intermediate (E) is analogous to site-specific hydrolysis of the circular IVS RNA (F) or the pre-rRNA ( Inoue , T . , et al . ( 1986 ) J. Mol. Biol. 189:143-165).
- Fig. 11 The L-19 IVS RNA catalyzes the dephosphorylation of oligo (cytidylic acid) 3'-phosphate.
- L-19 IVS RNA (0.16 uM) was incubated with p * C 5 (10 uM), p A, (10 uM), C 5 p * Cp (about 2 nM), and A 6 p * Cp (about 3 nM) in 20 mM MgCl 2 and 50 mM Tris-HCl, pH 7.5, at 42°C for the times indicated. Reaction products were separated by electrophoresis in a 20% polyacrylamide-7 M urea sequencing gel, an autoradiogram of which is shown.
- Fig. 12 Effect of pH on the phospho transfer and nucleotidyl transfer reactions.
- Lane 1 untreated C 5 p * Cp; lanes 2-11, C 5 p*Cp (15 nM) incubated with excess L-19 IVS RNA (500 nM) in 20 mM MgCl 2 and 50 mM buffer (NaOAc for pH 4.0 and 5.0,
- the observed first-order rate constant (k obsd ) was calculated as (In 2)/t 1/2 .
- NaOAc buffer was used for pH-4.0 and 5.0, MES for pH 5.5 and 6.0, and Tris-HCl for pH 7 (estimate based on a single point that showed about 50% reaction).
- Fig. 13 Phosphorylation of the enzyme is reversible.
- L-19 IVS RNA (0.2 uM) was phosphorylated by incubation with 2.5 uM unlabeled C 5 p for min at 42°C at pH 5.0.
- Fig. 15 Single active site model for the activity of the L-19 IVS RNA on phosphate diester and phosphate monoester substrates.
- A Reversible nucleotidylation of the L-19 IVS RNA, proposed to be the key step in the poly(C) polymerase reaction (Zaug & Cech, (1986) Science (Wash. D.C. 231:470-475.
- B Reversible phosphbrylation of the L-19 IVS RNA, which allows the enzyme to act as a phosphotransferase.
- the oligo (C) substrate base pairs to the oligo (Pyrimidine) binding site (six R's) to form a noncovalent complex.
- the binding site is nucleotides 22-27 of the IVS RNA and has the sequence GGAGGG (M.D. Been and T.R. Cech, (1986) Cell 47:206-216). Nucleophilic attack by the 3'-hydroxyl of the active site guanosine, G414, leads to formation of E-pC (A) or E-p (B) and the release of C 5 .
- the complex folded core structure of the IVS is depicted as a simple curved line.
- Plasmid pBGST7 contains a fragment with the IVS inserted into the multicloning site of a small pUC18 derivative which in turn contains a phage T7 promoter.
- the double line represents the plasmid DNA with the IVS. The relative positions of the promoters are indicated. The positions of the EcoRI and Hind III site are indicated by the arrowheads.
- the upper line represents the in vitro transcript made from purified plasmid DNA with phage T7 RNA polymerase. The numbers above it refer to the length, in nucleotides, of the exons and IVS.
- the lower line represents the in vivo transcript of the 5' end of lacZ'.
- the IVS (heavy line) contains stop codons in all three reading frames, so a functional alpha fragment can only be produced if the IVS is excised and the exons are joined by splicing in E. coli.
- the Tetrahymena rRNA intervening sequence is a catalytic RNA molecule or ribozyme. It mediates RNA self-splicing, accomplishing its own excision from the large ribosomal RNA precursor, and subsequently converts itself to a circular form
- the splice sites and cyclization sites can be viewed as intramolecular substrates for an activity that resides within the IVSJRNA (Zaug, A.J., et al. (1984) Science 224:574-578). This is not a true enzymatic reaction however since the RNA is not regenerated in its original form at the end of the self-splicing reaction.
- the IVS RNA when in its linear form is referred to as L IVS RNA.
- the L-19 IVS RNA acts as an enzyme with nucleotidyltransferase [poly(C) polymerase] and phosphodiesterase (ribonuclease) activities (Zaug, A.J. and Cech, T.R. (1986) Science 231:470-475).
- poly(C) polymerase nucleotidyltransferase
- ribonuclease ribonuclease activities
- 3'-phosphorylated oligo (C) substrates the same ribozyme acts as a phosphotransferase and an acid phosphatase (Zaug, A.J. and Cech, T.R. (1986) Biochemistry 25:4478-4482).
- a key mechanistic feature of all four of these reactions is the formation of valent enzyme-substrate intermediate in which a nucleotide or phosphate is esterified through the 3'-O of G 414 , the 3' terminal guanosine of the IVS RNA.
- the excised IVS RNA (Abbreviations: IVS, intervening sequence or intron: L-19 IVS- RNA (read "L minus 19"), a 395-nt RNA missing the first 19 nt of the L IVS RNA (the direct product of pre-ribosomal RNA splicing); p 32 p within an oligonucleotide, that is, is CpCpCpC 32 pC and is 32 pCpCpCpCpC; d-C 5 , deoxyC 5 ) undergoes a series of RNA-mediated cyclization and site-specific hydrolysis reactions.
- the final product, the L-19 IVS RNA is a linear molecule that does not have the first 19 nucleotides of the original excised IVS RNA (Zaug, A.J., et al., Science 224:574
- L IVS RNA is linear IVS RNA.
- oligonucleotide substrates we have now tested this by adding oligonucleotide substrates to the L-19 IVS RNA.
- each IVS RNA molecule can catalyze the cleavage and rejoining of many oligonucleotides.
- the L-19 IVS RNA is a true enzyme.
- the enzyme can act on RNA molecules of large size and complex sequence, we have found that studies with simple oligoribonucleotides like pC 5 (pentacytidylic acid) have been most valuable in revealing the minimum substrate requirements and reaction mechanism of this enzyme.
- rRNA ribosomal RNA
- the reaction mechanism resembles that, of rRNA precursor self-splicing. With pentacytidylic acid as the substrate, successive cleavage and rejoining reactions lead. to the synthesis of polycytidylic acid.
- RNA molecule can act as an RNA polymerase, differing from the protein enzyme in that it uses an internal rather than an external template.
- various heteropolymers would be constructed by varient RNA enzyme forms. This predicts the formation for example of messenger RNA molecules for particular peptides or proteins. This messenger could be synthesized with or without introns.
- the same RNA enzyme has activity as a sequence-specific ribonuclease.
- the L-19 IVS RNA makes poly(C) with chain lengths of 30 nucleotides and longer, acting as an RNA polymerase or nucleotidyl transferase.
- longer oligonucleotides can be formed from short oligonucleotide starting material .
- the number of P-O bonds is unchanged in the process.
- poly (C) on a poly (dG) template by RNA polymerase one CTP is cleaved for each residue polymerized.
- the RNA polymerase reaction is also conservative with respect to the number of P-O bonds in the system.
- the L-19 IVS RNA can therefore be considered to be a poly(C) polymerase that uses C 4 pC instead of pppC as a substrate. It incorporates pC units at the 3' end of the growing chain and releases C 4 ; the C 4 is analogous to the pyrophosphate released by RNA polymerase. Synthesis is directed by a template, but the template is internal to the RNA enzyme. It may be possible to physically separate the template portion fr ⁇ mrthe catalytic portion of the RNA enzyme with retention of activity. If so, the RNA enzyme could conceivably act as a primordial RNA replicase, catalyzing both its own replication and that of other RNA molecules (T.R. Cech, (1986) Proc. Nat'l. Acad. Sci. USA 83:4360-4363.
- the K m is typical of that of protein enzymes.
- the k cat and k cat /K m are lower than those of many protein enzymes.
- k cat is well within the range of values for proteins that recognize specific nucleic acid sequences and catalyze chain cleavage or initiation of polymerization.
- Another way to gauge the catalytic effectiveness of the L-19 IVS RNA is to compare the rate of the catalyzed reaction to the basal chemical rate.
- a transesterification reaction between two free oligonucleotides has never been observed, and hence the uncatalyzed rate is unknown.
- the rate of hydrolysis of simple phosphate diesters has been studied (Kumamoto, J., et al. (1956) J, Am. Chem. Soc. 78:4858; P.C. Haake et al. ibid. (1961) 83:1102; Kirby, A.J., et al. (1970) J. Chem. Soc. Ser. B., p.
- the second-order rate constant for alkaline hydrolysis of the labile phosphodiester bond in the circular IVS RNA is 12 orders of magnitude higher than that of dimethyl phosphate (Kumamoto, J., et al.
- RNA is expected to be more reactive than dimethyl phosphate by a factor of
- the estimate for RNA pertains to direct attack hy OH- on the phosphate, resulting in 3'-hydroxyl and 5'-phosphate termini.
- IVS RNA in its ribonuclease mode enhances the rate of hydrolysis of its substrate about 10 times.
- RNA moiety of ribonuclease P the enzyme responsible for cleaving transfer RNA (tRNA) precursors to generate the mature 5' end of the tRNA
- tRNA transfer RNA
- the same enzyme has activity toward phosphate monoesters.
- the 3'-phosphate of C 5 p or C 6 p is transferred to the 3'-terminal guanosine of the enzyme.
- the pH dependence of the reaction indicates that the enzyme has activity toward the dianion and much greater activity toward the monoanion form of the 3'-phosphate of the substrate.
- Phosphorylation of the enzyme is reversible by C 5 -OH and other oligo(pyrimidines) such as UCU-OH.
- the RNA enzyme acts as a phosphotransferase, transferring the 3'-terminal phosphate, of C 5 p to UCU-OH with multiple turnover.
- RNA enzyme dephosphorylates oligonucleotide substrates with high sequence specificity, which distinguishes it from known protein enzymes.
- the L-19 IVS RNA has transphosphorylation activity toward 3'-phosphorylated oligo (C) substrates.
- the properties of the transphosphorylation reaction indicate that it is taking place in the same active site as the poly (C) polymerase and ribonuclease reactions ( Figure 15).
- the properties include the specificity of the reactions for oligo (C) substrates, the production of oligo (C) products with 3'-hydroxyl termini, and the formation of similar covalent enzyme-substrate complexes.
- the presumptive intermediate is a phosphoenzyme, E-p, in the case of the phosphotransferase reaction and a nucleotidyl enzyme, E-pC or E-(pC) n , in the case of the poly(C) polymerase and ribonuclease reactions (Zaug & Cech, (1986) Science (Wash., D.C. 231:470-475).
- the presumptive covalent intermediate involves a phosphate ester linkage through the 3'-0 of G414 of the L-19 IVS RNA (Zaug and Cech, unpublished results).
- the transphosphorylation reaction is readily reversible.
- the phosphate can be transferred from the enzyme to an acceptor with a 3'-hydroxyl group, such as C 5 or UCU.
- C 5 p and UCU as cosubstrates, the L-19 IVS RNA can catalyze the reaction C 5 p + UCU-OH - C 5 -OH + UCUp.
- the proposed pathway is
- the L-19 IVS RNA has transphosphorylation activity resembling that of Escherichia coli alkaline phosphatase (Reid & Wilson, (1971) Enzymes (3rd Ed.)4:373-415); Coleman & Gettins, (1983) Adv. Enzymol. Relat. Area Mol. Biol., 55:381), acid phosphatase, and a variety of other phosphotransferases that form covalent enzyme-substrate intermediates (Knowles, (1980) Ann. Rev. Biochem. 49:877).
- the L-19 IVS RNA phosphoenzyme can transfer its phosphate to water at pH 4 and 5, indicating it has acid phosphatase activity.
- the phosphodiester bond following G414 is labile in the circular IVS RNA (Zaug et al., 1984 Science (Wash., D.C. 224:574), in the pre-rRNA (Inoue et al., 1986, J. Mol. Biol. 189:143), and in E-pC (Zaug, A.J., and Cech, T., 1986, Science (Wash., D.C.) 231:470-475), whereas the phosphomonoester bond following G414 is stable in E-p. Specific hydrolysis of the phosphodiester bonds involves attack of hydroxide ion (Zaug, A.J. et al., (1985) Biochemistry 24:6211).
- Biochemistry 15:4006 report that phosphoglucomutase transfers a phosphate to the C-6 hydroxyl of glucose
- the L-19 IVS RNA is unique among known enzymes in its ability to remove 3'-phosphates from RNA with high substrate specificity. E. coli and mammalian alkaline phosphatases are nonspecific. These enzymes remove 5'-, 3'-, and 2'-phosphates from RNA with little regard for the base sequence of the molecule (Garen & Levinthal, (1960) Biochem. Biophys. Acta. 38 : 470; Harkness, (1968) Arch. Biochem. Biophys. 126: 513).
- Polynucleotide kinase has 3'-phosphatase, 2'-phosphatase, and cyclic 2',3'-phosphatase activity (Cameron & Uhlenbeck, (1977) Biochemistry 16:5120; Weber, (1985) Ph.D. Thesis, University of Illinois). Substrates as diverse as U 5 p, A 6 Cp, and pCp are readily dephosphorylated, and where careful kinetic measurements have been made, the rates of dephosphorylation of different RNA substrates seldom vary by more than a factor of 2 (Weber, (1985) Supra).
- PI nuclease and mung bean nuclease have limited preference for certain nucleoside 3'-monophosphates (Shishido & Ando, (1982) Supra).
- the L-19 IVS RNA transfers the 3'-phosphate of RNA to a donor molecule with high substrate specificity; C 5 p and C 6 p are substrates, whereas pCp and A 6 pCp are not.
- This length and sequence specificity is explained by the requirement that the substance must bind to the enzyme by Watson-Crick base pairing to the guanosine-rich active site ( Figure 15). If this model is correct, it should be possible to alter the sequence specificity of the phosphotransferase by site-specific mutagenesis of the active site.
- RNA enzyme described here has cleavage-ligation activity as well as the dephosphorylation activity. Unless these activities can be separated, the usefulness of the enzyme as a reagent for dephosphorylation of RNA is limited.
- RNA which are enzymatically active on other RNA molecules. These RNA ribozymes act on exogenous RNA.
- the enzyme or ribozyme is composed of RNA and the substrate is RNA (or mixed RNA-DNA polymers).
- the ribozyme has high specificity for cleavage after the nucleotide sequence CUCU; under stringent conditions it can discriminate against sites that have a 3-out-of-4 match to this recognition sequence. For example, in a solution containing 2.5 M urea the ribozyme cleaves after CUCU while ignoring the related sequences CUGU and CGCU (Fig. 3c).
- the sequence specificity approaches that of the DNA restriction endonucleases (Nathans, D. and Smith, H.O. (1975) Annu. Rev. Biochem. 44:273-293).
- the L-19 has more base-sequence specificity for single-stranded RNA than any known protein ribonuclease, and may approach the specificity of some of the DNA restriction endonucleases.
- An attractive feature of this new RNA enribonuclease is that its substrate specificity can be completely and predictably changed by altering the sequence of the internal binding site.
- the endoribonuclease reaction is analogous to the first step of pre-rRNA self-splicing (Fig. 1). Both the enzymatic and the self-splicing reactions make use of the same two binding sites, an oligopyrimidine-binding site and a guanosine-binding site, to achieve specificity and to contribute to catalysis.
- the oligopyrimidine-binding site is also known as the 5' guide sequence (Waring, R.B., et al.
- the endoribonuclease activity of the L-19 IVS RNA does not require its 3'-terminal guanosine (G 414 ).
- L-19 IVS RNA is not restricted to reaction mechanisms involving formation of a covalent enzyme-substrate intermediate. It an also catalyze bisubstrate reactions by a single-displacement mechanism.
- Ribonuclease P an RNA enzyme that catalyzes cleavage by hydrolysis rather than by transesterification, also appears to act without formation of a covalent intermediate (Marsh, T.L., et al. (1985) Science
- Sequence-specific endoribonucleases might have many of the same applications for the study of RNA that DNA restriction endonucleases have for the study of DNA (Nathans, D. and Smith, H.O., (1975) Ann. Rev. Biochem. 44:273).
- the pattern of restriction fragments could be used to establish sequence relationships between two related RNAs, and large RNAs could be specifically cleaved to fragments of a size more useful for study.
- the 4-nucleotide specificity of the ribozyme is ideal for cleavage of RNAs of unknown sequence; an RNA of random sequence would have an average of 1 cleavage site. every 256 bases.
- the automatic end-labelling of one fragment during ribozyme cleavage is a practical advantage.
- RNA substrates The efficiency of cleavage of large RNA substrates needs to be increased so that complete digests father than partial digests can be obtained.
- denaturants such as urea and formamide must be further explored; they appear to increase the sequence specificity of cleavage, and at the same time they should meIt structure in the substrate to maximize the availability of target sequences.
- mutagenesis of the active site of the ribozyme by those skilled in the art can be accomplished to ascertain all possible permutations of the 256 possible tetranucleotide cleavage enzymes.
- RNA sequence recognition Protein ribonucleases can cleave RNA substrates with high specificity by recognizing a combination of RNA structure and sequence, with the emphasis on structure (e.g., RNase III (Robertson, H.D. (1982) Cell 30:669) and RNase M5 (Stahl, D.A., et al. (1980) Proc. Natl. Acad. Sci. USA 77:5644).
- Known proteins that cleave single-stranded RNA substrates have specificity only at the mononucleotide or dinucleotide level (e.g., RNase T 1 cleaves after guanosines [Egami, F., et al.
- the L-19 IVS RNA has considerably more base-sequence specificity for cleaving single-stranded RNA than any known protein ribonuclease.
- Cech, T.R., et al. have recently found a yet smaller piece of the L-19 IVS RNA which contains full enzymatic activity and comprises nucleotides 19-331 of the RNA. It is also found that the 21-331 piece is fully active. Plasmids have been constructed to produce the L-19 and L-21 IVS RNA strands directly. Here the promoter is moved to the 19 position or 21 position and the DNA coding for the restriction site is at the 331 position instead of the 414 site.
- RNA sequence elements can be considered to provide the minimum active site for ribozyme activity, based on (Cech, et al., PNAS (1983) and Waring & Davies Supra).
- Elements A and B interact with each other, as do 9L and 2. In many positions of the sequence, more than 1 base is allowed; the observed substitutions are shown by printing a letter directly below the base for which it can substitute. For example, at position 1 in sequence element A, the nucleotides A and U are observed, A being more common.
- a (also called P) B also called Q) optional 1 2345678910 5'-A UGCUGGAAA 5'-AAUCA(C)GCAGG
- N any base
- RNA "ribozyme" begins at the site indicated by the arrow and extends to the end (G 414 ) .
- the T's are U's.
- the first ribonucleotide for the L-19 IVS RNA at the 5'OH end is the equivalent of the nucleot ⁇ e 20 of the intact L IVS RNA.
- positions 23, 24, 25 etc. these are positions 23, 24, 25 of the L IVS RNA (as if the first 19 positions were present).
- L-19 IVS RNA Since dC 5 binds to the L-19 IVS RNA (see above), it is likely that the endoribonucleases will work on mixed polymers of RNA and DNA. For example, L-19 IVS RNA will bind the DNA portion while the RNA enzyme works on the RNA piece of the mixed polymer. Alteration of the binding site to bind the other nucleotides will result in an array of mixed polymer activity in a series of such endoribonucleases.
- IVS intervening sequence
- L-19 IVS RNA read “L minus 19”
- CHES 2-(cyclohexylamino)ethanesulfonic acid
- EDTA ethylenediaminetetraacetic acid
- MES MES
- RNA was transcribed from pSPTTlA3 with bacteriophage SP6 RNA polymerase in vitro.
- RNA can be transcribed from pT7-TTlA3 or from any of the plasmids in the pBG series with bacteriophage T7 RNA polymerasein vitro). Transcripts were further incubated to promote self-splicing and cyclization of the IVS RNA.
- RNA was subsequently incubated in MgCl 2 at pH 9.0 (site-specific hydrolysis conditions) to convert circular IVS RNA to L-19 IVS RNA.
- the L-19 IVS RNA was purified by polyacrylamide gel electrophoresis and Sephadex G-50 chromatography. Enzyme concentration was determined by spectrophotometry assuming a molar extinction coefficient at 260nm of 3.26 x 10 6 M -1 cm -1 .
- Active plasmids in use are as follows: PSPTT1A3, pT7-TTlA3, pBGST7, pBG/-2G:23C, pBG/23C, pBG/-3G:24C, pBG/24C, pBG/-4G:25C, pBG/25C, and pBG/23A 4 and pT7L-21.
- the PBG plasmid series is described in Been, M. and Cech, T.R. (1986) Cell
- the pBG/3G:24C and the pBG/24C plasmids produce the L-19 IVS RNA 24C variant which cleaves RNA after the CGCU 4 base sequence.
- These plasmids are on deposit and available at the Department of Chemistry and Biochemistry, University of Colorado,
- the plasmid pT7L-21 makes the L-21 IVS RNA wherein the first 21 bases are deleted. This plasmid
- RNA ligase New England Nuclear
- p * Cp RNA ligase (New England Nuclear)
- ATP ATP
- Products were purified by 20% polyacrylamide-7 M urea gel electrophoresis and Sephadex. G-25 chromatography.
- C 5 -p * was prepared from C 5 p * Cp by treatment with calf intestinal phosphatase and beta-elimination (Winter &
- C 5 p was prepared in a similar manner with unlabeled pCp as donor in the ligase reaction. Concentration was determined by spectrophotometry using a molar extinction coefficient at 270nm of 30 x 10 3 M -1 cm -1 .
- the E-p * was purified from unreacted C 5 p * by column chromatography on Sephadex G-100-120, which was equilibrated in 0 01 M Tris-HCl pH 7 5 0 25 M NaCl, and 0.001 M EDTA. The fractions that contained E-p * complex were pooled and precipitated with 3 volumes of ethanol. The dried precipitate was then dissolved in
- oligoribonucleotide substrate for example 10-100 uM pC 5
- ribozyme for example 0.1-2.0 uM L-19 IVS RNA
- RNA substrate for example 2.5 uM C 5 p
- ribozyme for example 0.1 uM L-19 IVS RNA
- acceptor oligonucleotide for example, 200 uM UpCpU
- RNA substrate for example 2.5 uM C 5 p
- ribozyme for example 2 . 5 uM L-19 IVS RNA
- Substrate RNA is pretreated with glyoxal according to the procedure of Carmichael and McMaster (1980) Meth in Enzymol. 65: 380-391 and then ethanol precipitated and the precipitate pelleted by centrifugation in an eppendorf centrifuge. The pellet is dried and the RNA re-suspended in water.
- the glyoxylated substrate RNA (0.2 uM) is incubated with ribozyme (for example L-19 IVS-beta RNA, 0.2 uM) at 50°C in 10 mM MgCl 2 , 10 mM NaCl, 50 mM Tris-HCl pH 7.5, 0.5 mM GTP, 2.5M Urea for 1 hour.
- the L-19 IVS RNA enzyme was prepared by incubation of pre-rRNA under conditions that promote self-splicing, cyclization, and site-s ⁇ ecific hydrolysis, (Zaug, A.J., et al. (1984) Science 224:574;
- the resulting ribozyme (L-19 IVS-beta) has greatly reduced activity as a nucleotidyl-transferase, assayed using [ 32 P]-p(C) 5 as a substrate.
- the ribozyme was able to cleave p(C) 5 as well as large RNA molecules.
- the 504 nt pAK105 transcript
- Fig. 2a As shown below, the 360 and 148 nt fragments can be explained as the 5' and 3' products of cleavage at position 360.
- the 464 nt fragment is the 3' product of cleavage at position 44, the 5' 44 nt fragment being to small to be observed.
- the absence of a major amount of a 316 nt RNA, the expected product of cleavage at both position 44 and 360, is indicative of partial digestion with few molecules cleaved more than once.
- L-19 IVS RNA was competent to catalyze the cleavagereaction, removal of G 414 from the ribozyme was not required for cleavage activity.
- the enzyme worked at the same rate whether or not G 414-had been removed.
- L-19 IVS RNA are protein-free.
- the L-19 IVS RNA is therefore a protein-free RNA enzyme (or ribozyme).
- L-19 IVS RNA and the like also function as enzymes in the absence of proteins. This applies to exogenous as well as endogenous protein. This is evidenced by retention of activity when subjected to protease activity, boiling or sodium dodecyl sulfate. Any RNA polymerase protein from the transcription. system used to produce IVS RNA is removed by phenol extraction. The ability to make the IVS RNA in a totally defined system in vitro and remove the RNA polymerase by phenol extraction is further evidence of the protein-free nature of the reaction.
- Example II Example II
- RNA (essentially pBR322 sequences) produced 4 major labeled fragments. These were sequenced in the same manner.
- pT7-1 RNA with an additional 122 nt at its 3' end produced by transcription of pT7-1 DNA that had been cleaved at the Sea I site, showed the expected increase in molecular weight of the labeled products.
- the L-19 IVS RNA became labeled, perhaps by the guanosine-exchange reaction proposed elsewhere (Zaug, A.J., et al. (1985) Science 229:1060-1064; Price, J.V., et al. (1987) J. Mol. Biol. in press).
- the sites of self-labeling were heterogeneous.
- Ml RNA the RNA subunit of E. coli RNase P (Reed, R.E., et al. (1982) Cell 30: 627-636), was not cleaved by L-19 IVS RNA-beta under standard reaction conditions (Fig. 2b).
- Ml RNA contains the sequence UCCUCU, which should be an excellent targent site. However, this sequence is involved in a stable hairpin stem (Guerrier-Takada, C., et al. (1984) Biochemistry 23:6327-6334; Pace, N.R., et al. (1985) Orig. of Life 16 : 97-116), which presumably makes it unavailable as a substrate.
- Oligoribonucleotide substrates were synthesized by the phage T7 RNA polymerase transcription method developed by Uhlenbeck and co-workers (Lowary, P., et al. (1986) NATO ASI Series, vol. 110, 69-76) (Fig. 3a).
- One substrate contained a perfect match to the tetranucleotide consensus sequence.
- Two-other substrates had single-base changes giving a 3-out-of-4 match to the consensus.
- the active site can be manipulated to recognize any base sequence so far that is XYZU, where X, Y and Z can be any of the four bases A,U,C,G and the nucleotides in the four base sequence can be the same or different.
- each ribozyme When variant ribozymes were incubated with the 504 nt pAKl05 RNA, each ribozyme gave a different pattern of cleavage products.
- One major cleavage site has been mapped for three variant ribozymes, including a 25C variant (G converted to C at position 25).
- the sites cleaved by the 23C, 24C and 25C ribozymes are preceded by CCCUGU, UCUGCU, and CUGUCU, respectively; the underlining indicates the base that would form a G .
- Each of these sequences can form 6 continuous base-pairs with the active site nucleotides of the variant ribozyme. While more cleavage sites must be sequenced before specificity can be properly assessed, these initial results are promising.
- Cleavage is catalytic:
- Fig. 4a The time course of cleavage of the oligonucleotide substrate GGCCCUCU*AAAAA (where the asterisk designates the cleavage site) by the wild-type ribozyme is shown in Fig. 4a.
- the reaction of 2.5 uM substrate with 0.2 uM ribozyme is 66% complete in 90 minutes.
- the ribozyme is acting catalytically.
- the reaction rate was determined at a series of substrate concentrations. The kinetics are adequately described by the Michaelis-Menten rate law.
- the dependence of the rate on GTP concentration is shown in the form of a Lineweaver-Burk plot in Fig. 4b.
- the K m for GTP is 44 uM.
- the dependence of the rate on RNA substance concentration at saturating GTP concentration is shown in Fig. 4C.
- the K m for this oligoribonucleotide substrate is 0.8 uM
- k cat is
- Example VII The L-19 IVS RNA catalyzes the cleavage and rejoining of oligonucleotides:
- Unlabeled L-19 IVS RNA was incubated with 5'- 32 P- labeled pC 5 in a solution containing 20 mM MgCl 2 , 50 mM tris-HCl, pH 7.5.
- the pC 5 was progressively converted to oligocytidylic acid with both longer and shorter chain length than the starting material (Fig. 5A).
- the longer products extended to at least pC 30 , as judged by a longer exposure of an autoradiogram such as that shown in Fig. 5A.
- THe shorter products were exclusively pC 4 and pC 3 .
- Incubation of pC 5 in the absence of the L-19 IVS RNA gave no reaction (Fig. 5C).
- the L-19 IVS RNA is regenerated after each reaction, such that each enzyme molecule can react with many substrate molecules.
- quantitation of the data shown in Fig. 5G revealed that 16 pmol of enzyme converted 1080 pmol of pC 5 to products in 60 minutes.
- Such numbers underestimate the turnover number of the enzyme; because the initial products are predominantly C 6 and C 4 , it is likely that the production of chains of length greater than six or less than four involves two or more catalytic cycles.
- Quantitation of the amount of radioactivity in each product also provides some indication of the reaction mechanism.
- the amount of radioactivity (a measure of numbers of chains) in products larger than pC 5 is approximately equal to that found in pC 4 plus pC 3 , consistent with a mechanism in which the total number of phosphodiester bonds is conserved in each reaction.
- the radioactivity distribution shifts toward the smaller products. This is most likely due to a competing hydrolysis reaction also catalyzed by the
- the stability of the enzyme was determined by preliminary incubation at 42°C for 1 hour in the presence of Mg 2+ (standard reaction conditions) or for 18 hours under the same conditions but without Mg 2+ .
- the L-19 IVS RNA is not a good substrate.
- the enzyme is also stable during storage at -20°C for periods of months. The specific activity of the enzyme is consistent between preparations.
- radioactivity became covalently attached to the L-19 IVS RNA (Fig. 7A)
- the radioactive phosphate was bonded covalently to the L-19 IVS RNA as judged by the following criteria: it remained associated when the complex was isolated and subjected to a second round of denaturing gel electrophoresis; it was released in the form of a mononucleotide upon RNase T 2 treatment; and it was released in the form of a series of unidentified oligonucleotides upon RNase T 1 treatment (A. Zaug and
- the first step consumes all the substrate, leaving insufficient C 5 to drive the second tr.ansesterification reaction.
- the model shown in Fig. 8 was tested by isolating the covalent enzyme-substrate complex prepared by reaction with and incubating it with unlabeled C 5 .
- This unreactive RNA could be a covalent intermediate that was denatured during isolation such that it lost reactivity, or it could represent a small amount of a different enzyme-substrate complex that was nonproductive and therefore accumulated during the reaction.
- G 414 -U 20 linkage in the C' IVS RNA, and the G 414 -U 415 linkage in the pre-rRNA are unusual phosphodiester bonds in that they are extremely labile to alkaline hydrolysis, leaving 5' phosphate and 3'-hydroxyl termini (Zaug, A.J. et al, (1984) Science 224:574 and
- a competitive inhibitor Deoxy C 5 , which is not a substrate for L-19 IVS RNA-catalyzed cleavage, inhibits the cleavage of pC 5 (Fig. 9A).
- Fig. 9B and C Analysis of the rate of the conversion of pC 5 to pC 4 and pC 3 as a function of d-C 5 concentration is summarized in Fig. 9B and C.
- K i 260 uM.
- d-A 5 inhibits the reaction only 16 percent as much as d-C 5 .
- inhibition by d-C 5 is not some general effect of introducing a deoxyoligonucleotide into the system but depends on sequence.
- EpC covalent enzyme-substrate intermediate
- K i k- 1 /k 1 , the dissociation constant for the noncovalent E . C 5 complex.
- K i for d-C 5 is within an order of magnitude of the K m for C 5 can then be interpreted in terms of d-C 5 and C 5 having similar binding constants for interaction with the active site on the enzyme. This fits well with the idea that the substrate binds to an oligopurine (R 5 ) sequence in the active site primarily by Watson-Crick base-pairing, in which case the C 5 . R 5 duplex and the d-C 5 . R 5 duplex should have similar stability.
- a transesterification reaction between the 3'-terminal guanosine residue of the enzyme and a phosphate ester of the substrate then produces a covalent enzyme-substrate intermediate.
- Transesterification is expected to be highly reversible. If the product C 4 rebinds to the enzyme, it can attack the covalent intermediate and reform the starting material, C 5 . Early in the reaction, however, the concentration of C 5 is much greater than the concentration of C 4 ; if C 5 binds and attacks the covalent intermediate, C 6 is produced (Fig. 8). The net reaction is 2 C 5 converted to C 6 + C 4 .
- the products are substrates for further reaction, for example, C 6 + C 5 is converted to C 7 + C 4 and C 4 + C 5 is converted to C 3 + C 6 .
- the absence of products smaller than C 3 is explicable in terms of the loss of binding interactions of C 3 relative to C 4 (C 3 could form only two base pairs in the binding mode that would be productive for cleavage).
- RNA ligation can occur without an external energy source as is required by RNA or DNA ligase.
- Hydrolysis of the covalent intermediate competes with transesterification.
- the net reaction is C 5 + H 2 O converted to C 4 + pC, with the L-19 IVS RNA acting as a ribonuclease.
- the catalytic strategies of the L-19 IVS RNA enzyme appear to be the same as those used by protein enzymes (Jencks, W.P., (1969) Catalysis in Chemistry and Enzymology (McGraw-Hill, New York).
- the RNA enzyme like protein enzymes, forms a specific noncovalent complex with its oligonucleotide substrate. This interaction is proposed to hold the oligonucleotide substrate at a distance and in an orientation such as to facilitate attack by the 3'-hydroxyl of the terminal guanosine of the enzyme.
- a covalent enzyme-substrate complex is a presumptive intermediate in the L-19 IVS RNA reaction.
- Covalent intermediates are prevalent in enzyme-catalyzed group transfer reactions.
- the phosphodiester bond formed in the covalent intermediate is unusually susceptible to hydrolysis, suggesting that it may be strained or activated to facilitate formation of the pentavalent transition state upon nucleophilic attack (Zaug, A.J., et al. (1985) Biochemistry 24:6211; Zaug, A.J., et al. (1984) Science 224:574).
- protein catalysts are thought to facilitate the formation of the transition state, for example, by providing active site groups that bind the transition state better than the unreacted substrate (Fersht, A.,
- Each L-19 IVS RNA-catalyzed transesterification and hydrolysis reaction is analogous to one of the steps in Tetrahymena pre-rRNA self-splicing or one of the related self-reactions (Fig. 10).
- the finding of enzymatic activity in a portion of the IVS RNA validates the view that the pre-rRNA carries its own splicing enzyme as an intrinsic part of its polynucleotide chain. It seems likely that the C 5 substrate binding site of the L-19 IVS RNA is the oligopyrimidine binding site that directs the choice of the 5' splice site and the various IVS RNA cyclization sites (Sullivan, F.X., et al.
- GGAGGG The putative binding site, GGAGGG, is located at nucleotides 22 to 27 of the intact Tetrahymena IVS RNA and at positions 3 to 8 very near the 5' end of the L-19 IVS RNA. If this is the substrate binding site, site-specific mutation of the sequence should change the substrate specificity of the enzyme in a predictable manner.
- the L-19 IVS RNA Dephosphorylates C 6 p.
- oligo cytidylic acid
- oligo (cytidylic acid) with a 3'-terminal hydroxyl group is incubated with the L-19 IVS RNA enzyme in 20 mM MgCl 2 , it is converted to oligo (C) with both larger and smaller chain lengths ( Figure 1A) as described previously (Examples VII and VIII and Zaug & Cech, (1986) Science (Wash., D.C.) 231:470-475.
- the reaction is specific for oligo (C); for example, pA 6 -OH is unreactive under the same conditions (Fig. 11A).
- the rate of conversion of G 5 p to C 5 -OH + E-p is pH-dependent with an optimum around pH 5.0.
- a sample of the data is shown in Fig. 12.
- the phospho transfer reaction is essentially pH-independent in the range pH 7.5-9 and proceeds at a rate similar to that of the nucleotidyl transfer reaction (Fig. 12A).
- the phospho. transfer reaction is accelerated more than 20-fold, while the nucleotidyl transfer reaction is unaffected.
- the enzyme still has substantial phospho transfer activity while its nucleotidyl transfer activity is greatly diminished.
- E-pC The covalent intermediate formed during the reaction of pC 5 -OH with the L-19 IVS RNA (E-pC) is alkali-labile; at pH 9.0 it undergoes hydrolysis, releasing the nucleotide pC and regenerating the free enzyme (Zaug & Cech, (1986) Science Supra).
- E-pC The covalent intermediate formed during the reaction of pC 5 -OH with the L-19 IVS RNA
- the terminal phosphate monoester of E-p underwent slow hydrolysis.
- the phosphate was released as P i at a rate of approximately 10%/h. The rate was slower at pH 4.0 and at pH 6.0 than at pH 5.0. Release of P i was also observed during the reaction of C 5 p * with L-19 IVS RNA at pH 5.0 at reaction times of 2 and 4h. Thus, the L-19 IVS RNA has acid phosphatase activity. This hydrolytic reaction is so slow, however, that we have not attempted to demonstrate multiple turnover.
- the L-19 IVS RNA Is a Phosphotransferase.
- the phospho- transfer reactions described thus far were all done in enzyme excess.
- L-19 IVS RNA was capable of transferring the 3'-terminal phosphate from C 5 p to UCU.
- the plasmid used for these studies (pBGST7) was derived from the cloning vector pUC18. The methodology for the following manipulations is described in Maniatis, T., et al. (1982) Molecular Cloning: A Laboratory Manual (Cold Spring Harbor, New York: Cold Spring Harbor).
- pUC18 was partially digested with Haell and unit length linear molecules were isolated by agarose gel electrophoresis and electroelution. The recovered DNA was treated with T4 DNA polymerase to make blunt ends and then dephosphorylated with calf intestinal phosphatase.
- pT7-2 (U.S. Biochemical Corp.) was cut with Pvull and HindlII and treated with T4 DNA polymerase, and the fragment containing the phage T7 promoter was isolated by polyacrylamide gel electrophoresis and electroelution. The promoter-containing fragment was ligated into the linearized pUC18 and the plasmid transformed into E. coli strain JM83. Individual colonies were picked and miniprep DNA was screened by restriction endonuclease digestion to locate the promoter fragment to the correct Haell site (position 680 on the map in the New England Biolabs Catalog).
- the orientation of the T7 promoter was determined by transcribing EcoRI-cut miniprep DNA with T7 RNA polymerase and determining the size of the product.
- This plasmid (pUT718) was then cut in the multicloning site with Kpnl and SphI and treated with T4 DNA polymerase followed by calf intestinal phosphatase.
- An IVS-containing BamHI DNA fragment was isolated from pJE457 (Price, J.V. and Cech, T.R., (1985) Science 228:719-722) and treated with S1 nuclease, phenol extracted, chloroform extracted, and ethanol precipitated.
- the SI-treated fragment containing short deletions at both ends, was ligated into the KpnI/Sphl-cut pUT718.
- E. coli strain JM83 was transformed with the recombinant plasmid and plated on LB agar containing ampicillin and X-gal (5-bromo-4-chloro-3-indolyl-beta-D-galactoside). DNA isolated from blue colonies was assayed by agarose gels electrophoresis for IVS-size inserts. Exon sequences were determined by dideoxy-sequencing the miniprep DNA.
- Oligonucleotide-directed mutagenesis on plasmid DNA was done essentially as described by Inouye, S. and Inouye M. (1986) In DNA and RNA Synthesis, S. Narang, ed. (New York: Academic Press), in press.
- pBGST7 DNA was cleaved in the gene coding for ampicillin resistance with Xmnl.
- pBGST7 DNA was cut with EcoRI and Hindlll, sites that flank the IVS and exon sequences.
- the vector portion of the plasmid was separated from the IVS-containing fragment by agarose gel electrophoresis and recovered by electroelution.
- Xmnl-cut DNA was mixed with the vector fragment in the presence of the oligonucleotide containing the mismatched base, heated to 95 °C for 5 min, placed at 37°C for 30 min, then at 4°C for 30 min and then put on ice. The products were treated with dNTPs and Klenow fragment of DNA pol I at room temperature for 2 hr. E. coli strain JM83 was transformed with the DNA and ampicillin-resistant colonies were picked on the basis of color (white or light blue indicating loss of splicing activity) and the miniprep DNA was sequenced.
- the double mutants were made using the plasmid DNA of single mutants and screening for restored beta-galactosidase activity.
- pBG/-2G:23C was made from pBG/-2G and a second oligonucleotide directed at position 23.
- pBG/-3G:24C was made starting with pBG/24C and using the oligonucleotide directed at position -3.
- pBG/-4G:25C was made by generating a circular heteroduplex from pBG/-4G:25C that had been linearized. at-different positions. Transformation of these heteroduplexes generated blue and light blue colonies, both at a low frequency. The blue colonies were wild-type sequence the light blues double mutant.
- the Thai fragment of Tetrahymena ribosomal RNA gene contains the IVS and small portions of the flanking exons. Hind III linkers were ligated onto the ends of the Thai fragment and it was inserted into the Hind III site in the polylinker of pSP62 (New England Nuclear), which contains the SP6 promoter. The recombinant plasmid was cloned in E. coli by standard methods.
- pT7TTlA3 was identical to pSPTTlA3 except that the ThaI fragment was cloned into the Hind III site of pT7-2 (U.S. Biochemical Corp.) which contains the T7 promoter.
- pT7 L-21 plasmid pBGST7 (described in Been & Cech, (1986) Cell 47:207 was cleaved with restriction endonucleases SphI and Hind III and the small fragment containing the IVS minus its first 44 nucleotides was purified.
- pUC18 was cleaved with SpH I and Hind III, mixed with the Sph-HIND III fragment from pBGST7 and treated with DNA ligase.
- coli cells were transformed, colonies were picked, plasmid DNA was isolated from individual colonies and sequenced.
- a plasmid containing the Sphl-Hind III fragment of the IVS properly inserted into pUC18 was selected for the next step.
- This plasmid was cleaved with SphI and EcoRI restriction endonucleases and a synthetic oligonucleotide was inserted into the plasmid using DNA ligase.
- the synthetic oligonucleotide contained one-half of the EcoRI restriction site, the T7 promoter, and nucleotides 22-44 of the Tetrahymena IVS, ending at the SphI site.
- E coli cells were transformed, colonies were picked, plasmid DNA was isolated from individual colonies and sequenced.
- the final plasmid pT7L-21 was found by sequence analysis to contain the T7 promoter properly juxtaposed to nucleotide 22 of the IVS. (See Figure 16)
- these defined pieces can be 5'-OH or 3'-OH end pieces, or center pieces containing the active site for study and production of varient RNA forms.
- aE-p * was incubated with 10 microM oligonucleotide (or mono- or dinucleotide) in 20 mM MgCl 2 and 50 mM Tris-HCl, pH 7.5, 42°C for 30 min. Transfer of the phosphate to the oligonucleotide was assayed by sequencing gel electrophoresis and autoradiography. ++, approximately the same activity as C 5 ; +/-, barely detectable activity, estimated as approximately 1% that of C 5 ; -, no activity detectable under these conditions.
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Crystallography & Structural Chemistry (AREA)
- Enzymes And Modification Thereof (AREA)
- Saccharide Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE3751567T DE3751567T2 (en) | 1986-12-03 | 1987-12-02 | RNS RIBOZYME RESTRICTION ENDORIBONUCLEASES AND METHOD. |
EP88901380A EP0291533B1 (en) | 1986-12-03 | 1987-12-02 | Rna ribozyme restriction endoribonucleases and methods |
HK188395A HK188395A (en) | 1986-12-03 | 1995-12-14 | Rna ribozyme restriction endoribonucleases and methods |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US06/937,327 US4987071A (en) | 1986-12-03 | 1986-12-03 | RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods |
US937,327 | 1986-12-03 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1988004300A1 true WO1988004300A1 (en) | 1988-06-16 |
Family
ID=25469785
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1987/003161 WO1988004300A1 (en) | 1986-12-03 | 1987-12-02 | Rna ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods |
Country Status (7)
Country | Link |
---|---|
US (6) | US4987071A (en) |
EP (1) | EP0291533B1 (en) |
JP (1) | JP2530906B2 (en) |
AT (1) | ATE129251T1 (en) |
DE (1) | DE3751567T2 (en) |
HK (1) | HK188395A (en) |
WO (1) | WO1988004300A1 (en) |
Cited By (153)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0321201A2 (en) * | 1987-12-15 | 1989-06-21 | Gene Shears Pty. Limited | Ribozymes |
EP0334383A2 (en) * | 1988-03-25 | 1989-09-27 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Transgenic plant with modified physiology, morphology and modified hormone metabolism, tissue cultures of this plant and process for its preparation |
EP0360257A2 (en) * | 1988-09-20 | 1990-03-28 | The Board Of Regents For Northern Illinois University | RNA catalyst for cleaving specific RNA sequences |
JPH02195883A (en) * | 1988-07-29 | 1990-08-02 | Sankyo Co Ltd | Cutting method of specific part of polyribonucleotide by ribozyme |
EP0387775A1 (en) * | 1989-03-16 | 1990-09-19 | BOEHRINGER INGELHEIM INTERNATIONAL GmbH | Genetic construct for inhibiting RNA function |
EP0389299A1 (en) * | 1989-03-24 | 1990-09-26 | University Patents, Inc. | RNA ribozyme restriction endoribonucleases and methods |
WO1991004324A1 (en) * | 1989-09-25 | 1991-04-04 | Innovir Laboratories, Inc. | Ribozyme compositions and methods for use |
WO1991018913A1 (en) * | 1990-06-07 | 1991-12-12 | City Of Hope | Ribozyme mediated reversal of transformation by cleavage of the hras oncogene rna |
WO1991019789A1 (en) * | 1990-06-19 | 1991-12-26 | Commonwealth Scientific And Industrial Research Organisation | Endonucleases |
WO1992003566A1 (en) * | 1990-08-17 | 1992-03-05 | Yale University | Therapeutic ribozyme compositions |
WO1992007065A1 (en) * | 1990-10-12 | 1992-04-30 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Modified ribozymes |
WO1992013070A1 (en) * | 1991-01-25 | 1992-08-06 | United States Biochemical Corporation | Regulation of nucleic acid translation |
US5180818A (en) * | 1990-03-21 | 1993-01-19 | The University Of Colorado Foundation, Inc. | Site specific cleavage of single-stranded dna |
WO1993015187A1 (en) * | 1992-01-31 | 1993-08-05 | Massachusetts Institute Of Technology | Nucleozymes |
US5409823A (en) * | 1992-09-24 | 1995-04-25 | Ciba-Geigy Corporation | Methods for the production of hybrid seed |
WO1995013379A1 (en) * | 1993-11-12 | 1995-05-18 | Ribozyme Pharmaceuticals, Inc. | Alteration of sequence of a target molecule |
JPH07507683A (en) * | 1992-04-28 | 1995-08-31 | エール ユニバーシティ | Targeted cleavage of RNA using eukaryotic ribonuclease P and external guide sequences |
US5624824A (en) * | 1989-03-24 | 1997-04-29 | Yale University | Targeted cleavage of RNA using eukaryotic ribonuclease P and external guide sequence |
US5641673A (en) * | 1991-01-17 | 1997-06-24 | The General Hospital Corporation | Cell ablation using trans-splicing ribozymes |
US5683873A (en) * | 1995-01-13 | 1997-11-04 | Innovir Laboratories, Inc. | EGS-mediated inactivation of target RNA |
WO1997047316A1 (en) | 1996-06-10 | 1997-12-18 | Millennium Pharmaceuticals, Inc. | Screening methods for compounds useful in the regulation of body weight |
US5728521A (en) * | 1989-03-24 | 1998-03-17 | Yale University | Targeted cleavage of RNA using eukaryotic ribonuclease P and external guide sequence |
US5817635A (en) * | 1993-08-09 | 1998-10-06 | Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. | Modified ribozymes |
US5830850A (en) * | 1996-08-28 | 1998-11-03 | Mount Sinai School Of Medicine Of The City Of New York | Methods for the treatment of bone resorption disorders, including osteoporosis |
US5856188A (en) * | 1988-09-20 | 1999-01-05 | The Board Of Regents For Northern Illinois University Of Dekalb | Hairpin ribozymes |
US5866412A (en) * | 1997-03-27 | 1999-02-02 | Millennium Pharmaceuticals, Inc. | Chromosome 18 marker |
US5874414A (en) * | 1991-01-17 | 1999-02-23 | The General Hospital Corporation | Trans-splicing ribozymes |
US5877162A (en) * | 1996-03-14 | 1999-03-02 | Innovir Laboratories, Inc. | Short external guide sequences |
US5914394A (en) * | 1997-03-27 | 1999-06-22 | Millenium Pharmaceuticals, Inc. | Methods and compositions for the diagnosis and treatment of neuropsychiatric disorders |
US5939316A (en) * | 1997-03-27 | 1999-08-17 | Millennium Pharmaceuticals, Inc. | Chromosome 18 marker |
US5955355A (en) * | 1997-03-27 | 1999-09-21 | Millennium Pharmaceuticals, Inc. | Chromosome 18 marker |
US5976874A (en) * | 1996-08-16 | 1999-11-02 | Yale University | Phenotypic conversion of drug-resistant bacteria to drug-sensitivity |
US6001648A (en) * | 1995-06-07 | 1999-12-14 | Commonwealth Scientific And Industrial Research Organization | Optimized minizymes and miniribozymes and uses thereof |
WO1999065926A1 (en) * | 1998-06-17 | 1999-12-23 | Bio Merieux | Method for marking a ribonucleic acid and resulting marked rna fragments |
US6010904A (en) * | 1995-06-07 | 2000-01-04 | The General Hospital Corporation | Cell ablation using trans-splicing ribozymes |
US6013447A (en) * | 1997-11-21 | 2000-01-11 | Innovir Laboratories, Inc. | Random intracellular method for obtaining optimally active nucleic acid molecules |
US6025167A (en) * | 1986-12-03 | 2000-02-15 | Competitive Technologies, Inc. | RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods |
US6057109A (en) * | 1994-08-23 | 2000-05-02 | Millennium Pharmaceuticals, Inc. | Compositions for the treatment of body weight disorders including obesity |
US6057153A (en) * | 1995-01-13 | 2000-05-02 | Yale University | Stabilized external guide sequences |
US6080851A (en) * | 1992-12-04 | 2000-06-27 | American Home Products Corporation | Ribozymes with linked anchor sequences |
US6248525B1 (en) | 1998-03-30 | 2001-06-19 | Yale University | Method for identifying essential or functional genes |
WO2001044506A1 (en) * | 1999-12-17 | 2001-06-21 | Bio Merieux | Process for labeling a ribonucleic acid, and labeled rna fragments which are obtained thereby |
US6258941B1 (en) | 1990-06-14 | 2001-07-10 | Washington University | RNA hydrolysis |
US6277634B1 (en) | 1995-06-07 | 2001-08-21 | Commonwealth Scientific And Industrial Research Organization | Optimized minizymes and miniribozymes and uses thereof |
US6322792B1 (en) | 1998-11-19 | 2001-11-27 | Elliott D. Kieff | Rhadino virus LANA acts in trans on a unit of rhadino virus DNA to mediate efficient episome persistance |
US6342351B1 (en) | 1998-03-16 | 2002-01-29 | Millennium Pharmaceuticals, Inc. | Methods and compositions for diagnosing and treating chromosome-18p related disorders |
WO2002090558A1 (en) | 2001-05-03 | 2002-11-14 | Fit Biotech Oyj Plc | Novel expression vectors and uses thereof |
US6489114B2 (en) | 1999-12-17 | 2002-12-03 | Bio Merieux | Process for labeling a ribonucleic acid, and labeled RNA fragments which are obtained thereby |
JP2003516763A (en) * | 1999-12-17 | 2003-05-20 | ベーイーオー・メリュー | Nucleic acid labeling method |
US6610478B1 (en) | 1996-08-16 | 2003-08-26 | Yale University | Phenotypic conversion of cells mediated by external guide sequences |
US6620805B1 (en) | 1996-03-14 | 2003-09-16 | Yale University | Delivery of nucleic acids by porphyrins |
US6642369B1 (en) | 1997-11-18 | 2003-11-04 | Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E. V. | Nucleic acids involved in the responder phenotype and applications thereof |
US6696250B1 (en) | 1986-12-03 | 2004-02-24 | Competitive Technologies, Inc. | RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods |
US6803211B2 (en) | 2000-08-25 | 2004-10-12 | Pfizer Inc. | Methods and compositions for diagnosing and treating disorders involving angiogenesis |
US6897016B1 (en) | 1993-11-12 | 2005-05-24 | The Regents Of The University Of Colorado | Alteration of sequence of a target molecule |
US6902891B2 (en) | 1999-12-17 | 2005-06-07 | Bio Merieux | Process for labeling a nucleic acid |
US7229823B2 (en) | 1997-04-14 | 2007-06-12 | Richard Jude Samulski | Methods for increasing the efficiency of recombinant AAV product |
WO2007117996A2 (en) | 2006-04-03 | 2007-10-18 | University Of Leicester | Methods for treating conditions associated with masp-2 dependent complement activation |
US7319145B2 (en) | 2001-12-03 | 2008-01-15 | Rima Rozen | Methylenetetrahydrofolate reductase inhibitors and use thereof |
WO2008063933A2 (en) | 2006-11-10 | 2008-05-29 | Massachusetts Institute Of Technology | Pak modulators |
WO2008119057A2 (en) | 2007-03-27 | 2008-10-02 | Omeros Corporation | The use of pde7 inhibitors for the treatment of movement disorders |
EP1980257A1 (en) | 2003-04-07 | 2008-10-15 | Prospect Therapeutics, Inc. | Compositions and uses of galectin antagonists |
EP2002827A2 (en) | 2001-12-05 | 2008-12-17 | The Baylor College Of Medicine | Methods and compositions for control of bone formation via modulation of sympathetic tone |
US7498314B2 (en) | 2001-05-03 | 2009-03-03 | Fit Biotech Oyj Plc | Expression vectors and uses thereof |
WO2009039175A2 (en) | 2007-09-17 | 2009-03-26 | Amgen Inc. | Method for inhibiting bone resorption |
EP2042597A1 (en) | 2000-06-23 | 2009-04-01 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis |
EP2075253A1 (en) | 2000-06-23 | 2009-07-01 | Genentech, Inc. | Compositions and methds for the diagnosis and treatment of disorders involving angiogensis |
US7585497B2 (en) | 2000-05-17 | 2009-09-08 | Oregon Health & Science University | Induction of apoptosis and cell growth inhibition by protein 4.33 |
WO2009123764A2 (en) | 2008-04-04 | 2009-10-08 | Calando Pharmaceuticals, Inc. | Compositions and use of epas1 inhibitors |
EP2123306A1 (en) | 2004-12-03 | 2009-11-25 | Fondazione Telethon | Use of a decoy protein that interferes with the hedgehog signalling pathway for the manufacture of a medicament for preventing, inhibiting, and/or reversing ocular diseases related with ocular neovascularization |
WO2010030813A2 (en) | 2008-09-10 | 2010-03-18 | Genentech, Inc. | Methods for inhibiting ocular angiogenesis |
US7722886B2 (en) | 2003-05-20 | 2010-05-25 | Wyeth | Compositions and methods for treatment of severe acute respiratory syndrome (SARS) |
WO2010115868A2 (en) | 2009-04-03 | 2010-10-14 | Fundacio Privada Institucio Catalana De Recerca I Estudis Avancats (Icrea) | Therapeutic agents for the treatment of diseases associated with undesired cell proliferation |
EP2246363A1 (en) | 2002-11-15 | 2010-11-03 | Novartis Vaccines and Diagnostics, Inc. | Methods for preventing and treating cancer metastasis and bone loss associated with cancer metastasis |
WO2010132609A2 (en) | 2009-05-12 | 2010-11-18 | The Regents Of The University Of California | Methods and compositions for treating neurodegenerative disorders and alzheimer's disease and improving normal memory |
EP2281885A1 (en) | 2003-08-27 | 2011-02-09 | Ophthotech Corporation | Combination therapy for the treatment of ocular neovascular disorders |
EP2287340A2 (en) | 2005-05-11 | 2011-02-23 | Aarhus Universitet | Method for diagnosis and treatment of a mental disease |
WO2011047346A1 (en) | 2009-10-16 | 2011-04-21 | Omeros Corporation | Methods for treating disseminated intravascular coagulation by inhibiting masp-2 dependent complement activation |
EP2314322A1 (en) | 2000-03-31 | 2011-04-27 | Novarx | Compositions containing genetically modified lung cancer cells expressing a TGF-beta inhibitor |
EP2319939A2 (en) | 1999-10-21 | 2011-05-11 | Case Western Reserve University | Gene expression profiling of inflammatory bowel disease |
WO2011054820A1 (en) | 2009-11-03 | 2011-05-12 | Universidad Del País Vasco | Methods and compositions for the treatment of white matter ischemia |
US7968762B2 (en) | 2004-07-13 | 2011-06-28 | Van Andel Research Institute | Immune-compromised transgenic mice expressing human hepatocyte growth factor (hHGF) |
EP2338492A1 (en) | 2009-12-24 | 2011-06-29 | Universidad del Pais Vasco | Methods and compositions for the treatment of alzheimer |
EP2351859A1 (en) | 2004-07-21 | 2011-08-03 | PTC Therapeutics, Inc. | Methods and agents for screening for compounds capable of modulating gene expression |
EP2359842A1 (en) | 2004-07-14 | 2011-08-24 | University of Utah Research Foundation | Netrin-related compositions and uses |
EP2360249A1 (en) | 2005-03-31 | 2011-08-24 | Calando Pharmaceuticals, Inc. | Inhibitors of ribonucleotide reductase subunit 2 and uses thereof |
US8014957B2 (en) | 2005-12-15 | 2011-09-06 | Fred Hutchinson Cancer Research Center | Genes associated with progression and response in chronic myeloid leukemia and uses thereof |
US8021833B2 (en) | 2003-02-12 | 2011-09-20 | Functional Genetics, Inc. | Method for reducing HIV viral budding by administering a VPS28-specfic antibody that disrupts Gag-TSG101-VPS28 binding interactions |
EP2382991A1 (en) | 2004-06-10 | 2011-11-02 | Omeros Corporation | Methods for treating conditions associated with MASP-2 dependent complement activation |
WO2011161295A2 (en) | 2010-06-23 | 2011-12-29 | Fundación Centro Nacional De Investigaciones Cardiovasculares Carlos Iii | Use of anticalcineurin compounds for the treatment of pathologies involving ocular neovascularisation |
US8158595B2 (en) | 2006-11-09 | 2012-04-17 | California Institute Of Technology | Modular aptamer-regulated ribozymes |
WO2012064667A2 (en) | 2010-11-08 | 2012-05-18 | Omeros Corporation | Treatment of addiction and impulse-control disorders using pde7 inhibitors |
WO2012100835A1 (en) | 2011-01-28 | 2012-08-02 | Laboratorios Del Dr. Esteve, S.A. | Methods and compositions for the treatment of aids |
WO2012122515A1 (en) | 2011-03-10 | 2012-09-13 | Genentech, Inc. | Treatment of disorders with altered vascular barrier function |
WO2012139081A2 (en) | 2011-04-08 | 2012-10-11 | University Of Leicester | Methods for treating conditions associated with masp-2 dependent complement activation |
US8329882B2 (en) | 2009-02-18 | 2012-12-11 | California Institute Of Technology | Genetic control of mammalian cells with synthetic RNA regulatory systems |
WO2013003112A1 (en) | 2011-06-27 | 2013-01-03 | The Jackson Laboratory | Methods and compositions for treatment of cancer and autoimmune disease |
WO2013015152A1 (en) | 2011-07-22 | 2013-01-31 | 公立大学法人横浜市立大学 | TECHNIQUE FOR CLEAVING OUT PART OF poly(A) CHAIN AND/OR 3'-TERMINAL SEQUENCE OF mRNA TO INHIBIT TRANSLATION REACTION |
US8367815B2 (en) | 2007-08-28 | 2013-02-05 | California Institute Of Technology | Modular polynucleotides for ligand-controlled regulatory systems |
EP2596807A1 (en) | 2006-03-08 | 2013-05-29 | Archemix LLC | Complement binding aptamers and anti-C5 agents useful in the treatment of ocular disorders |
EP2628486A2 (en) | 2007-12-14 | 2013-08-21 | Amgen, Inc. | Method for treating bone fracture with anti-sclerostin antibodies |
US8586726B2 (en) | 2007-07-18 | 2013-11-19 | The Trustees Of Columbia University In The City Of New York | Tissue-specific MicroRNAs and compositions and uses thereof |
US8772464B2 (en) | 2004-10-05 | 2014-07-08 | California Institute Of Technology | Aptamer regulated nucleic acids and uses thereof |
US8778633B2 (en) | 2006-04-07 | 2014-07-15 | Molecular Discover Systems | Transcription factor modulator |
US8865667B2 (en) | 2007-09-12 | 2014-10-21 | California Institute Of Technology | Higher-order cellular information processing devices |
EP2806036A1 (en) | 2004-05-24 | 2014-11-26 | PTC Therapeutics, Inc. | Methods and agents for screening for compounds capable of modulating VEGF expression |
US8906381B2 (en) | 2008-10-12 | 2014-12-09 | Massachusetts Institute Of Technology | Immunonanotherapeutics that provide IGG humoral response without T-cell antigen |
US8932595B2 (en) | 2008-10-12 | 2015-01-13 | Massachusetts Institute Of Technology | Nicotine immunonanotherapeutics |
WO2015017529A2 (en) | 2013-07-31 | 2015-02-05 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for modulating thermogenesis using pth-related and egf-related molecules |
US8999634B2 (en) | 2007-04-27 | 2015-04-07 | Quest Diagnostics Investments Incorporated | Nucleic acid detection combining amplification with fragmentation |
WO2015058143A1 (en) | 2013-10-17 | 2015-04-23 | Omeros Corporation | Methods for treating conditions associated with masp-2 dependent complement activation |
US9029524B2 (en) | 2007-12-10 | 2015-05-12 | California Institute Of Technology | Signal activated RNA interference |
US9040495B2 (en) | 2007-08-28 | 2015-05-26 | California Institute Of Technology | General composition framework for ligand-controlled RNA regulatory systems |
US9080014B2 (en) | 2006-05-15 | 2015-07-14 | Massachusetts Institute Of Technology | Polymers for functional particles |
US9145555B2 (en) | 2009-04-02 | 2015-09-29 | California Institute Of Technology | Integrated—ligand-responsive microRNAs |
US9217129B2 (en) | 2007-02-09 | 2015-12-22 | Massachusetts Institute Of Technology | Oscillating cell culture bioreactor |
US9233072B2 (en) | 2008-10-12 | 2016-01-12 | Massachusetts Institute Of Technology | Adjuvant incorporation in immunonanotherapeutics |
US9267937B2 (en) | 2005-12-15 | 2016-02-23 | Massachusetts Institute Of Technology | System for screening particles |
US9279127B2 (en) | 2006-11-01 | 2016-03-08 | The Medical Research Fund At The Tel-Aviv Sourasky Medical Center | Adipocyte-specific constructs and methods for inhibiting platelet-type 12 lipoxygenase expression |
US9308280B2 (en) | 2008-10-12 | 2016-04-12 | Massachusetts Institute Of Technology | Targeting of antigen presenting cells with immunonanotherapeutics |
WO2016061144A1 (en) | 2014-10-14 | 2016-04-21 | The Regents Of The University Of California | Use of cdk9 and brd4 inhibitors to inhibit inflammation |
US9333179B2 (en) | 2007-04-04 | 2016-05-10 | Massachusetts Institute Of Technology | Amphiphilic compound assisted nanoparticles for targeted delivery |
WO2016094273A1 (en) | 2014-12-08 | 2016-06-16 | Dana-Farber Cancer Institute, Inc. | Methods for upregulating immune responses using combinations of anti-rgmb and anti-pd-1 agents |
US9381477B2 (en) | 2006-06-23 | 2016-07-05 | Massachusetts Institute Of Technology | Microfluidic synthesis of organic nanoparticles |
US9474717B2 (en) | 2007-10-12 | 2016-10-25 | Massachusetts Institute Of Technology | Vaccine nanotechnology |
WO2016178233A1 (en) | 2015-05-05 | 2016-11-10 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd | Nucleic acid-cationic polymer compositions and methods of making and using the same |
US9492400B2 (en) | 2004-11-04 | 2016-11-15 | Massachusetts Institute Of Technology | Coated controlled release polymer particles as efficient oral delivery vehicles for biopharmaceuticals |
US9512430B2 (en) | 2013-07-03 | 2016-12-06 | Wisconsin Alumni Research Foundation | Compositions and methods to promote erythropoiesis |
WO2017066561A2 (en) | 2015-10-16 | 2017-04-20 | President And Fellows Of Harvard College | Regulatory t cell pd-1 modulation for regulating t cell effector immune responses |
WO2017075329A2 (en) | 2015-10-29 | 2017-05-04 | Dana-Farber Cancer Institute, Inc. | Methods for identification, assessment, prevention, and treatment of metabolic disorders using pm20d1 and n-lipidated amino acids |
US9644035B2 (en) | 2011-04-08 | 2017-05-09 | Omeros Corporation | Methods for treating conditions associated with MASP-2 dependent complement activation |
WO2017079227A1 (en) | 2015-11-05 | 2017-05-11 | University Of Connecticut | Compositions and methods for the treatment of liver fibrosis |
EP3168232A1 (en) | 2009-11-13 | 2017-05-17 | Dana-Farber Cancer Institute, Inc. | Compositions, kits, and methods for the diagnosis, prognosis, monitoring, treatment and modulation of post-transplant lymphoproliferative disorders and hypoxia associated angiogenesis disorders using galectin-1 |
WO2017083371A1 (en) | 2015-11-09 | 2017-05-18 | Omeros Corporation | Methods for treating conditions associated with masp-2 dependent complement activation |
WO2017165412A2 (en) | 2016-03-21 | 2017-09-28 | Dana-Farber Cancer Institute, Inc. | T-cell exhaustion state-specific gene expression regulators and uses thereof |
EP3293275A1 (en) | 2013-06-06 | 2018-03-14 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for identification, assessment prevention, and treatment of cancer using pd-l1 isoforms |
WO2019036460A1 (en) | 2017-08-15 | 2019-02-21 | Omeros Corporation | Methods for treating and/or preventing graft-versus-host disease and/or diffuse alveolar hemorrhage and/or veno-occlusive disease associated with hematopoietic stem cell transplant |
EP3486653A1 (en) | 2007-05-24 | 2019-05-22 | The United States Government as represented by The Department of Veterans Affairs | Treatment of skeletal muscle disorder using ent2 |
EP3613765A1 (en) | 2012-08-03 | 2020-02-26 | Dana-Farber Cancer Institute, Inc. | Antibody against repulsive guidance molecule b (rgmb) |
US10584315B2 (en) | 2015-09-24 | 2020-03-10 | Wisconsin Alumni Research Foundation | Methods of expanding hematopoietic stem cells, compositions, and methods of use thereof |
WO2020097261A1 (en) | 2018-11-06 | 2020-05-14 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | New compositions and methods for treating beta-globinopathies |
US10736960B2 (en) | 2016-01-05 | 2020-08-11 | Omeros Corporation | Methods for inhibiting fibrosis in a subject in need thereof |
WO2020223121A1 (en) | 2019-04-30 | 2020-11-05 | Dana-Farber Cancer Institute, Inc. | Methods for treating cancer using combinations of anti-cx3cr1 and immune checkpoint blockade agents |
US10870708B2 (en) | 2016-03-31 | 2020-12-22 | University Of Leicester | Methods for inhibiting angiogenesis in a subject in need thereof |
EP3757130A1 (en) | 2013-09-26 | 2020-12-30 | Costim Pharmaceuticals Inc. | Methods for treating hematologic cancers |
WO2022034474A1 (en) | 2020-08-10 | 2022-02-17 | Novartis Ag | Treatments for retinal degenerative diseases |
WO2022240824A1 (en) | 2021-05-13 | 2022-11-17 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Compositions and methods for treating sickle cell diseases |
WO2022261183A2 (en) | 2021-06-08 | 2022-12-15 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for treating and/or identifying an agent for treating intestinal cancers |
US11584714B2 (en) | 2018-05-29 | 2023-02-21 | Omeros Corporation | MASP-2 inhibitors and methods of use |
WO2023097119A2 (en) | 2021-11-29 | 2023-06-01 | Dana-Farber Cancer Institute, Inc. | Methods and compositions to modulate riok2 |
US11807641B2 (en) | 2019-12-04 | 2023-11-07 | Omeros Corporation | MASP-2 inhibitors and methods of use |
WO2024038089A1 (en) | 2022-08-18 | 2024-02-22 | Mitodicure Gmbh | Use of a therapeutic agent with phosphodiesterase-7 inhibitory activity for the treatment and prevention of diseases associated with chronic fatigue, exhaustion and/or exertional intolerance |
WO2024042160A1 (en) | 2022-08-26 | 2024-02-29 | Mitodicure Gmbh | Use of a therapeutic agent with sodium-hydrogen antiporter 1 inhibitory activity for the treatment and prevention of diseases associated with chronic fatigue, exhaustion and/or exertional intolerance |
Families Citing this family (1085)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5254678A (en) * | 1987-12-15 | 1993-10-19 | Gene Shears Pty. Limited | Ribozymes |
US5543508A (en) * | 1987-12-15 | 1996-08-06 | Gene Shears Pty. Limited | Ribozymes |
US5225347A (en) * | 1989-09-25 | 1993-07-06 | Innovir Laboratories, Inc. | Therapeutic ribozyme compositions and expression vectors |
DE3933384A1 (en) * | 1989-10-06 | 1991-04-18 | Hoechst Ag | MULTIFUNCTIONAL RNA WITH SELF-PROCESSING ACTIVITY, THEIR PRODUCTION AND THEIR USE |
JPH05503423A (en) * | 1990-01-12 | 1993-06-10 | スクリップス クリニック アンド リサーチ ファウンデーション | Nucleic acid enzyme for DNA cutting |
US6365730B1 (en) * | 1990-06-19 | 2002-04-02 | Gene Shears Pty. Limited | DNA-Armed ribozymes and minizymes |
US6008343A (en) * | 1990-06-19 | 1999-12-28 | Gene Shears Pty. Ltd. | Nucleotide based endonucleases |
US5246921A (en) * | 1990-06-26 | 1993-09-21 | The Wistar Institute Of Anatomy And Biology | Method for treating leukemias |
US6605712B1 (en) * | 1990-12-20 | 2003-08-12 | Arch Development Corporation | Gene transcription and ionizing radiation: methods and compositions |
US6313146B1 (en) | 1991-08-23 | 2001-11-06 | Nps Pharmaceuticals, Inc. | Calcium receptor-active molecules |
US5858684A (en) * | 1991-08-23 | 1999-01-12 | The Brigham And Women's Hospital, Inc. | Method of screening calcium receptor-active molecules |
US5688938A (en) * | 1991-08-23 | 1997-11-18 | The Brigham & Women's Hospital, Inc. | Calcium receptor-active molecules |
US6001884A (en) * | 1991-08-23 | 1999-12-14 | Nps Pharmaceuticals, Inc. | Calcium receptor-active molecules |
US6011068A (en) * | 1991-08-23 | 2000-01-04 | Nps Pharmaceuticals, Inc. | Calcium receptor-active molecules |
US5763569A (en) * | 1991-08-23 | 1998-06-09 | The Brigham And Women's Hospital, Inc | Calcium receptor-active molecules |
US6031003A (en) * | 1991-08-23 | 2000-02-29 | Nps Pharmaceuticals, Inc. | Calcium receptor-active molecules |
US6030954A (en) * | 1991-09-05 | 2000-02-29 | University Of Connecticut | Targeted delivery of poly- or oligonucleotides to cells |
CA2127461A1 (en) * | 1992-01-13 | 1993-07-22 | Michael D. Been | Enzymatic rna molecules |
CA2135646A1 (en) * | 1992-05-11 | 1993-11-25 | Kenneth G. Draper | Method and reagent for inhibiting viral replication |
US6469158B1 (en) | 1992-05-14 | 2002-10-22 | Ribozyme Pharmaceuticals, Incorporated | Synthesis, deprotection, analysis and purification of RNA and ribozymes |
US6007989A (en) | 1992-05-13 | 1999-12-28 | Board Of Regents, The University Of Texas System | Methods of screening for compounds that derepress or increase telomerase activity |
US5972699A (en) | 1992-05-14 | 1999-10-26 | Ribozyme Pharmaceuticals, Inc. | Method and reagent for inhibiting herpes simplex virus replication |
US5693535A (en) * | 1992-05-14 | 1997-12-02 | Ribozyme Pharmaceuticals, Inc. | HIV targeted ribozymes |
US20040054156A1 (en) * | 1992-05-14 | 2004-03-18 | Kenneth Draper | Method and reagent for inhibiting hepatitis B viral replication |
US5977343A (en) | 1992-05-14 | 1999-11-02 | Ribozyme Pharmaceuticals, Inc. | Synthesis, deprotection, analysis and purification of RNA and ribozymes |
US20030125270A1 (en) * | 2000-12-18 | 2003-07-03 | Lawrence Blatt | Enzymatic nucleic acid treatment of diseases or conditions related to hepatitis C virus infection |
US5686599A (en) * | 1992-05-14 | 1997-11-11 | Ribozyme Pharmaceuticals, Inc. | Synthesis, deprotection, analysis and purification of RNA and ribozymes |
US5610054A (en) * | 1992-05-14 | 1997-03-11 | Ribozyme Pharmaceuticals, Inc. | Enzymatic RNA molecule targeted against Hepatitis C virus |
US5804683A (en) * | 1992-05-14 | 1998-09-08 | Ribozyme Pharmaceuticals, Inc. | Deprotection of RNA with alkylamine |
US5714383A (en) * | 1992-05-14 | 1998-02-03 | Ribozyme Pharmaceuticals, Inc. | Method and reagent for treating chronic myelogenous leukemia |
US5610052A (en) * | 1992-08-26 | 1997-03-11 | Ribozyme Pharmaceuticals Inc. | Enzymatic RNA with activity to ras |
US5989906A (en) * | 1992-05-14 | 1999-11-23 | Ribozyme Pharmaceuticals, Inc. | Method and reagent for inhibiting P-glycoprotein (mdr-1-gene) |
US20040127446A1 (en) * | 1992-05-14 | 2004-07-01 | Lawrence Blatt | Oligonucleotide mediated inhibition of hepatitis B virus and hepatitis C virus replication |
US5646042A (en) * | 1992-08-26 | 1997-07-08 | Ribozyme Pharmaceuticals, Inc. | C-myb targeted ribozymes |
US5891684A (en) * | 1992-10-15 | 1999-04-06 | Ribozyme Pharmaceuticals, Inc. | Base-modified enzymatic nucleic acid |
JPH08507203A (en) * | 1992-12-04 | 1996-08-06 | イノーバー ラボラトリーズ,インコーポレイテッド | Regulatable nucleic acid therapies and methods of their use |
US5811300A (en) * | 1992-12-07 | 1998-09-22 | Ribozyme Pharmaceuticals, Inc. | TNF-α ribozymes |
US5616490A (en) * | 1992-12-07 | 1997-04-01 | Ribozyme Pharmaceuticals, Inc. | Ribozymes targeted to TNF-α RNA |
US5837542A (en) * | 1992-12-07 | 1998-11-17 | Ribozyme Pharmaceuticals, Inc. | Intercellular adhesion molecule-1 (ICAM-1) ribozymes |
US5612215A (en) * | 1992-12-07 | 1997-03-18 | Ribozyme Pharmaceuticals, Inc. | Stromelysin targeted ribozymes |
US5616488A (en) * | 1992-12-07 | 1997-04-01 | Ribozyme Pharmaceuticals, Inc. | IL-5 targeted ribozymes |
US5658780A (en) * | 1992-12-07 | 1997-08-19 | Ribozyme Pharmaceuticals, Inc. | Rel a targeted ribozymes |
US5821398A (en) * | 1992-12-15 | 1998-10-13 | Commonwealth Scientific & Industrial Research Org. | DNA molecules encoding inducible plant promoters and tomato ADH2 enzyme |
US5436143A (en) * | 1992-12-23 | 1995-07-25 | Hyman; Edward D. | Method for enzymatic synthesis of oligonucleotides |
US5516664A (en) * | 1992-12-23 | 1996-05-14 | Hyman; Edward D. | Enzymatic synthesis of repeat regions of oligonucleotides |
US5639655A (en) * | 1993-01-19 | 1997-06-17 | Ribozyme Pharmaceuticals, Inc. | PML-RARA targeted ribozymes |
US5962314A (en) * | 1993-02-23 | 1999-10-05 | Nps Pharmaceuticals, Inc. | Calcium receptor-active molecules |
US6077668A (en) * | 1993-04-15 | 2000-06-20 | University Of Rochester | Highly sensitive multimeric nucleic acid probes |
US6096880A (en) | 1993-04-15 | 2000-08-01 | University Of Rochester | Circular DNA vectors for synthesis of RNA and DNA |
US7135312B2 (en) * | 1993-04-15 | 2006-11-14 | University Of Rochester | Circular DNA vectors for synthesis of RNA and DNA |
US5670361A (en) * | 1993-05-17 | 1997-09-23 | The Regents Of The University Of California | HIV-specific ribozymes |
US5773244A (en) * | 1993-05-19 | 1998-06-30 | Regents Of The University Of California | Methods of making circular RNA |
EP0748382B1 (en) | 1993-09-02 | 2002-11-06 | Ribozyme Pharmaceuticals, Inc. | Non-nucleotide containing enzymatic nucleic acid |
DE69415343T2 (en) * | 1993-10-27 | 1999-08-26 | Ribozyme Pharmaceuticals | 2'-AMIDO AND 2'-PEPTIDO-MODIFIED OLIGONUCLEOTIDES |
US6225059B1 (en) | 1993-11-01 | 2001-05-01 | Nanogen, Inc. | Advanced active electronic devices including collection electrodes for molecular biological analysis and diagnostics |
US6331274B1 (en) | 1993-11-01 | 2001-12-18 | Nanogen, Inc. | Advanced active circuits and devices for molecular biological analysis and diagnostics |
US6207373B1 (en) | 1998-02-25 | 2001-03-27 | Nanogen, Inc. | Methods for determining nature of repeat units in DNA |
EP0728204A1 (en) | 1993-11-08 | 1996-08-28 | Ribozyme Pharmaceuticals, Inc. | Base-modified enzymatic nucleic acid |
PL314522A1 (en) * | 1993-11-23 | 1996-09-16 | Ciba Corning Diagnostics Corp | Application of antisense oligomers in a contamination controlling process during nucleic acids amplification reactions |
US5693532A (en) * | 1994-11-04 | 1997-12-02 | Ribozyme Pharmaceuticals, Inc. | Respiratory syncytial virus ribozymes |
US5639647A (en) * | 1994-03-29 | 1997-06-17 | Ribozyme Pharmaceuticals, Inc. | 2'-deoxy-2'alkylnucleotide containing nucleic acid |
US5834440A (en) * | 1994-03-07 | 1998-11-10 | Immusol Incorporated | Ribozyme therapy for the inhibition of restenosis |
US6551618B2 (en) | 1994-03-15 | 2003-04-22 | University Of Birmingham | Compositions and methods for delivery of agents for neuronal regeneration and survival |
US5627053A (en) * | 1994-03-29 | 1997-05-06 | Ribozyme Pharmaceuticals, Inc. | 2'deoxy-2'-alkylnucleotide containing nucleic acid |
US5631148A (en) * | 1994-04-22 | 1997-05-20 | Chiron Corporation | Ribozymes with product ejection by strand displacement |
US6103890A (en) * | 1994-05-18 | 2000-08-15 | Ribozyme Pharmaceuticals, Inc. | Enzymatic nucleic acids that cleave C-fos |
US5688670A (en) * | 1994-09-01 | 1997-11-18 | The General Hospital Corporation | Self-modifying RNA molecules and methods of making |
US6350934B1 (en) | 1994-09-02 | 2002-02-26 | Ribozyme Pharmaceuticals, Inc. | Nucleic acid encoding delta-9 desaturase |
US5599706A (en) * | 1994-09-23 | 1997-02-04 | Stinchcomb; Dan T. | Ribozymes targeted to apo(a) mRNA |
US5700923A (en) * | 1994-09-29 | 1997-12-23 | Hybridon, Inc. | Finderons and methods of their preparation and use |
US5643877A (en) | 1994-12-05 | 1997-07-01 | University Of Maryland Biotechnology Institute | Compounds comprising gonadotropin releasing hormone (GnRH) and methods for controlling reproduction in fish |
US5672501A (en) * | 1994-12-23 | 1997-09-30 | Ribozyme Pharmaceuticals, Inc. | Base-modified enzymatic nucleic acid |
US5716824A (en) * | 1995-04-20 | 1998-02-10 | Ribozyme Pharmaceuticals, Inc. | 2'-O-alkylthioalkyl and 2-C-alkylthioalkyl-containing enzymatic nucleic acids (ribozymes) |
US6107027A (en) * | 1994-12-14 | 2000-08-22 | University Of Washington | Ribozymes for treating hepatitis C |
US5705388A (en) * | 1994-12-23 | 1998-01-06 | Ribozyme Pharmaceuticals, Inc. | CETP Ribozymes |
US5872241A (en) * | 1995-01-25 | 1999-02-16 | The Trustees Of Columbia University In The City Of New York | Multiple component RNA catalysts and uses thereof |
US5646031A (en) * | 1995-05-16 | 1997-07-08 | Northern Illinois University | SArMV and sCYMVI hairpin ribozymes |
US5877021A (en) | 1995-07-07 | 1999-03-02 | Ribozyme Pharmaceuticals, Inc. | B7-1 targeted ribozymes |
US20030207837A1 (en) * | 1995-07-07 | 2003-11-06 | Ribozyme Pharmaceuticals, Inc. | Method and reagent for the induction of graft tolerance and reversal of immune responses |
US6482803B1 (en) | 1995-09-01 | 2002-11-19 | Board Of Regents, The University Of Texas System | Modification of mutated P53 gene in tumors by retroviral delivery of ribozyme A |
US7034009B2 (en) * | 1995-10-26 | 2006-04-25 | Sirna Therapeutics, Inc. | Enzymatic nucleic acid-mediated treatment of ocular diseases or conditions related to levels of vascular endothelial growth factor receptor (VEGF-R) |
US20040220128A1 (en) * | 1995-10-26 | 2004-11-04 | Sirna Therapeutics, Inc. | Nucleic acid based modulation of female reproductive diseases and conditions |
US20040142895A1 (en) * | 1995-10-26 | 2004-07-22 | Sirna Therapeutics, Inc. | Nucleic acid-based modulation of gene expression in the vascular endothelial growth factor pathway |
US6346398B1 (en) | 1995-10-26 | 2002-02-12 | Ribozyme Pharmaceuticals, Inc. | Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor |
US20040102389A1 (en) * | 1995-10-26 | 2004-05-27 | Ribozyme Pharmaceuticals, Inc. | Nucleic acid-mediated treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor (VEGF-R) |
US5739313A (en) * | 1995-11-13 | 1998-04-14 | Regents Of The University Of Minnesota | Radionuclide labeling of vitamin B12 and coenzymes thereof |
US5998203A (en) * | 1996-04-16 | 1999-12-07 | Ribozyme Pharmaceuticals, Inc. | Enzymatic nucleic acids containing 5'-and/or 3'-cap structures |
US6087129A (en) | 1996-01-19 | 2000-07-11 | Betagene, Inc. | Recombinant expression of proteins from secretory cell lines |
EP0907746B1 (en) | 1996-04-05 | 2008-02-20 | Novartis Vaccines and Diagnostics, Inc. | Recombinant alphavirus-based vectors with reduced inhibition of cellular macromolecular synthesis |
ATE302599T1 (en) | 1996-05-24 | 2005-09-15 | Angiotech Pharm Inc | PREPARATIONS AND METHODS FOR THE TREATMENT OR PREVENTION OF DISEASES OF THE BODY PASSAGES |
EP0963440A4 (en) * | 1996-11-20 | 2004-12-29 | Regents Board Of | Improved methods for transducing cells |
US5807743A (en) * | 1996-12-03 | 1998-09-15 | Ribozyme Pharmaceuticals, Inc. | Interleukin-2 receptor gamma-chain ribozymes |
US7008776B1 (en) * | 1996-12-06 | 2006-03-07 | Aventis Pharmaceuticals Inc. | Compositions and methods for effecting the levels of high density lipoprotein (HDL) cholesterol and apolipoprotein AI very low density lipoprotein (VLDL) cholesterol and low density lipoprotein (LDL) cholesterol |
EP0948609B1 (en) | 1996-12-06 | 2005-03-16 | Aventis Pharmaceuticals Inc. | Llg polypeptides of the triacylglycerol lipase family, and compositions and methods for their use in enzymatic hydrolysis, and protein and gene therapies |
US6248878B1 (en) | 1996-12-24 | 2001-06-19 | Ribozyme Pharmaceuticals, Inc. | Nucleoside analogs |
AU5927598A (en) | 1997-01-23 | 1998-08-18 | Immusol Incorporated | Gene functional analysis and discovery using randomized or target-specific ribozyme gene vector libraries |
US6057156A (en) | 1997-01-31 | 2000-05-02 | Robozyme Pharmaceuticals, Inc. | Enzymatic nucleic acid treatment of diseases or conditions related to levels of epidermal growth factor receptors |
US20030186909A1 (en) * | 1997-01-27 | 2003-10-02 | Ribozyme Pharmaceuticals, Inc. | Nucleic acid treatment of diseases or conditions related to levels of epidermal growth factor receptors |
US6482795B1 (en) | 1997-01-30 | 2002-11-19 | Myriad Genetics, Inc. | Tumor suppressor designated TS10q23.3 |
US6262242B1 (en) | 1997-01-30 | 2001-07-17 | Board Of Regents, The University Of Texas System | Tumor suppressor designated TS10Q23.3 |
US6159951A (en) * | 1997-02-13 | 2000-12-12 | Ribozyme Pharmaceuticals Inc. | 2'-O-amino-containing nucleoside analogs and polynucleotides |
US6011197A (en) | 1997-03-06 | 2000-01-04 | Infigen, Inc. | Method of cloning bovines using reprogrammed non-embryonic bovine cells |
US6251666B1 (en) | 1997-03-31 | 2001-06-26 | Ribozyme Pharmaceuticals, Inc. | Nucleic acid catalysts comprising L-nucleotide analogs |
ATE353964T1 (en) | 1997-04-16 | 2007-03-15 | Millennium Pharm Inc | CRSP PROTEINS (CYSTEIN-RICH SECRETED PROTEINS), THE NUCLEIC ACIDS THAT ENCOD THEM AND THEIR USES |
US6787319B2 (en) * | 1997-04-16 | 2004-09-07 | American Home Products Corp. | β-amyloid peptide-binding proteins and polynucleotides encoding the same |
US7005295B1 (en) | 1997-04-16 | 2006-02-28 | Wyeth | β-amyloid peptide-binding proteins and polynucleotides encoding the same |
NZ500427A (en) | 1997-04-21 | 2002-12-20 | Univ Florida | The use of ribozyme treatment for retinal diseases |
US20050096282A1 (en) * | 1997-04-21 | 2005-05-05 | Lewin Alfred S. | Adeno-associated virus-delivered ribozyme compositions and methods for the treatment of retinal diseases |
AU746775B2 (en) | 1997-06-03 | 2002-05-02 | University Of Chicago, The | Plant artificial chromosome (PLAC) compositions and methods |
US6183959B1 (en) | 1997-07-03 | 2001-02-06 | Ribozyme Pharmaceuticals, Inc. | Method for target site selection and discovery |
US6316612B1 (en) | 1997-08-22 | 2001-11-13 | Ribozyme Pharmaceuticals, Inc. | Xylofuranosly-containing nucleoside phosphoramidites and polynucleotides |
JP2001516582A (en) | 1997-09-16 | 2001-10-02 | クロップデザイン エヌ.ブイ. | Cyclin-dependent kinase inhibitors and uses thereof |
US6054576A (en) | 1997-10-02 | 2000-04-25 | Ribozyme Pharmaceuticals, Inc. | Deprotection of RNA |
JP4891477B2 (en) | 1997-10-02 | 2012-03-07 | マックス−プランク−ゲゼルシャフト ツール フォーデルング デル ヴィッセンシャフテン エー.ヴェー. | Methods for the regulation of angiogenesis and / or development of side arteries and / or other arteries from existing arteriole networks |
JP2001520170A (en) | 1997-10-16 | 2001-10-30 | ボード・オヴ・リージェンツ,ザ・ユニヴァーシティ・オヴ・テキサス・システム | Animal models for cardiac hypertrophy and treatment methods related to NF-AT3 function |
CN100342008C (en) * | 1997-10-24 | 2007-10-10 | 茵维特罗根公司 | Recombinational cloning using nucleic acids having recombinatin sites |
US6087172A (en) * | 1997-10-31 | 2000-07-11 | Hisamitsu Pharmaceutical Co., Inc. | Ribozymes targeted to human IL-15 mRNA |
US6482932B1 (en) | 1997-11-05 | 2002-11-19 | Ribozyme Pharmaceuticals, Incorporated | Nucleoside triphosphates and their incorporation into oligonucleotides |
US6617438B1 (en) | 1997-11-05 | 2003-09-09 | Sirna Therapeutics, Inc. | Oligoribonucleotides with enzymatic activity |
US6610497B1 (en) * | 1997-12-11 | 2003-08-26 | Millennium Pharmaceuticals, Inc. | Angiotensin converting enzyme homolog and therapeutic and diagnostic uses therefor |
ATE281518T1 (en) | 1998-01-15 | 2004-11-15 | King S College London | RIBOZYMAL NUCLEIC ACID THAT CUT CCR5 OR CXCR4 |
EP1053317B1 (en) * | 1998-02-13 | 2006-11-02 | Köster, Hubert | Use of ribozymes for functionating genes |
US20020147143A1 (en) | 1998-03-18 | 2002-10-10 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of lung cancer |
WO1999054459A2 (en) * | 1998-04-20 | 1999-10-28 | Ribozyme Pharmaceuticals, Inc. | Nucleic acid molecules with novel chemical compositions capable of modulating gene expression |
US6733991B1 (en) * | 1998-05-08 | 2004-05-11 | Osi Pharmaceuticals, Inc. | AGS proteins and nucleic acid molecules and uses therefor |
US6746852B1 (en) | 1998-05-08 | 2004-06-08 | Osi Pharmaceuticals, Inc. | AGS proteins and nucleic acid molecules and uses thereof |
US20040259079A1 (en) * | 1998-07-22 | 2004-12-23 | Immusol, Inc. | Substantially complete ribozyme libraries |
US7157418B1 (en) | 1998-07-22 | 2007-01-02 | Osprey Pharmaceuticals, Ltd. | Methods and compositions for treating secondary tissue damage and other inflammatory conditions and disorders |
US20030215421A1 (en) * | 1999-07-21 | 2003-11-20 | Mcdonald John R. | Methods and compositions for treating secondary tissue damage and other inflammatory conditions and disorders |
JP2002522029A (en) | 1998-07-27 | 2002-07-23 | ジェネンテック・インコーポレーテッド | Improved transformation efficiency in phage display by modification of coat protein |
US6414223B1 (en) | 1998-08-03 | 2002-07-02 | Cargill, Incorporated | Plants, seeds and oils having an elevated total monounsaturated fatty acid content |
US6281375B1 (en) | 1998-08-03 | 2001-08-28 | Cargill, Incorporated | Biodegradable high oxidative stability oils |
CN1219064C (en) | 1998-08-04 | 2005-09-14 | 嘉吉有限公司 | Plant fatty acid desaturase promoters |
US20050079558A1 (en) * | 1998-08-28 | 2005-04-14 | New York University | Methods to identify compounds useful for the treatment of proliferative and differentiative disorders |
NZ510312A (en) * | 1998-08-28 | 2004-01-30 | Univ New York | A nucleic acid encoding an F-box protein |
US20060088846A1 (en) * | 1998-08-28 | 2006-04-27 | Michele Pagano | Methods to identify compounds useful for the treatment of proliferative and differentiative disorders |
US20050086718A1 (en) | 1999-03-23 | 2005-04-21 | Mendel Biotechnology, Inc. | Plant transcriptional regulators of abiotic stress |
US7897843B2 (en) | 1999-03-23 | 2011-03-01 | Mendel Biotechnology, Inc. | Transcriptional regulation of plant biomass and abiotic stress tolerance |
US6713117B1 (en) | 1998-10-02 | 2004-03-30 | Dharma Kodali | Vegetable oil having elevated stearic acid content |
US6743906B1 (en) | 1998-10-02 | 2004-06-01 | Board Of Regents, The University Of Texas | PPP2R1B is a tumor suppressor |
US6995259B1 (en) * | 1998-10-23 | 2006-02-07 | Sirna Therapeutics, Inc. | Method for the chemical synthesis of oligonucleotides |
US20030027998A1 (en) * | 1998-10-30 | 2003-02-06 | Holtzman Douglas A. | Novel genes encoding proteins having prognostic, diagnostic, preventive, therapeutic, and other uses |
EP2322634B1 (en) | 1998-11-12 | 2014-04-23 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Chimeric promoters capable of mediating gene expression in plants upon pathogen infection and uses thereof |
US6855549B1 (en) | 1998-11-23 | 2005-02-15 | The University Of Iowa Research Foundation | Methods and compositions for increasing the infectivity of gene transfer vectors |
US6258998B1 (en) | 1998-11-24 | 2001-07-10 | Infigen, Inc. | Method of cloning porcine animals |
US6700037B2 (en) | 1998-11-24 | 2004-03-02 | Infigen, Inc. | Method of cloning porcine animals |
US20030224516A1 (en) * | 2002-06-03 | 2003-12-04 | Isis Pharmaceuticals Inc. | Antisense modulation of prox-1 expression |
CA2352532C (en) | 1998-11-27 | 2014-10-14 | Darwin Discovery Ltd. | Compositions and methods for increasing bone mineralization |
US20040009535A1 (en) | 1998-11-27 | 2004-01-15 | Celltech R&D, Inc. | Compositions and methods for increasing bone mineralization |
WO2000034461A2 (en) * | 1998-12-10 | 2000-06-15 | Board Of Regents, The University Of Texas System | Compositions and methods of modulating cholesterol metabolism |
US7063850B1 (en) | 1998-12-22 | 2006-06-20 | University Of Tennessee Research Foundation | Protective antigen of group A Streptococci |
US20040005673A1 (en) * | 2001-06-29 | 2004-01-08 | Kevin Jarrell | System for manipulating nucleic acids |
ATE439437T1 (en) * | 1999-01-05 | 2009-08-15 | Univ Boston | IMPROVED CLONING PROCESS |
US6358712B1 (en) | 1999-01-05 | 2002-03-19 | Trustee Of Boston University | Ordered gene assembly |
DE19956568A1 (en) * | 1999-01-30 | 2000-08-17 | Roland Kreutzer | Method and medicament for inhibiting the expression of a given gene |
US6156515A (en) | 1999-02-09 | 2000-12-05 | Urocor, Inc. | Prostate-specific gene for diagnosis, prognosis and management of prostate cancer |
AU3382800A (en) | 1999-02-26 | 2000-09-14 | Millennium Pharmaceuticals, Inc. | Secreted proteins and uses thereof |
US6878514B1 (en) | 1999-03-30 | 2005-04-12 | Purdue Research Foundation | Methods for identifying agents that inhibit serum aging factors and uses and compositions thereof |
US6911429B2 (en) * | 1999-04-01 | 2005-06-28 | Transition Therapeutics Inc. | Compositions and methods for treating cellular response to injury and other proliferating cell disorders regulated by hyaladherin and hyaluronans |
US6864235B1 (en) | 1999-04-01 | 2005-03-08 | Eva A. Turley | Compositions and methods for treating cellular response to injury and other proliferating cell disorders regulated by hyaladherin and hyaluronans |
WO2000060932A1 (en) * | 1999-04-09 | 2000-10-19 | Mcgill University | Non-human transgenic animal whose germ cells and somatic cells contain a knockout mutation in dna encoding 4e-bp1 |
US6806363B1 (en) * | 1999-04-16 | 2004-10-19 | Mayo Foundation For Medical Education & Research | Cobalamin conjugates useful as antitumor agents |
CA2368194A1 (en) * | 1999-04-30 | 2000-11-09 | University Of Florida | Adeno-associated virus-delivered ribozyme compositions and methods of use |
US6429357B1 (en) | 1999-05-14 | 2002-08-06 | Dekalb Genetics Corp. | Rice actin 2 promoter and intron and methods for use thereof |
US20040023874A1 (en) * | 2002-03-15 | 2004-02-05 | Burgess Catherine E. | Therapeutic polypeptides, nucleic acids encoding same, and methods of use |
US6974684B2 (en) * | 2001-08-08 | 2005-12-13 | Curagen Corporation | Therapeutic polypeptides, nucleic acids encoding same, and methods of use |
US20040229779A1 (en) * | 1999-05-14 | 2004-11-18 | Ramesh Kekuda | Therapeutic polypeptides, nucleic acids encoding same, and methods of use |
EP1754488A1 (en) | 1999-05-24 | 2007-02-21 | Introgen Therapeutics, Inc. | Methods and compositions for non-viral gene therapy for treatment of hyperproliferative diseases |
US20040067490A1 (en) * | 2001-09-07 | 2004-04-08 | Mei Zhong | Therapeutic polypeptides, nucleic acids encoding same, and methods of use |
WO2000075341A1 (en) | 1999-06-07 | 2000-12-14 | Basf Plant Science Gmbh | Δ6-acetylenase and δ6-desaturase from ceratodon purpureus |
US7485715B2 (en) * | 1999-06-18 | 2009-02-03 | Ceres, Inc. | Sequence-determined DNA encoding AP2 domain polypeptides |
ES2178979T1 (en) | 1999-06-25 | 2003-01-16 | Basf Ag | CORYNEBACTERIUM GLUTAMICUM GENES THAT CODIFY PROTEINS INVOLVED IN CARBON METABOLISM AND ENERGY PRODUCTION. |
US7291714B1 (en) | 1999-06-30 | 2007-11-06 | Millennium Pharmaceuticals, Inc. | Glycoprotein VI and uses thereof |
EP1702980A1 (en) | 1999-07-01 | 2006-09-20 | Basf Aktiengesellschaft | Corynebacterium glutamicum gene encoding Hpr of phosphoenolpyruvate:sugar phosphotransferase system |
TR200700069T2 (en) | 1999-07-01 | 2007-02-21 | Basf Aktiengesellschaft | Corynebacterium glutamicum gene encoding phosphoenol pyruvate: sugar phosphotransferase system protein. |
AU778695B2 (en) | 1999-07-20 | 2004-12-16 | Ges. Fur Erwerb Und Verwertung Von Schutzrechten-Gvs Mbh | Novel method for the generation and selection of transgenic linseed/flax plants |
US7479555B2 (en) * | 1999-07-21 | 2009-01-20 | Ceres, Inc. | Polynucleotides having a nucleotide sequence that encodes a polypeptide having MOV34 family activity |
SK782002A3 (en) | 1999-07-21 | 2003-08-05 | Lexigen Pharm Corp | FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens |
CA2925551A1 (en) | 1999-08-23 | 2001-03-01 | Dana-Farber Cancer Institute, Inc. | Pd-1, a receptor for b7-4, and uses therefor |
US6429303B1 (en) | 1999-09-03 | 2002-08-06 | Curagen Corporation | Nucleic acids encoding members of the human B lymphocyte activation antigen B7 family and methods of using the same |
US7332275B2 (en) | 1999-10-13 | 2008-02-19 | Sequenom, Inc. | Methods for detecting methylated nucleotides |
US6855806B1 (en) * | 1999-10-15 | 2005-02-15 | Curagen Corporation | Thymosin beta 10-like proteins and nucleic acids encoding same |
US7591995B2 (en) * | 1999-10-15 | 2009-09-22 | Mayo Foundation For Medical Education And Research | Cobalamin conjugates useful as imaging and therapeutic agents |
JP2003512038A (en) * | 1999-10-19 | 2003-04-02 | キュラジェン コーポレイション | Obesity-related genes and methods for using obesity-related genes |
US20060194958A1 (en) * | 1999-11-10 | 2006-08-31 | Nickolai Alexandrov | Sequence-determined DNA fragments encoding AN1-like zinc finger proteins |
DK1230345T3 (en) | 1999-11-17 | 2008-10-13 | Mendel Biotechnology Inc | Tolerance genes for environmental stress |
EP1950306A1 (en) | 1999-11-17 | 2008-07-30 | Mendel Biotechnology, Inc. | Environmental stress tolerance genes |
DE10100586C1 (en) * | 2001-01-09 | 2002-04-11 | Ribopharma Ag | Inhibiting gene expression in cells, useful for e.g. treating tumors, by introducing double-stranded complementary oligoRNA having unpaired terminal bases |
WO2001039722A2 (en) | 1999-11-30 | 2001-06-07 | Mayo Foundation For Medical Education And Research | B7-h1, a novel immunoregulatory molecule |
US8642284B1 (en) | 1999-12-15 | 2014-02-04 | Massachusetts Institute Of Technology | Methods for identifying agents that alter NAD-dependent deacetylation activity of a SIR2 protein |
US7452664B2 (en) * | 1999-12-15 | 2008-11-18 | Massachusetts Institute Of Technology | Methods for identifying agents which alter histone protein acetylation |
US6682902B2 (en) | 1999-12-16 | 2004-01-27 | Schering Aktiengesellschaft | DNA encoding a novel RG1 polypeptide |
DE60045115D1 (en) | 1999-12-22 | 2010-11-25 | Basf Plant Science Gmbh | Stress-related transcription factor proteins and plant utilization methods |
GB9930616D0 (en) * | 1999-12-24 | 2000-02-16 | Mathilda & Terence Kennedy Ins | Activation and inhibition of the immune system |
JP3365500B2 (en) * | 2000-01-19 | 2003-01-14 | ウシオ電機株式会社 | Narrow band ArF excimer laser device |
CN1247784C (en) | 2000-02-09 | 2006-03-29 | 巴斯福股份公司 | Novel elongase gene and method for producing multiple-unsaturated fatty acids |
AU3811101A (en) * | 2000-02-11 | 2001-08-20 | Lawrence Blatt | Method and reagent for the modulation and diagnosis of cd20 and nogo gene expression |
US8202979B2 (en) * | 2002-02-20 | 2012-06-19 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid |
US7491805B2 (en) * | 2001-05-18 | 2009-02-17 | Sirna Therapeutics, Inc. | Conjugates and compositions for cellular delivery |
US7833992B2 (en) * | 2001-05-18 | 2010-11-16 | Merck Sharpe & Dohme | Conjugates and compositions for cellular delivery |
WO2002081628A2 (en) * | 2001-04-05 | 2002-10-17 | Ribozyme Pharmaceuticals, Incorporated | Modulation of gene expression associated with inflammation proliferation and neurite outgrowth, using nucleic acid based technologies |
EP2143796A3 (en) | 2000-02-29 | 2010-03-17 | Millennium Pharmaceuticals, Inc. | 1983, 52881, 2398, 45449, 50289, and 52872, G protein-coupled receptors and uses therefor |
US20040002068A1 (en) | 2000-03-01 | 2004-01-01 | Corixa Corporation | Compositions and methods for the detection, diagnosis and therapy of hematological malignancies |
JP2003525634A (en) * | 2000-03-03 | 2003-09-02 | キュラジェン コーポレイション | Protein named FCTRX and nucleic acid encoding the same |
US20030065155A1 (en) * | 2000-03-06 | 2003-04-03 | Nassim Usman | Nucleic acid sensor molecules |
US20040009510A1 (en) * | 2000-03-06 | 2004-01-15 | Scott Seiwert | Allosteric nucleic acid sensor molecules |
AU4945001A (en) | 2000-03-22 | 2001-10-03 | Curagen Corp | Angiogenesis associated proteins, and nucleic acids encoding the same |
KR100872884B1 (en) | 2000-03-24 | 2008-12-10 | 바이오스피어 메디칼 인코포레이티드 | Microspheres for active embolization |
US20030212022A1 (en) * | 2001-03-23 | 2003-11-13 | Jean-Marie Vogel | Compositions and methods for gene therapy |
GB0018307D0 (en) | 2000-07-26 | 2000-09-13 | Aventis Pharm Prod Inc | Polypeptides |
ATE354666T1 (en) | 2000-04-07 | 2007-03-15 | Basf Plant Science Gmbh | STRESS-COUPLED GTP-BINDING PROTEIN AND ITS USE IN PLANTS |
US7691991B2 (en) * | 2000-04-17 | 2010-04-06 | Ceres, Inc. | Sequence-determined DNA fragments encoding cytochrome P450 proteins |
US6808876B1 (en) | 2000-05-02 | 2004-10-26 | Immusol, Inc. | Cellular regulators of infectious agents and methods of use |
US20040005554A1 (en) * | 2000-05-08 | 2004-01-08 | Tayar Nabil El | Novel glycoproteins and methods of use thereof |
US20030219786A1 (en) * | 2000-08-11 | 2003-11-27 | Applied Research Systems Ars Holding N.V. | Novel glycoproteins and methods of use thereof |
EP1714661A3 (en) | 2000-05-19 | 2012-03-14 | The Center for Blood Research, INC. | Methods for diagnosing and treating hemostatic disorders by modulating p-selectin activity |
EP1950297A2 (en) | 2000-05-31 | 2008-07-30 | Novartis Vaccines and Diagnostics, Inc. | Compositions and methods for treating neoplastic disease using chemotherapy and radiation sensitizers |
AU2001265268A1 (en) * | 2000-06-01 | 2001-12-11 | Pharmacia And Upjohn Company | Mice heterozygous for wfs1 gene as mouse models for depression |
WO2002000174A2 (en) | 2000-06-28 | 2002-01-03 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of lung cancer |
US6958214B2 (en) * | 2000-07-10 | 2005-10-25 | Sequenom, Inc. | Polymorphic kinase anchor proteins and nucleic acids encoding the same |
US20040023259A1 (en) * | 2000-07-26 | 2004-02-05 | Luca Rastelli | Therapeutic polypeptides, nucleic acids encoding same, and methods of use |
US7198924B2 (en) * | 2000-12-11 | 2007-04-03 | Invitrogen Corporation | Methods and compositions for synthesis of nucleic acid molecules using multiple recognition sites |
WO2002015675A1 (en) | 2000-08-22 | 2002-02-28 | Mendel Biotechnology, Inc. | Genes for modifying plant traits iv |
EP1197550A3 (en) * | 2000-08-25 | 2002-11-20 | Pfizer Products Inc. | Methods and compositions for diagnosing and treating disorders involving angiogenesis |
US20050209179A1 (en) * | 2000-08-30 | 2005-09-22 | Sirna Therapeutics, Inc. | RNA interference mediated treatment of Alzheimer's disease using short interfering nucleic acid (siNA) |
US20080032942A1 (en) * | 2000-08-30 | 2008-02-07 | Mcswiggen James | RNA interference mediated treatment of Alzheimer's disease using short interfering nucleic acid (siNA) |
US20020150936A1 (en) * | 2000-09-01 | 2002-10-17 | Leonid Beigelman | Methods for synthesizing nucleosides, nucleoside derivatives and non-nucleoside derivatives |
AU2001286959B2 (en) | 2000-09-01 | 2007-09-06 | Ribozyme Pharmaceuticals, Incorporated | Methods for synthesizing nucleosides, nucleoside derivatives and non-nucleoside derivatives |
US20040052762A1 (en) * | 2001-09-10 | 2004-03-18 | Hua Yu | Stat3 agonists and antagonists and therapeutic uses thereof |
CA2318517A1 (en) * | 2000-09-15 | 2002-03-15 | Her Majesty In Right Of Canada As Represented By The Minister Of Agricul Of Agriculture And Agri-Food | Modulation of homologous recombination with single stranded dna binding proteins |
UA83458C2 (en) | 2000-09-18 | 2008-07-25 | Байоджен Айдек Ма Інк. | The isolated polypeptide baff-r (the receptor of the factor of activation of b-cells of the family tnf) |
US20110052546A1 (en) * | 2000-09-19 | 2011-03-03 | University Of South Florida | Inhibition of SHIP to Enhance Stem Cell Harvest and Transplantation |
US20020165192A1 (en) * | 2000-09-19 | 2002-11-07 | Kerr William G. | Control of NK cell function and survival by modulation of ship activity |
US20020151525A1 (en) * | 2000-10-25 | 2002-10-17 | Collins Douglas A. | Transcobalamin receptor binding conjugates useful for treating abnormal cellular proliferation |
US6821264B1 (en) | 2000-11-27 | 2004-11-23 | Gautam Khurana | Gene delivery device and gene delivery method |
EP2295606A1 (en) | 2000-11-28 | 2011-03-16 | Wyeth LLC | Expression analysis of KIAA nucleic acids and polypeptides useful in the diagnosis and treatment of prostate cancer |
AU2002241524A1 (en) | 2000-11-28 | 2002-06-11 | Wyeth | Expression analysis of FKBP nucleic acids and polypeptides useful in the diagnosis and treatment of prostate cancer |
JP2004522742A (en) | 2000-12-08 | 2004-07-29 | ベイラー カレッジ オブ メディシン | TREM-1 splice variants for use in modifying an immune response |
CA2431517A1 (en) | 2000-12-12 | 2002-08-01 | University Of Connecticut | Polynucleotides encoding cellular transporters and methods of use thereof |
US20030082647A1 (en) * | 2000-12-12 | 2003-05-01 | Reenan Robert A. | Transporter protein |
US7572575B2 (en) * | 2000-12-13 | 2009-08-11 | Massachusetts Institute Of Technology | SIR2 activity |
JP2004522432A (en) * | 2000-12-22 | 2004-07-29 | シノヴィス・リミテッド | Methods of modulating TOLL-related receptor (TRR) signaling |
US7385046B2 (en) * | 2001-01-03 | 2008-06-10 | Ceres, Inc. | Sequence-determined DNA fragments encoding ethylene responsive element binding proteins |
US7767802B2 (en) * | 2001-01-09 | 2010-08-03 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of anti-apoptotic genes |
ATE502648T1 (en) * | 2001-01-09 | 2011-04-15 | Baylor Res Inst | METHOD FOR TREATING AUTOIMMUNE DISEASES IN A SUBJECT AND DIAGNOSTIC IN VITRO ASSAY |
US7423142B2 (en) | 2001-01-09 | 2008-09-09 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of anti-apoptotic genes |
US6964849B2 (en) | 2001-01-11 | 2005-11-15 | Curagen Corporation | Proteins and nucleic acids encoding same |
US20040043928A1 (en) * | 2001-08-02 | 2004-03-04 | Ramesh Kekuda | Therapeutic polypeptides, nucleic acids encoding same, and methods of use |
CA2438433A1 (en) * | 2001-02-14 | 2002-08-22 | Tularik Inc. | Methods for the diagnosis and treatment of tumors employing the hepsin gene |
ES2328796T3 (en) | 2001-03-14 | 2009-11-18 | Myriad Genetics, Inc. | TSG101-GAG INTERACTION AND USE OF THE SAME. |
US20090081199A1 (en) * | 2001-03-20 | 2009-03-26 | Bioxell S.P.A. | Novel receptor trem (triggering receptor expressed on myeloid cells) and uses thereof |
US8231878B2 (en) * | 2001-03-20 | 2012-07-31 | Cosmo Research & Development S.P.A. | Receptor trem (triggering receptor expressed on myeloid cells) and uses thereof |
CA2342376C (en) * | 2001-03-20 | 2013-11-12 | Marco Colonna | A receptor trem (triggering receptor expressed on myeloid cells) and uses thereof |
US8981061B2 (en) | 2001-03-20 | 2015-03-17 | Novo Nordisk A/S | Receptor TREM (triggering receptor expressed on myeloid cells) and uses thereof |
GB0107510D0 (en) | 2001-03-26 | 2001-05-16 | Univ Bristol | New elongase gene and a process for the production of -9-polyunsaturated fatty acids |
EP1383782A1 (en) * | 2001-03-26 | 2004-01-28 | Sirna Therpeutics, Inc. | Oligonucleotide mediated inhibition of hepatitis b virus and hepatitis c virus replication |
PL367162A1 (en) | 2001-04-02 | 2005-02-21 | Wyeth | Pd-1, a receptor for b7-4, and uses therefor |
US20030148298A1 (en) * | 2001-04-03 | 2003-08-07 | O''toole Margot | Methods for diagnosing and treating systemic lupus erythematosus disease and compositions thereof |
US20040242523A1 (en) * | 2003-03-06 | 2004-12-02 | Ana-Farber Cancer Institue And The Univiersity Of Chicago | Chemo-inducible cancer gene therapy |
US8034791B2 (en) | 2001-04-06 | 2011-10-11 | The University Of Chicago | Activation of Egr-1 promoter by DNA damaging chemotherapeutics |
ES2380007T3 (en) * | 2001-04-06 | 2012-05-07 | The University Of Chicago | Induction by chemotherapeutic agents of the activity of the Egr-1 promoter in gene therapy |
ATE527375T1 (en) | 2001-04-12 | 2011-10-15 | Imp Innovations Ltd | DIAGNOSIS AND TREATMENT OF BREAST CANCER WITH SCN5A |
KR20080081201A (en) | 2001-04-16 | 2008-09-08 | 와이어쓰 홀딩스 코포레이션 | Novel streptococcus pneumoniae open reading frames encoding polypeptide antigens and a composition comprising the same |
US20030017159A1 (en) * | 2001-05-02 | 2003-01-23 | Jerome Ritz | Immunogenic tumor antigens: nucleic acids and polypeptides encoding the same and methods of use thereof |
CA2446112C (en) | 2001-05-08 | 2011-04-26 | Darwin Molecular Corporation | A method for regulating immune function in primates using the foxp3 protein |
US7309783B2 (en) * | 2001-05-09 | 2007-12-18 | The University Of Connecticut | Mammalian early developmental regulator gene |
EP1988097A1 (en) | 2001-05-09 | 2008-11-05 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of prostate cancer |
US20050159380A1 (en) * | 2001-05-18 | 2005-07-21 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of angiopoietin gene expression using short interfering nucleic acid (siNA) |
US20050182006A1 (en) * | 2001-05-18 | 2005-08-18 | Sirna Therapeutics, Inc | RNA interference mediated inhibition of protein kinase C alpha (PKC-alpha) gene expression using short interfering nucleic acid (siNA) |
US20050222066A1 (en) * | 2001-05-18 | 2005-10-06 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA) |
US20050164966A1 (en) * | 2001-05-18 | 2005-07-28 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of type 1 insulin-like growth factor receptor gene expression using short interfering nucleic acid (siNA) |
US20050014172A1 (en) * | 2002-02-20 | 2005-01-20 | Ivan Richards | RNA interference mediated inhibition of muscarinic cholinergic receptor gene expression using short interfering nucleic acid (siNA) |
US20050119212A1 (en) * | 2001-05-18 | 2005-06-02 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of FAS and FASL gene expression using short interfering nucleic acid (siNA) |
US20050196765A1 (en) * | 2001-05-18 | 2005-09-08 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of checkpoint Kinase-1 (CHK-1) gene expression using short interfering nucleic acid (siNA) |
US20070042983A1 (en) * | 2001-05-18 | 2007-02-22 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using short interfering nucleic acid (siNA) |
US20050164967A1 (en) * | 2001-05-18 | 2005-07-28 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of platelet-derived endothelial cell growth factor (ECGF1) gene expression using short interfering nucleic acid (siNA) |
US20040198682A1 (en) * | 2001-11-30 | 2004-10-07 | Mcswiggen James | RNA interference mediated inhibition of placental growth factor gene expression using short interfering nucleic acid (siNA) |
US20050176666A1 (en) * | 2001-05-18 | 2005-08-11 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of GPRA and AAA1 gene expression using short interfering nucleic acid (siNA) |
US20050287128A1 (en) * | 2001-05-18 | 2005-12-29 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of TGF-beta and TGF-beta receptor gene expression using short interfering nucleic acid (siNA) |
US20050233344A1 (en) * | 2001-05-18 | 2005-10-20 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of platelet derived growth factor (PDGF) and platelet derived growth factor receptor (PDGFR) gene expression using short interfering nucleic acid (siNA) |
US20060019913A1 (en) * | 2001-05-18 | 2006-01-26 | Sirna Therapeutics, Inc. | RNA interference mediated inhibtion of protein tyrosine phosphatase-1B (PTP-1B) gene expression using short interfering nucleic acid (siNA) |
US20050159379A1 (en) * | 2001-05-18 | 2005-07-21 | Sirna Therapeutics, Inc | RNA interference mediated inhibition of gastric inhibitory polypeptide (GIP) and gastric inhibitory polypeptide receptor (GIPR) gene expression using short interfering nucleic acid (siNA) |
US20040209831A1 (en) * | 2002-02-20 | 2004-10-21 | Mcswiggen James | RNA interference mediated inhibition of hepatitis C virus (HCV) gene expression using short interfering nucleic acid (siNA) |
US20080188430A1 (en) * | 2001-05-18 | 2008-08-07 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of hypoxia inducible factor 1 (HIF1) gene expression using short interfering nucleic acid (siNA) |
US20050164224A1 (en) * | 2001-05-18 | 2005-07-28 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of cyclin D1 gene expression using short interfering nucleic acid (siNA) |
US20050159376A1 (en) * | 2002-02-20 | 2005-07-21 | Slrna Therapeutics, Inc. | RNA interference mediated inhibition 5-alpha reductase and androgen receptor gene expression using short interfering nucleic acid (siNA) |
WO2002097114A2 (en) * | 2001-05-29 | 2002-12-05 | Sirna Therapeutics, Inc. | Nucleic acid treatment of diseases or conditions related to levels of ras, her2 and hiv |
US20050187174A1 (en) * | 2001-05-18 | 2005-08-25 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of intercellular adhesion molecule (ICAM) gene expression using short interfering nucleic acid (siNA) |
US20050233997A1 (en) * | 2001-05-18 | 2005-10-20 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of matrix metalloproteinase 13 (MMP13) gene expression using short interfering nucleic acid (siNA) |
US7109165B2 (en) * | 2001-05-18 | 2006-09-19 | Sirna Therapeutics, Inc. | Conjugates and compositions for cellular delivery |
US20050282188A1 (en) * | 2001-05-18 | 2005-12-22 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using short interfering nucleic acid (siNA) |
US20050233996A1 (en) * | 2002-02-20 | 2005-10-20 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of hairless (HR) gene expression using short interfering nucleic acid (siNA) |
US20050130181A1 (en) * | 2001-05-18 | 2005-06-16 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of wingless gene expression using short interfering nucleic acid (siNA) |
US20050124567A1 (en) * | 2001-05-18 | 2005-06-09 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of TRPM7 gene expression using short interfering nucleic acid (siNA) |
US20050182007A1 (en) * | 2001-05-18 | 2005-08-18 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of interleukin and interleukin receptor gene expression using short interfering nucleic acid (SINA) |
US7517864B2 (en) * | 2001-05-18 | 2009-04-14 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA) |
US20050153915A1 (en) * | 2001-05-18 | 2005-07-14 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of early growth response gene expression using short interfering nucleic acid (siNA) |
US9994853B2 (en) | 2001-05-18 | 2018-06-12 | Sirna Therapeutics, Inc. | Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference |
EP2415486B1 (en) | 2001-05-18 | 2017-02-22 | Sirna Therapeutics, Inc. | Conjugates and compositions for cellular delivery |
US20050137155A1 (en) * | 2001-05-18 | 2005-06-23 | Sirna Therapeutics, Inc. | RNA interference mediated treatment of Parkinson disease using short interfering nucleic acid (siNA) |
US20070270579A1 (en) * | 2001-05-18 | 2007-11-22 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using short interfering nucleic acid (siNA) |
US20050196767A1 (en) * | 2001-05-18 | 2005-09-08 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of GRB2 associated binding protein (GAB2) gene expression using short interfering nucleic acis (siNA) |
US20050176665A1 (en) * | 2001-05-18 | 2005-08-11 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of hairless (HR) gene expression using short interfering nucleic acid (siNA) |
US20030130186A1 (en) * | 2001-07-20 | 2003-07-10 | Chandra Vargeese | Conjugates and compositions for cellular delivery |
US20050080031A1 (en) * | 2001-05-18 | 2005-04-14 | Sirna Therapeutics, Inc. | Nucleic acid treatment of diseases or conditions related to levels of Ras, HER2 and HIV |
US20050054598A1 (en) * | 2002-02-20 | 2005-03-10 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition hairless (HR) gene expression using short interfering nucleic acid (siNA) |
US20050288242A1 (en) * | 2001-05-18 | 2005-12-29 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of RAS gene expression using short interfering nucleic acid (siNA) |
US20050143333A1 (en) * | 2001-05-18 | 2005-06-30 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of interleukin and interleukin receptor gene expression using short interfering nucleic acid (SINA) |
US20060142226A1 (en) * | 2001-05-18 | 2006-06-29 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of cholesteryl ester transfer protein (CETP) gene expression using short interfering nucleic acid (siNA) |
US20050119211A1 (en) * | 2001-05-18 | 2005-06-02 | Sirna Therapeutics, Inc. | RNA mediated inhibition connexin gene expression using short interfering nucleic acid (siNA) |
US20050124568A1 (en) * | 2001-05-18 | 2005-06-09 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of acetyl-CoA-carboxylase gene expression using short interfering nucleic acid (siNA) |
US20050191638A1 (en) * | 2002-02-20 | 2005-09-01 | Sirna Therapeutics, Inc. | RNA interference mediated treatment of polyglutamine (polyQ) repeat expansion diseases using short interfering nucleic acid (siNA) |
US20060241075A1 (en) * | 2001-05-18 | 2006-10-26 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of desmoglein gene expression using short interfering nucleic acid (siNA) |
US20050209180A1 (en) * | 2001-05-18 | 2005-09-22 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of hepatitis C virus (HCV) expression using short interfering nucleic acid (siNA) |
US20040006035A1 (en) * | 2001-05-29 | 2004-01-08 | Dennis Macejak | Nucleic acid mediated disruption of HIV fusogenic peptide interactions |
US20050176664A1 (en) * | 2001-05-18 | 2005-08-11 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of cholinergic muscarinic receptor (CHRM3) gene expression using short interfering nucleic acid (siNA) |
US20050136436A1 (en) * | 2001-05-18 | 2005-06-23 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of G72 and D-amino acid oxidase (DAAO) gene expression using short interfering nucleic acid (siNA) |
US20050256068A1 (en) * | 2001-05-18 | 2005-11-17 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of stearoyl-CoA desaturase (SCD) gene expression using short interfering nucleic acid (siNA) |
US20080161256A1 (en) * | 2001-05-18 | 2008-07-03 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using short interfering nucleic acid (siNA) |
US20050227935A1 (en) * | 2001-05-18 | 2005-10-13 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of TNF and TNF receptor gene expression using short interfering nucleic acid (siNA) |
US20050182009A1 (en) * | 2001-05-18 | 2005-08-18 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of NF-Kappa B / REL-A gene expression using short interfering nucleic acid (siNA) |
US20050079610A1 (en) * | 2001-05-18 | 2005-04-14 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of Fos gene expression using short interfering nucleic acid (siNA) |
US20050153914A1 (en) * | 2001-05-18 | 2005-07-14 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of MDR P-glycoprotein gene expression using short interfering nucleic acid (siNA) |
WO2002095002A2 (en) | 2001-05-22 | 2002-11-28 | University Of Chicago | N4 virion single-stranded dna dependent rna polymerase |
NZ529597A (en) * | 2001-05-30 | 2005-12-23 | Chromos Molecular Systems Inc | Plant artificial chromosomes, uses thereof and methods of preparing plant artificial chromosomes |
CN1535315A (en) | 2001-05-31 | 2004-10-06 | ����ֲ | Compositions and methods of increasing stress tolerance in plants |
AU2002305858B2 (en) | 2001-06-04 | 2007-08-23 | Basf Plant Science Gmbh | Sugar and lipid metabolism regulators in plants II |
EP1925671A1 (en) | 2001-06-06 | 2008-05-28 | Bioriginal Food & Science Corp. | Flax (Linum usitatissimum L.) seed-specific promoters |
US7193134B2 (en) | 2001-06-06 | 2007-03-20 | Bioriginal Food & Science Corp. | Flax (Linum usitatissimum L.) fatty acid desaturase |
CA2449649A1 (en) * | 2001-06-07 | 2002-12-19 | Wyeth | A g-protein coupled receptor and uses therefor |
US20030140362A1 (en) * | 2001-06-08 | 2003-07-24 | Dennis Macejak | In vivo models for screening inhibitors of hepatitis B virus |
US20030087274A1 (en) * | 2001-07-05 | 2003-05-08 | Anderson David W. | Therapeutic polypeptides, nucleic acids encoding same, and methods of use |
GB0116249D0 (en) * | 2001-07-05 | 2001-08-29 | Imp College Innovations Ltd | Methods |
US20030129613A1 (en) * | 2001-07-05 | 2003-07-10 | Fernandes Elma R. | Novel human proteins and polynucleotides encoding them |
US20040029790A1 (en) * | 2001-07-05 | 2004-02-12 | Meera Patturajan | Novel human proteins, polynucleotides encoding them and methods of using the same |
US7205399B1 (en) | 2001-07-06 | 2007-04-17 | Sirna Therapeutics, Inc. | Methods and reagents for oligonucleotide synthesis |
WO2003006025A1 (en) * | 2001-07-09 | 2003-01-23 | Mayo Foundation For Medical Education And Research | Methods and materials for treating bone conditions |
CA2452633A1 (en) | 2001-07-12 | 2003-01-23 | Mcgill University | Nuclear fertility restorer genes and methods of use in plants |
US8022272B2 (en) | 2001-07-13 | 2011-09-20 | Sungene Gmbh & Co. Kgaa | Expression cassettes for transgenic expression of nucleic acids |
AU2002313699A1 (en) * | 2001-07-20 | 2003-03-03 | Ribozyme Pharmacuticals, Inc. | Enzymatic nucleic acid peptide conjugates |
ATE481497T1 (en) * | 2001-08-01 | 2010-10-15 | Univ Utah | N-TERMINUS TRUNCATED ISOFORMS OF CYCLIC PHOSPHODIESTERASES PDE3A |
US20040030096A1 (en) * | 2001-08-02 | 2004-02-12 | Linda Gorman | Novel human proteins, polynucleotides encoding them and methods of using the same |
AU2002326613B2 (en) | 2001-08-10 | 2007-06-14 | Basf Plant Science Gmbh | Sugar and lipid metabolism regulators in plants III |
US20030082140A1 (en) * | 2001-08-20 | 2003-05-01 | Fisher Paul B. | Combinatorial methods for inducing cancer cell death |
CA2459183A1 (en) * | 2001-08-27 | 2003-03-06 | Tularik Inc. | Amplified oncogenes and their involvement in cancer |
AU2002324792A1 (en) * | 2001-08-27 | 2003-03-10 | Tularik Inc. | Amplified gene involved in cancer |
US7270960B2 (en) | 2001-08-29 | 2007-09-18 | Pacific Northwest Research Institute | Diagnosis of ovarian carcinomas |
US7456335B2 (en) * | 2001-09-03 | 2008-11-25 | Basf Plant Science Gmbh | Nucleic acid sequences and their use in methods for achieving pathogen resistance in plants |
WO2003020914A2 (en) | 2001-09-05 | 2003-03-13 | Basf Plant Science Gmbh | Protein phosphatase stress-related polypeptides and methods of use in plants |
US20030050266A1 (en) * | 2001-09-07 | 2003-03-13 | Fisher Paul B. | Anti-tumor effects of prostate carcinoma tumor antigen-1 |
US20060068405A1 (en) * | 2004-01-27 | 2006-03-30 | Alex Diber | Methods and systems for annotating biomolecular sequences |
US20040142325A1 (en) * | 2001-09-14 | 2004-07-22 | Liat Mintz | Methods and systems for annotating biomolecular sequences |
CA2461705A1 (en) * | 2001-09-28 | 2003-04-03 | Mayo Foundation For Medical Education And Research | Coadministration of transport protein with conjugated cobalamin to deliver agents |
US20030199442A1 (en) * | 2001-10-09 | 2003-10-23 | Alsobrook John P. | Therapeutic polypeptides, nucleic acids encoding same, and methods of use |
CA2464527A1 (en) * | 2001-10-26 | 2003-08-14 | Id Biomedical Corporation Of Washington | Multivalent streptococcal vaccine compositions and methods for use |
AU2002367785A1 (en) * | 2001-11-05 | 2003-11-03 | Sirna Therapeutics, Inc | Allosteric nucleic acid sensor molecules |
US7220585B2 (en) | 2001-11-09 | 2007-05-22 | Basf Plant Science Gmbh | Transcription factor stress-related polypeptides and methods of use in plants |
WO2003040171A2 (en) | 2001-11-09 | 2003-05-15 | Basf Plant Science Gmbh | Protein kinase stress-related polypeptides and methods of use in plants |
WO2003044161A2 (en) * | 2001-11-15 | 2003-05-30 | Tularik Inc. | Gene amplification and overexpression in cancer |
WO2003050241A2 (en) | 2001-12-12 | 2003-06-19 | The Government Of The United States Of America As Represented By The Secretary, Department Of Healthand Human Services | Methods for using extracellular adenosine inhibitors and adenosine receptor inhibitors to enhance immune response and inflammation |
ES2405790T3 (en) | 2001-12-17 | 2013-06-03 | Corixa Corporation | Compositions and methods for therapy and diagnosis of inflammatory bowel disease |
US20030170691A1 (en) * | 2001-12-19 | 2003-09-11 | Millennium Pharmaceuticals, Inc. | Human diacylglycerol acyltransferase 2 (DGAT2) family members and uses therefor |
EP1463834A4 (en) * | 2001-12-20 | 2005-08-10 | Tularik Inc | Identification of an amplified gene and target for drug intervention |
US20060084056A1 (en) | 2002-02-13 | 2006-04-20 | Nadia Harbeck | Methods for selecting treatment regimens and predicting outcomes in cancer patients |
US20050042632A1 (en) * | 2002-02-13 | 2005-02-24 | Sirna Therapeutics, Inc. | Antibodies having specificity for nucleic acids |
US7071311B2 (en) * | 2002-02-13 | 2006-07-04 | Sirna Therapeutics, Inc. | Antibodies having specificity for 2′-C-allyl nucleic acids |
US20030235533A1 (en) * | 2002-02-19 | 2003-12-25 | Idec Pharmaceuticals Corporation | Prostate specific genes and the use thereof in design or therapeutics |
US9181551B2 (en) | 2002-02-20 | 2015-11-10 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
US20050222064A1 (en) * | 2002-02-20 | 2005-10-06 | Sirna Therapeutics, Inc. | Polycationic compositions for cellular delivery of polynucleotides |
US20050137153A1 (en) * | 2002-02-20 | 2005-06-23 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of alpha-1 antitrypsin (AAT) gene expression using short interfering nucleic acid (siNA) |
WO2003106476A1 (en) * | 2002-02-20 | 2003-12-24 | Sirna Therapeutics, Inc | Nucleic acid mediated inhibition of enterococcus infection and cytolysin toxin activity |
US9657294B2 (en) | 2002-02-20 | 2017-05-23 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
GB2385852A (en) | 2002-02-27 | 2003-09-03 | Rothamsted Ex Station | Delta 6-desaturases from Primulaceae |
CA2374388C (en) | 2002-02-28 | 2005-07-12 | Matthew C. Coffey | The use of ribozymes in the detection of adventitious agents |
US20040005546A1 (en) * | 2002-02-28 | 2004-01-08 | Oncolytics Biotech Inc. | Use of ribozymes in the detection of adventitious agents |
US7153685B2 (en) * | 2002-03-11 | 2006-12-26 | The Board Of Trustees Of The University Of Illinois | Tamoxifen and 4-hydroxytamoxifen-activated system for regulated production of proteins in eukaryotic cells |
AU2003221506A1 (en) * | 2002-03-19 | 2003-09-29 | Novartis Ag | Methods for the identification of compounds useful for the suppression of chronic neuropathic pain and compositions thereof |
EP1497642A2 (en) * | 2002-03-19 | 2005-01-19 | Tularik, Inc. | Gene amplification in cancer |
DE10212892A1 (en) | 2002-03-20 | 2003-10-09 | Basf Plant Science Gmbh | Constructs and methods for regulating gene expression |
US7357928B2 (en) * | 2002-04-08 | 2008-04-15 | University Of Louisville Research Foundation, Inc. | Method for the diagnosis and prognosis of malignant diseases |
US7541150B2 (en) * | 2002-04-08 | 2009-06-02 | University Of Louisville Research Foundation, Inc | Method for the diagnosis and prognosis of malignant diseases |
US7226771B2 (en) | 2002-04-19 | 2007-06-05 | Diversa Corporation | Phospholipases, nucleic acids encoding them and methods for making and using them |
BR0309391A (en) | 2002-04-19 | 2005-10-25 | Diversa Corp | Phospholipases, nucleic acids encoding them and methods for preparing and using them |
US20030199464A1 (en) | 2002-04-23 | 2003-10-23 | Silviu Itescu | Regeneration of endogenous myocardial tissue by induction of neovascularization |
AU2003237159A1 (en) * | 2002-04-30 | 2003-11-17 | University Of Florida | Treatment for phenylketonuria |
US7432342B2 (en) * | 2002-05-03 | 2008-10-07 | Sequenom, Inc. | Kinase anchor protein muteins, peptides thereof and related documents |
US20040005615A1 (en) * | 2002-05-24 | 2004-01-08 | Jing Li | Amplification and overexpression of oncogenes |
US6949365B2 (en) * | 2002-06-12 | 2005-09-27 | University Of New Hampshire | Polynucleotides encoding lamprey GnRH-III |
WO2004003150A2 (en) | 2002-06-26 | 2004-01-08 | Yale University | Modulators and modulation of the interacton between rgm and neogenin |
US20040132049A1 (en) * | 2002-06-26 | 2004-07-08 | Bates Paula J. | Method for the detection of apoptosis |
US7655790B2 (en) * | 2002-07-12 | 2010-02-02 | Sirna Therapeutics, Inc. | Deprotection and purification of oligonucleotides and their derivatives |
US6989442B2 (en) * | 2002-07-12 | 2006-01-24 | Sirna Therapeutics, Inc. | Deprotection and purification of oligonucleotides and their derivatives |
AU2003253992A1 (en) * | 2002-07-18 | 2004-02-09 | Robert P. Bennett | Viral vectors containing recombination sites |
EP1527183B1 (en) | 2002-07-26 | 2008-08-20 | BASF Plant Science GmbH | Novel selection method |
US7057087B2 (en) * | 2002-07-26 | 2006-06-06 | Board Of Control Of Michigan Technological University | Application of aspen MADS-box genes to alter reproduction and development in trees |
EP2272966A3 (en) | 2002-08-02 | 2011-07-06 | BASF Plant Science GmbH | Sugar and lipid metabolism regulators in plants IV |
AU2003246349B2 (en) | 2002-08-07 | 2011-02-03 | Basf Plant Science Gmbh | Nucleic acid sequences encoding proteins associated with abiotic stress response |
US20050059011A1 (en) * | 2002-08-07 | 2005-03-17 | Sin Wun Chey | Amplification and overexpression of oncogenes |
US7977049B2 (en) | 2002-08-09 | 2011-07-12 | President And Fellows Of Harvard College | Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms |
ATE519862T1 (en) | 2002-08-20 | 2011-08-15 | Millennium Pharm Inc | COMPOSITIONS, KITS AND METHODS FOR THE IDENTIFICATION, ASSESSMENT, PREVENTION AND THERAPY OF CERVICAL CANCER |
US7265264B2 (en) * | 2002-08-28 | 2007-09-04 | Washington University | Gene for a Dof transcription factor capable of altering the size and stature of a plant |
US20080214437A1 (en) * | 2002-09-06 | 2008-09-04 | Mohapatra Shyam S | Methods and compositions for reducing activity of the atrial natriuretic peptide receptor and for treatment of diseases |
US8071560B2 (en) * | 2004-02-17 | 2011-12-06 | University Of South Florida | Materials and methods for reducing inflammation by inhibition of the atrial natriuretic peptide receptor |
US20080260744A1 (en) * | 2002-09-09 | 2008-10-23 | Omeros Corporation | G protein coupled receptors and uses thereof |
CA2498264A1 (en) * | 2002-09-09 | 2004-05-13 | Nura, Inc. | G protein coupled receptors and uses thereof |
US20040052161A1 (en) * | 2002-09-17 | 2004-03-18 | Steven Liao | Mechanical clock having wireless manipulation and adjustment function |
EP1546170A4 (en) * | 2002-09-20 | 2007-08-29 | Univ Yale | Riboswitches, methods for their use, and compositions for use with riboswitches |
JP2006503110A (en) * | 2002-10-09 | 2006-01-26 | トーラーレックス, インク. | Molecules that selectively bind to effector T cells or regulatory T cells and methods of use thereof |
WO2004036188A2 (en) * | 2002-10-18 | 2004-04-29 | Cylene Pharmaceuticals, Inc. | Processes for identifying quadruplex-targeted antiviral molecules |
WO2004041197A2 (en) * | 2002-11-01 | 2004-05-21 | Case Western Reserve University | Methods of inhibiting glial scar formation |
US20040086892A1 (en) * | 2002-11-06 | 2004-05-06 | Crothers Donald M. | Universal tag assay |
EP2112229A3 (en) | 2002-11-25 | 2009-12-02 | Sequenom, Inc. | Methods for identifying risk of breast cancer and treatments thereof |
US20060100131A1 (en) * | 2002-12-10 | 2006-05-11 | Lynn Megeney | Modulation of stem cell differentiation by modulation of caspase-3 activity |
AU2003296945A1 (en) * | 2002-12-12 | 2004-07-09 | Chiron Corporation | Device and method for in-line blood testing using biochips |
US20040231231A1 (en) * | 2002-12-20 | 2004-11-25 | Cataldo Dominic A. | Use of colloidal clays for sustained release of active ingredients |
CN101018864A (en) | 2002-12-26 | 2007-08-15 | 先正达合作有限公司 | Cell proliferation-related polypeptides and uses therefor |
JP2006517790A (en) * | 2003-01-09 | 2006-08-03 | インヴィトロジェン コーポレーション | Cellular delivery and activation of polypeptide-nucleic acid complexes |
US20040235019A1 (en) * | 2003-03-06 | 2004-11-25 | Agouron Pharmaceuticals, Inc. | Diagnostics and therapeutics for the gene expression signature of PPAR-gamma receptor ligand |
EP3023498B1 (en) | 2003-03-06 | 2018-11-28 | BASF Enzymes LLC | Amylases, nucleic acids encoding them and methods for making and using them |
US7638122B2 (en) * | 2003-03-07 | 2009-12-29 | University Of South Florida | Stat3 antagonists and their use as vaccines against cancer |
US20070141570A1 (en) * | 2003-03-07 | 2007-06-21 | Sequenom, Inc. | Association of polymorphic kinase anchor proteins with cardiac phenotypes and related methods |
BRPI0408157B8 (en) | 2003-03-07 | 2021-05-25 | Dsm Food Specialties B V | recombinant nucleic acid, recombinant polypeptide with lipase activity, transformed cell, methods employing them and composition |
JP2006523209A (en) | 2003-03-12 | 2006-10-12 | アリゾナ ボード オブ リージェンツ オン ビハーフ オブ ザ ユニバーシティー オブ アリゾナ | Method for modulating angiogenesis by an apelin composition |
CA2520510A1 (en) * | 2003-03-27 | 2004-10-14 | Ptc Therapeutics, Inc. | Methods of identifying compounds that target trna splicing endonuclease and uses of said compounds as anti-fungal agents |
EP2363025A1 (en) * | 2003-03-27 | 2011-09-07 | PTC Therapeutics, Inc. | Targeting enzymes of the TRNA splicing pathway for identification of anti-fungal and/or anti-proliferative molecules |
WO2004087069A2 (en) * | 2003-03-27 | 2004-10-14 | Ptc Therapeutics, Inc. | METHODS OF IDENTIFYING COMPOUNDS THAT TARGET tRNA SPLICING ENDONUCLEASE AND USES OF SAID COMPOUNDS AS ANTI-PROLIFERATIVE AGENTS |
ES2545639T3 (en) | 2003-04-04 | 2015-09-14 | Basf Enzymes Llc | Pectate liases, nucleic acids that encode them and methods for their preparation and use |
US20040223971A1 (en) * | 2003-04-07 | 2004-11-11 | Glycogenesys, Inc. | Composition and uses of galectin antagonists |
EP2194135A3 (en) | 2003-04-15 | 2010-10-06 | BASF Plant Science GmbH | Nucleic acid sequences from yeast encoding proteins associated with abiotic stress response and transformed plant cells and plants with increased tolerance to environmental stress |
JP4850698B2 (en) | 2003-04-25 | 2012-01-11 | ノース・キャロライナ・ステイト・ユニヴァーシティ | Lactobacillus acidophilus nucleic acid sequences encoding cell surface protein homologues and uses thereof |
EP1622572B1 (en) | 2003-04-30 | 2017-12-20 | Sirna Therapeutics, Inc. | Conjugates and compositions for cellular delivery |
EP3552627A1 (en) * | 2003-05-06 | 2019-10-16 | Bioverativ Therapeutics Inc. | Clotting factor-fc chimeric proteins to treat hemophilia |
TWI353991B (en) * | 2003-05-06 | 2011-12-11 | Syntonix Pharmaceuticals Inc | Immunoglobulin chimeric monomer-dimer hybrids |
US7348004B2 (en) * | 2003-05-06 | 2008-03-25 | Syntonix Pharmaceuticals, Inc. | Immunoglobulin chimeric monomer-dimer hybrids |
BRPI0410787A (en) * | 2003-05-21 | 2006-06-20 | Univ Texas | c-mu protein kinase (pkd) inhibition as a treatment for cardiac hypertrophy and heart failure |
EP2264170B1 (en) | 2003-05-21 | 2017-02-08 | Andes Biotechnologies S.A. | Markers for pre-cancer and cancer cells and the method to interfere with cell proliferation therein |
US20070010008A1 (en) * | 2005-06-29 | 2007-01-11 | Tissuetech, Inc. | Ex vivo expansion of primary animal cells |
US20040241657A1 (en) * | 2003-05-28 | 2004-12-02 | Perlegen Sciences, Inc. | Liver related disease compositions and methods |
US20050026194A1 (en) * | 2003-06-20 | 2005-02-03 | Tularik Inc. | Gene amplification and overexpression in cancer |
EP1651750B1 (en) | 2003-06-23 | 2011-04-06 | North Carolina State University | Lactobacillus acidophilus nucleic acids encoding fructo-oligosaccharide utilization compounds and uses thereof |
EP2295586A3 (en) | 2003-06-27 | 2011-06-29 | Chromatin, Inc. | Plant centromere compositions |
BR0318377A (en) | 2003-06-27 | 2006-07-25 | Chromatin Inc | plant centromere compositions |
JP4990621B2 (en) * | 2003-07-02 | 2012-08-01 | ピーティーシー セラピューティクス,インコーポレーテッド | RNA processing protein complex and use thereof |
EP2404929B1 (en) | 2003-07-02 | 2014-06-18 | BP Corporation North America Inc. | Glucanases, nucleic acids encoding them and methods for making and using them |
US20050136429A1 (en) * | 2003-07-03 | 2005-06-23 | Massachusetts Institute Of Technology | SIRT1 modulation of adipogenesis and adipose function |
EP1660631B1 (en) | 2003-08-01 | 2013-04-24 | Life Technologies Corporation | Compositions and methods for purifying short rna molecules |
EP1654368A2 (en) | 2003-08-01 | 2006-05-10 | BASF Plant Science GmbH | Process for the production of fine chemicals |
EP1654383A1 (en) * | 2003-08-08 | 2006-05-10 | Licentia, Ltd. | Materials and methods for colorectal cancer screening, diagnosis, and therapy |
EP1687323A4 (en) | 2003-08-08 | 2009-08-12 | Life Technologies Corp | Methods and compositions for seamless cloning of nucleic acid molecules |
EP1668111A4 (en) | 2003-08-08 | 2008-07-02 | Genenews Inc | Osteoarthritis biomarkers and uses thereof |
WO2005021714A2 (en) | 2003-08-11 | 2005-03-10 | Diversa Corporation | Laccases, nucleic acids encoding them and methods for making and using them |
IN234535B (en) | 2003-08-11 | 2009-07-17 | Kweek En Researchbed Agrico Bv | |
EP1675454A4 (en) * | 2003-08-19 | 2007-03-21 | 22Nd Century Ltd Llc | Reduced-exposure tobacco products |
CA2536086C (en) | 2003-08-20 | 2013-03-19 | University Of Miami | Inhibition of dr3 in the treatment of allergic lung inflammation |
WO2005074417A2 (en) * | 2003-09-03 | 2005-08-18 | Salk Institute For Biological Studies | Multiple antigen detection assays and reagents |
GB0322689D0 (en) * | 2003-09-27 | 2003-10-29 | Medical Res Council | Methods |
CN102517381A (en) | 2003-10-07 | 2012-06-27 | 千年药品公司 | Nucleic acid molecules and proteins for the identification, assessment, prevention, and therapy of ovarian cancer |
CN1910293B (en) | 2003-10-23 | 2011-04-13 | 伊洛默格生物科学公司 | Detection of mutations in a gene associated with resistance to viral infection, OASI |
US20050287668A1 (en) * | 2003-11-04 | 2005-12-29 | Cell Therapeutics, Inc. (Cti) | RNA interference compositions and screening methods for the identification of novel genes and biological pathways |
US20050164969A1 (en) * | 2003-11-19 | 2005-07-28 | Massachusetts Institute Of Technology | Method of extending life span |
US7807646B1 (en) * | 2003-11-20 | 2010-10-05 | University Of South Florida | SHIP-deficiency to increase megakaryocyte progenitor production |
WO2005052194A2 (en) * | 2003-11-24 | 2005-06-09 | Amgen Inc. | Gene amplification and overexpression in cancer |
WO2005054438A2 (en) * | 2003-12-01 | 2005-06-16 | Invitrogen Corporation | Nucleic acid molecules containing recombination sites and methods of using the same |
CA2487098A1 (en) * | 2003-12-22 | 2005-06-22 | F. Hoffmann-La Roche Ag | Novel targets for obesity from fat tissue |
CA2487107A1 (en) * | 2003-12-22 | 2005-06-22 | F. Hoffmann-La Roche Ag | Novel targets for obesity from skeletal muscle |
CA2805816A1 (en) | 2003-12-23 | 2005-07-14 | Basf Plant Science Gmbh | Transgenic plants expressing a putative palmitoyl protein thioesterase |
US20050155097A1 (en) * | 2004-01-12 | 2005-07-14 | Lee James J. | Eosinophil-deficient transgenic animals |
AU2005206389A1 (en) * | 2004-01-27 | 2005-08-04 | Compugen Ltd. | Methods of identifying putative gene products by interspecies sequence comparison and biomolecular sequences uncovered thereby |
US20050226947A1 (en) * | 2004-02-04 | 2005-10-13 | Dale Kern | Agents for sequestering serum aging factors and uses therefore |
US20060235212A1 (en) * | 2004-12-22 | 2006-10-19 | Nickolai Alexandrov | Nucleic acid sequences encoding zinc finger proteins |
WO2005078139A2 (en) | 2004-02-09 | 2005-08-25 | Thomas Jefferson University | DIAGNOSIS AND TREATMENT OF CANCERS WITH MicroRNA LOCATED IN OR NEAR CANCER-ASSOCIATED CHROMOSOMAL FEATURES |
WO2005094420A2 (en) * | 2004-02-17 | 2005-10-13 | University Of South Florida | Materials and methods for treatment of inflammatory and cell proliferation disorders |
JP2008506356A (en) | 2004-02-24 | 2008-03-06 | アメリカ合衆国 | RAB9A, RAB11A, and these modulators for infectious diseases |
WO2005082415A2 (en) * | 2004-02-25 | 2005-09-09 | Dana Farber Cancer Institute, Inc. | Inhibitors of insulin-like growth factor receptor-1 for inhibiting tumor cell growth |
US7459289B2 (en) | 2004-03-08 | 2008-12-02 | North Carolina State University | Lactobacillus acidophilus nucleic acid sequences encoding carbohydrate utilization-related proteins and uses therefor |
GB0406415D0 (en) | 2004-03-22 | 2004-04-21 | Inst Of Cancer Res The | Materials and methods for treatment of cancer |
US20060292554A1 (en) * | 2004-05-18 | 2006-12-28 | Genentech, Inc. | Major coat protein variants for C-terminal and bi-terminal display |
MXPA06013483A (en) * | 2004-05-19 | 2007-01-23 | Wyeth Corp | Modulation of immunoglobulin production and atopic disorders. |
US10508277B2 (en) | 2004-05-24 | 2019-12-17 | Sirna Therapeutics, Inc. | Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference |
EP1774031A2 (en) * | 2004-05-26 | 2007-04-18 | Wisconsin Alumni Research Foundation | Cancer treatment method by inhibiting mage gene expression or function |
US7323347B2 (en) * | 2004-05-27 | 2008-01-29 | Sensata Technologies, Inc. | Biosensor surface structures and methods |
EP1602926A1 (en) | 2004-06-04 | 2005-12-07 | University of Geneva | Novel means and methods for the treatment of hearing loss and phantom hearing |
WO2006007432A2 (en) | 2004-06-16 | 2006-01-19 | Basf Plant Science Gmbh | Nucleic acid molecules encoding wrinkled1-like polypeptides and methods of use in plants |
CN103173282A (en) | 2004-06-16 | 2013-06-26 | 帝斯曼知识产权资产管理有限公司 | Compositions and methods for enzymatic decolorization of chlorophyll |
WO2006069610A2 (en) | 2004-07-02 | 2006-07-06 | Metanomics Gmbh | Process for the production of fine chemicals |
WO2006014798A2 (en) * | 2004-07-27 | 2006-02-09 | Mount Sinai School Of Medicine | Methods and compositions for using sax2 |
EP1789437A4 (en) * | 2004-07-30 | 2008-11-05 | Sinai School Medicine | Npc1l1 and npc1l1 inhibitors and methods of use thereof |
EP1781784A2 (en) | 2004-08-02 | 2007-05-09 | BASF Plant Science GmbH | Method for isolation of transcription termination sequences |
WO2006020684A2 (en) | 2004-08-10 | 2006-02-23 | Institute For Multiple Myeloma And Bone Cancer Research | Methods of regulating differentiation and treating of multiple myeloma |
AU2005276145C1 (en) | 2004-08-26 | 2011-01-06 | Engeneic Molecular Delivery Pty Ltd | Delivering functional nucleic acids to mammalian cells via bacterially derived, intact minicells |
AU2005276144B2 (en) | 2004-08-26 | 2010-08-05 | The University Of Western Ontario | Pharmaceutical compositions comprising inhibitors of iron transport, and method of identifying iron transport inhibitors, FN Staphylococcus aureus |
US7595433B2 (en) | 2004-09-14 | 2009-09-29 | Ceres, Inc. | Modulations of amino acid and sugar content in plants |
US20060059585A1 (en) * | 2004-09-14 | 2006-03-16 | Boris Jankowski | Modulating plant sugar levels |
US20060063187A1 (en) * | 2004-09-15 | 2006-03-23 | Hotamisligil Gokhan S | Modulation of XBP-1 activity for treatment of metabolic disorders |
FI20041204A0 (en) | 2004-09-16 | 2004-09-16 | Riikka Lund | Methods for the utilization of new target genes associated with immune-mediated diseases |
ATE486606T1 (en) | 2004-09-18 | 2010-11-15 | Univ Maryland | THERAPEUTIC AGENTS FOR TARGETING THE NCCA ATP CHANNEL AND METHOD OF USE THEREOF |
CN101076594A (en) | 2004-09-20 | 2007-11-21 | 巴斯福植物科学有限公司 | Arabidopsis genes encoding proteins involved in sugar and lipid metabolism and methods of use |
CA2579800A1 (en) | 2004-09-24 | 2006-03-30 | Basf Plant Science Gmbh | Nucleic acid sequences encoding proteins associated with abiotic stress response and plant cells and plants with increased tolerance to environmental stress |
CA2579927A1 (en) | 2004-09-24 | 2006-03-30 | Basf Plant Science Gmbh | Plant cells and plants with increased tolerance to environmental stress |
GB0421639D0 (en) | 2004-09-29 | 2004-10-27 | Proteome Sciences Plc | Methods and compositions relating to alzheimer's disease |
AU2005295038B2 (en) | 2004-10-06 | 2012-05-17 | Mayo Foundation For Medical Education And Research | B7-H1 and methods of diagnosis, prognosis, and treatment of cancer |
US7429692B2 (en) * | 2004-10-14 | 2008-09-30 | Ceres, Inc. | Sucrose synthase 3 promoter from rice and uses thereof |
WO2006055635A2 (en) * | 2004-11-15 | 2006-05-26 | Mount Sinai School Of Medicine Of New York University | Compositions and methods for altering wnt autocrine signaling |
GB0426146D0 (en) | 2004-11-29 | 2004-12-29 | Bioxell Spa | Therapeutic peptides and method |
US9758790B2 (en) | 2004-12-08 | 2017-09-12 | Ceres, Inc. | Modulating the level of components within plants |
US7329797B2 (en) * | 2004-12-08 | 2008-02-12 | Ceres, Inc. | Modulating plant carbon levels |
WO2007050625A1 (en) * | 2005-10-25 | 2007-05-03 | Ceres, Inc. | Modulation of triterpenoid content in plants |
NZ561148A (en) | 2004-12-08 | 2008-12-24 | Sirion Therapeutics Inc | Methods, assays and compositions for treating retinol-related diseases |
AU2005316863A1 (en) * | 2004-12-16 | 2006-06-22 | Ceres Inc. | Modulating plant nitrogen levels |
EP1974049A2 (en) | 2004-12-17 | 2008-10-01 | Metanomics GmbH | Process for the control of production of fine chemicals |
EP1846444A2 (en) * | 2004-12-22 | 2007-10-24 | Lipopeptide AB | Agents inhibiting the cathelin-like protein cap18/ll-37 |
US7335760B2 (en) * | 2004-12-22 | 2008-02-26 | Ceres, Inc. | Nucleic acid sequences encoding zinc finger proteins |
MX2007007948A (en) | 2004-12-28 | 2007-09-11 | Pioneer Hi Bred Int | Improved grain quality through altered expression of seed proteins. |
US7554018B2 (en) | 2005-01-14 | 2009-06-30 | University Of Guelph | Nitrogen-regulated sugar sensing gene and protein and modulation thereof |
US7718625B2 (en) * | 2005-01-27 | 2010-05-18 | University Of South Florida | Polynucleotides targeted against the extended 5′-UTR region of argininosuccinate synthase and uses thereof |
US8455437B2 (en) | 2005-02-04 | 2013-06-04 | The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services | Method to predict and prevent oxygen-induced inflammatory tissue injury |
WO2006086242A2 (en) | 2005-02-07 | 2006-08-17 | Genenews, Inc. | Mild osteoarthritis biomarkers and uses thereof |
WO2006084352A1 (en) | 2005-02-09 | 2006-08-17 | Bioriginal Food & Science Corp. | Novel omega-3 fatty acid desaturase family members and uses thereof |
WO2006086681A2 (en) * | 2005-02-09 | 2006-08-17 | Beth Israel Deaconess Medical Center, Inc. | Methods of inhibiting smooth muscle cell migration and proliferation |
AU2006213610B2 (en) | 2005-02-10 | 2012-04-05 | Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Diagnosing and treating cancer using beta-catenin splice variants |
WO2006123246A2 (en) * | 2005-02-11 | 2006-11-23 | Aurelium Biopharma Inc. | Methods for identifying chemotherapeutic resistance in non-hematopoietic tumors |
CA2597411C (en) | 2005-02-14 | 2014-08-12 | University Of Iowa Research Foundation | Use of complement factor h polymorphisms in treatment and diagnosis of age-related macular degeneration |
CA2597945C (en) | 2005-02-17 | 2016-07-12 | Biogen Idec Ma Inc. | Treating neurological disorders |
US7531523B2 (en) * | 2005-02-17 | 2009-05-12 | Vertex Pharmaceuticals Incorporated | Sodium channel protein type III alpha-subunit splice variant |
AU2006216715A1 (en) * | 2005-02-22 | 2006-08-31 | Ceres Inc. | Modulating plant alkaloids |
WO2006091194A1 (en) | 2005-02-23 | 2006-08-31 | North Carolina State University | Alteration of tobacco alkaloid content through modification of specific cytochrome p450 genes |
WO2006091459A2 (en) | 2005-02-24 | 2006-08-31 | Joslin Diabetes Center, Inc. | Compositions and methods for treating vascular permeability |
EP2886658A1 (en) | 2005-03-10 | 2015-06-24 | BASF Enzymes LLC | Lyase enzymes, nucleic acids encoding them and methods for making and using them |
BRPI0609140A2 (en) | 2005-03-15 | 2010-02-17 | Verenium Corp | cellulases, nucleic acids that encode them and methods for their production and use |
KR20140068234A (en) | 2005-03-31 | 2014-06-05 | 더 제너럴 하스피탈 코포레이션 | Monitoring and modulating hgf/hgfr activity |
WO2006113559A2 (en) | 2005-04-15 | 2006-10-26 | President And Fellows Of Harvard College | Methods for modulating bone formation and mineralization by modulating krc activity |
WO2006115575A1 (en) * | 2005-04-20 | 2006-11-02 | Ceres Inc. | Regulatory regions from papaveraceae |
US20070099830A1 (en) | 2005-04-21 | 2007-05-03 | Massachusetts Institute Of Technology | Sirt4 activities |
US8071559B2 (en) * | 2005-05-02 | 2011-12-06 | Cold Spring Harbor Laboratory | Compositions and methods for cancer diagnosis and treatment |
US7585818B2 (en) * | 2005-05-10 | 2009-09-08 | Halliburton Energy Services, Inc. | Nonnatural galactomannans and methods of use |
EP1893043A4 (en) | 2005-05-11 | 2013-07-31 | Vector Tobacco Inc | Reduced risk tobacco products and methods of making same |
BRPI0610419A2 (en) * | 2005-05-17 | 2012-10-23 | Cargill Inc | granular lecithin, lysolecithin, process for producing granular lecithin, granular composition, process for producing a granular lecithin composition, product, and, processes for producing granular lysolecithin and for producing a granular lysolecithin composition |
EP1896595A2 (en) | 2005-05-25 | 2008-03-12 | Pioneer-Hi-Bred International, Inc. | Methods for improving crop plant architecture and yield |
US8124839B2 (en) * | 2005-06-08 | 2012-02-28 | Ceres, Inc. | Identification of terpenoid-biosynthesis related regulatory protein-regulatory region associations |
US8124111B2 (en) * | 2005-06-10 | 2012-02-28 | Children's Hospital & Research Center At Oakland | Immunomodulation by altering sphingosine 1-phosphate lyase (SPL) activity |
WO2006134162A2 (en) | 2005-06-17 | 2006-12-21 | Basf Plant Science Gmbh | Lecitin-like protein kinase stress-related polypeptides and methods of use in plants |
US20100129288A1 (en) * | 2005-06-28 | 2010-05-27 | Elior Peles | Gliomedin, Fragments Thereof and Methods of Using Same |
US20100162434A1 (en) | 2005-07-18 | 2010-06-24 | Basf Plant Science Gmbh | Yield Increase in Plants Overexpressing the SHSRP Genes |
BRPI0613632A2 (en) | 2005-07-18 | 2009-03-24 | Basf Plant Science Gmbh | transgenic cultivation plant transformed with an isolated nucleic acid, transgenic plant transformed with an isolated nucleic acid, method for producing a transgenic cultivation plant containing an isolated nucleic acid encoding a polypeptide, cultivation plant seed produced by a cultivation plant transgenic, plant seed produced by the transgenic plant, isolated nucleic acid, and recombinant expression vector comprising an isolated nucleic acid |
WO2007020198A2 (en) | 2005-08-12 | 2007-02-22 | Basf Plant Science Gmbh | Nucleic acid sequences encoding proteins associated with abiotic stress response and plant cells and plants with increased tolerance to environmental stress |
US20090176725A1 (en) * | 2005-08-17 | 2009-07-09 | Sirna Therapeutics Inc. | Chemically modified short interfering nucleic acid molecules that mediate rna interference |
WO2007024589A2 (en) * | 2005-08-24 | 2007-03-01 | The Trustees Of Columbia University In The City Of New York | Phagocyte enhancement therapy for atherosclerosis |
DK1919954T3 (en) | 2005-08-30 | 2017-01-30 | Univ Miami | Immune modulating tumor necrosis factor receptor (TNFR25) - agonists, antagonists and immunotoxins |
US8193328B2 (en) * | 2005-09-08 | 2012-06-05 | Philadelphia Health & Education Corporation | Identification of modulators of serine protease inhibitor Kazal and their use as anti-cancer and anti-viral agents |
WO2007041536A2 (en) * | 2005-09-30 | 2007-04-12 | Ceres, Inc. | Modulating plant tocopherol levels |
CA2624562A1 (en) | 2005-09-30 | 2007-04-12 | Abbott Gmbh & Co. Kg | Binding domains of proteins of the repulsive guidance molecule (rgm) protein family and functional fragments thereof, and their use |
US20080200408A1 (en) * | 2005-09-30 | 2008-08-21 | Mccormack Kenneth | Deletion mutants of tetrodotoxin-resistant sodium channel alpha subunit |
US7972813B2 (en) * | 2005-09-30 | 2011-07-05 | Vertex Pharmaceuticals Incorporated | Tetrodotoxin-resistant sodium channel alpha subunit |
US20100218271A1 (en) | 2005-10-05 | 2010-08-26 | Crop Design N.V. | Plants having improved characteristics and method for making the same |
WO2007041773A1 (en) * | 2005-10-07 | 2007-04-19 | Biopharmica Ltd | Sumoylation control agent and uses thereof |
EP1934348B1 (en) * | 2005-10-11 | 2018-05-02 | Ben-Gurion University Of The Negev Research And Development Authority | Compositions for silencing the expression of vdac1 and uses thereof |
CN102260742A (en) | 2005-10-21 | 2011-11-30 | 基因信息股份有限公司 | Method and apparatus for correlating levels of biomarker products with disease |
WO2007056113A2 (en) * | 2005-11-02 | 2007-05-18 | Cylene Pharmaceuticals, Inc. | Methods for targeting quadruplex sequences |
EP1948682A1 (en) | 2005-11-08 | 2008-07-30 | CropDesign N.V. | Plants having improved growth characteristics and a method for making the same |
EP1948806A2 (en) | 2005-11-08 | 2008-07-30 | BASF Plant Science GmbH | Use of armadillo repeat (arm1) polynucleotides for obtaining pathogen resistance in plants |
AU2006320596B2 (en) | 2005-12-01 | 2013-02-07 | Cropdesign N.V. | Plants having improved growth characteristics and methods for making the same |
EP1974024A2 (en) | 2005-12-09 | 2008-10-01 | BASF Plant Science GmbH | Nucleic acid molecules encoding polypeptides involved in regulation of sugar and lipid metabolism and methods of use viii |
US8313901B2 (en) * | 2005-12-21 | 2012-11-20 | Yale University | Methods and compositions related to the modulation of riboswitches |
US7592505B2 (en) | 2005-12-30 | 2009-09-22 | Pioneer Hi-Bred International, Inc. | UDP-xylose synthases (UXS) polynucleotides, polypeptides, and uses thereof |
ES2553442T3 (en) | 2006-01-05 | 2015-12-09 | The Ohio State University Research Foundation | Procedures based on microRNAs for the diagnosis, prognosis and treatment of lung cancer |
US20100015642A1 (en) * | 2006-01-05 | 2010-01-21 | Kwon Eugene D | B7-h1 and survivin in cancer |
EP2468891B1 (en) | 2006-01-05 | 2015-04-29 | The Ohio State University Research Foundation | MicroRNA-based methods for the diagnosis of prostate cancer or stomach cancers |
WO2007082154A2 (en) * | 2006-01-05 | 2007-07-19 | Mayo Foundation For Medical Education And Research | B7-h1 and b7-h4 in cancer |
EP1968622B1 (en) | 2006-01-05 | 2014-08-27 | The Ohio State University Research Foundation | Microrna expression abnormalities in pancreatic endocrine and acinar tumors |
ES2464315T3 (en) | 2006-01-12 | 2014-06-02 | Basf Plant Science Gmbh | Use of stomatin polynucleotides (STM1) to achieve resistance to pathogens in plants |
EP1981910B1 (en) | 2006-01-13 | 2013-06-26 | A Chan Holding B.V. | Method for identifying inhibitor of the glypican-sclerostin interaction |
CN100562342C (en) * | 2006-01-17 | 2009-11-25 | 奥林格斯技术有限公司 | The oligonucleotide drug of control influenza infection |
EP1984522B1 (en) | 2006-01-18 | 2010-08-11 | The General Hospital Corporation | Methods of increasing lymphatic function |
US20090304901A1 (en) * | 2006-01-25 | 2009-12-10 | Steven Craig Bobzin | Modulating plant protein levels |
US8222482B2 (en) * | 2006-01-26 | 2012-07-17 | Ceres, Inc. | Modulating plant oil levels |
WO2007092314A2 (en) | 2006-02-02 | 2007-08-16 | Verenium Corporation | Esterases and related nucleic acids and methods |
CN101421295B (en) | 2006-02-09 | 2012-05-02 | 先锋高级育种国际公司 | Genes for enhancing nitrogen utilization efficiency in crop plants |
DK2450439T3 (en) | 2006-02-10 | 2014-02-10 | Verenium Corp | Cellulose-degrading enzymes, nucleic acids encoding them, and methods of preparing and utilizing them |
US8043839B2 (en) | 2006-02-14 | 2011-10-25 | Verenium Corporation | Xylanases, nucleic acids encoding them and methods for making and using them |
GB0602992D0 (en) * | 2006-02-15 | 2006-03-29 | Morvus Technology Ltd | Methods, genes and proteins |
US20070199090A1 (en) * | 2006-02-22 | 2007-08-23 | Nestor Apuya | Modulating alkaloid biosynthesis |
WO2007120989A2 (en) * | 2006-02-24 | 2007-10-25 | Ceres, Inc. | Shade regulatory regions |
EP1991706B1 (en) | 2006-03-02 | 2014-01-15 | The Ohio State University Research Foundation | Microrna expression profile associated with pancreatic cancer |
CN101437954B (en) | 2006-03-07 | 2015-09-09 | 嘉吉公司 | The nucleic acid of zymohexase and coding zymohexase and their preparation and application |
KR101622894B1 (en) | 2006-03-07 | 2016-05-19 | 바스프 엔자임스 엘엘씨 | Aldolases, nucleic acids encoding them and methods for making and using them |
US7820883B2 (en) * | 2006-03-15 | 2010-10-26 | Dow Agrosciences Llc | Resistance to auxinic herbicides |
EP2369011A1 (en) | 2006-03-20 | 2011-09-28 | The Ohio State University Research Foundation | Microrna fingerprints during human megakaryocytopoiesis |
US20090172834A1 (en) | 2006-03-24 | 2009-07-02 | Basf Plant Science Gmbh | Proteins Associated With Abiotic Stress Response And Homologs |
AU2007231553B2 (en) * | 2006-03-28 | 2012-10-25 | Molecular Discovery Systems | Agent for the treatment of hormone-dependent disorders and uses thereof |
JP2009534309A (en) | 2006-03-31 | 2009-09-24 | マサチューセッツ インスティテュート オブ テクノロジー | System for targeted delivery of therapeutic agents |
WO2007113237A2 (en) | 2006-03-31 | 2007-10-11 | Basf Plant Science Gmbh | Plants having enhanced yield-related traits and a method for making the same |
CA2644273A1 (en) | 2006-04-05 | 2008-03-27 | Metanomics Gmbh | Process for the production of a fine chemical |
EP2010226B1 (en) | 2006-04-07 | 2014-01-15 | The Research Foundation of State University of New York | Transcobalamin receptor polypeptides, nucleic acids, and modulators thereof, and related methods of use in modulating cell growth and treating cancer and cobalamin deficiency |
US20090222957A1 (en) * | 2006-04-07 | 2009-09-03 | Ceres Inc. | Regulatory protein-regulatory region associations related to alkaloid biosynthesis |
GB0607354D0 (en) * | 2006-04-12 | 2006-05-24 | Bioinvent Int Ab | Agent, Composition And Method |
US7557266B2 (en) | 2006-04-19 | 2009-07-07 | Pioneer Hi-Bred International, Inc. | Isolated polynucleotide molecules corresponding to mutant and wild-type alleles of the maize D9 gene and methods of use |
WO2007124361A2 (en) * | 2006-04-20 | 2007-11-01 | Mayo Foundation For Medical Education And Research | Soluble b7-h1 |
US20070258976A1 (en) * | 2006-05-04 | 2007-11-08 | Ward Keith W | Combination Therapy for Diseases Involving Angiogenesis |
US20100024070A1 (en) * | 2006-05-15 | 2010-01-28 | Steven Craig Bobzin | Modulation of oil levels in plants |
WO2007137117A2 (en) * | 2006-05-17 | 2007-11-29 | Massachusetts Institute Of Technology | Aptamer-directed drug delivery |
MX2008014615A (en) | 2006-05-17 | 2009-01-15 | Pioneer Hi Bred Int | Artificial plant minichromosomes. |
EP2030021B1 (en) | 2006-05-18 | 2012-11-21 | Andreas Reichert | Method for diagnosing mitochondrial dysfunction |
WO2007137300A2 (en) | 2006-05-23 | 2007-11-29 | Bellicum Pharmaceuticals, Inc. | Modified dendritic cells having enhanced survival and immunogenicity and related compositions and methods |
ES2685802T3 (en) | 2006-05-25 | 2018-10-11 | Biogen Ma Inc. | VLA-1 antagonist for use in the treatment of a stroke |
CA2652446C (en) | 2006-05-30 | 2016-02-09 | Cropdesign N.V. | Plants having enhanced yield-related traits and a method for making the same |
WO2007140599A1 (en) | 2006-06-05 | 2007-12-13 | Cancer Care Ontario | Assessment of risk for colorectal cancer |
ES2362941T3 (en) * | 2006-06-06 | 2011-07-15 | Massachusetts Institute Of Technology | CHOLESTEROL REGULATOR COMPLEX OF SIRT1 AND LXR AND METHODS OF USE. |
WO2007147068A2 (en) * | 2006-06-14 | 2007-12-21 | Ceres, Inc. | Increasing uv-b tolerance in plants |
US20090320165A1 (en) * | 2006-06-21 | 2009-12-24 | Steven Craig Bobzin | Modulation of protein levels in plants |
WO2008012695A2 (en) * | 2006-06-23 | 2008-01-31 | Engeneic Molecular Delivery Pty Ltd. | Targeted delivery of drugs, therapeutic nucleic acids and functional nucleic acids to mammalian cells via intact killed bacterial cells |
US8097596B2 (en) * | 2006-06-30 | 2012-01-17 | Lakewood-Amedex, Inc. | Compositions and methods for the treatment of muscle wasting |
US20130191941A1 (en) | 2006-07-05 | 2013-07-25 | Shing Kwok | Modulating light response pathways in plants, increasing light-related tolerances in plants, and increasing biomass in plants |
AU2007314477B2 (en) | 2006-07-11 | 2012-03-29 | Rutgers, The State University Of New Jersey | MG53 compositions and methods of use |
EP2479284B1 (en) | 2006-07-13 | 2017-09-20 | University of Iowa Research Foundation | Methods and reagents for treatment and diagnosis of vascular disorders and age-related macular degeneration |
EP2436785B1 (en) | 2006-07-13 | 2013-09-11 | The Ohio State University Research Foundation | MIR-29a for diagnosing poor survival prognosis colon adenocarcinoma. |
AU2007276793B2 (en) * | 2006-07-28 | 2014-01-16 | Sanofi | Composition and method for treatment of tumors |
ES2451669T3 (en) | 2006-08-02 | 2014-03-28 | Cropdesign N.V. | Plants that have improved characteristics and a manufacturing process for them |
EP2444413A1 (en) | 2006-08-04 | 2012-04-25 | Verenium Corporation | Methods for oil or gas well drilling, washing and/or fracturing |
WO2008022035A2 (en) * | 2006-08-10 | 2008-02-21 | The Scripps Research Institute | Methods for identifying cellular modulators of disaggregation activity or aggregation activity in an animal |
ES2484142T3 (en) | 2006-09-06 | 2014-08-11 | The Regents Of The University Of California | Molecular diagnosis and classification of malignant melanoma |
WO2008033866A2 (en) * | 2006-09-11 | 2008-03-20 | Yale University | Methods and compositions for the use of lysine riboswitches |
EP1900749A1 (en) | 2006-09-12 | 2008-03-19 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Nucleic acids for expressing a polynucleotide of interest in mammalian cancer cells |
CA2663001A1 (en) | 2006-09-21 | 2008-03-27 | Verenium Corporation | Phospholipases, nucleic acids encoding them and methods for making and using them |
EP2617818B1 (en) | 2006-09-21 | 2016-03-23 | BASF Enzymes LLC | Phytases, nucleic acids encoding them and methods for making and using them |
WO2008060785A2 (en) | 2006-10-06 | 2008-05-22 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Prevention of tissue ischemia, related methods and compositions |
EP2121936A2 (en) | 2006-10-13 | 2009-11-25 | BASF Plant Science GmbH | Plants with increased yield |
US8362322B2 (en) | 2006-10-27 | 2013-01-29 | Ceres, Inc. | Modulating lignin in plants |
US9102948B2 (en) | 2006-11-17 | 2015-08-11 | 22Nd Century Limited, Llc | Regulating alkaloids |
US20100303723A1 (en) * | 2006-11-20 | 2010-12-02 | Massachusetts Institute Of Technology | Drug delivery systems using fc fragments |
WO2008064128A2 (en) * | 2006-11-22 | 2008-05-29 | Ceres, Inc. | Broadly expressing regulatory regions |
CA2664987A1 (en) | 2006-11-24 | 2008-05-29 | Cropdesign N.V. | Transgenic plants comprising as transgene a class i tcp or clavata 1 (clv1) or cah3 polypeptide having increased seed yield and a method for making the same |
WO2008067840A1 (en) | 2006-12-08 | 2008-06-12 | Swetree Technologies Ab | Plants having improved growth characteristics and method for making the same |
MX2009006782A (en) | 2006-12-21 | 2009-09-21 | Verenium Corp | Amylases and glucoamylases, nucleic acids encoding them and methods for making and using them. |
EP2913341A1 (en) | 2006-12-22 | 2015-09-02 | University of Utah Research Foundation | Method of detecting ocular diseases and pathologic conditions and treatment of same |
EP3103451A1 (en) | 2007-01-12 | 2016-12-14 | University of Maryland, Baltimore | Targetting ncca-atp channel for organ protection following ischemic episode |
DK2202314T3 (en) * | 2007-01-15 | 2014-06-16 | Basf Plant Science Gmbh | Use of Subtilisin (RNR9) Polynucleotides to Achieve Pathogen Resistance in Plants |
US20100119512A1 (en) * | 2007-01-25 | 2010-05-13 | Joslin Diabetes Center | Methods of diagnosing, treating, and preventing increased vascular permeability |
CA2676613A1 (en) * | 2007-01-29 | 2008-08-07 | Wyeth | Immunophilin ligands and methods for modulating immunophilin and calcium channel activity |
NZ598285A (en) | 2007-01-30 | 2013-10-25 | Syngenta Participations Ag | Enzymes for the treatment of lignocellulosics, nucleic acids encoding them and methods for making and using them |
CN103233037A (en) | 2007-01-31 | 2013-08-07 | 巴斯福植物科学有限公司 | Plants having enhanced yield-related traits and/or increased abiotic stress resistance, and a method for making the same |
CA2676036A1 (en) * | 2007-02-02 | 2008-08-14 | Amgen Inc. | Hepcidin, hepcidin antagonists and methods of use |
CN101631868B (en) | 2007-02-16 | 2016-02-10 | 巴斯福植物科学有限公司 | For regulating the nucleotide sequence of embryo-specific expression in monocotyledons |
US20080207885A1 (en) * | 2007-02-23 | 2008-08-28 | Silverman Scott K | Method for site-specific labeling of RNA using a deoxyribozyme |
AU2008221383B2 (en) | 2007-02-28 | 2012-09-13 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Brachyury polypeptides and methods for use |
EP2243834A1 (en) | 2007-03-05 | 2010-10-27 | Cancer Care Ontario | Assessment of risk for colorectal cancer |
US20100119474A1 (en) * | 2007-03-06 | 2010-05-13 | Cornell University | Chronic obstructive pulmonary disease susceptibility and related compositions and methods |
WO2008115387A2 (en) * | 2007-03-15 | 2008-09-25 | University Hospitals Of Cleveland | Screening, diagnosing, treating and prognosis of pathophysiologic states by rna regulation |
EP2139330B1 (en) | 2007-03-23 | 2014-09-24 | The Board of Regents of The University of Texas System | Methods involving aldose reductase inhibitors |
WO2008124634A1 (en) | 2007-04-04 | 2008-10-16 | Massachusetts Institute Of Technology | Polymer-encapsulated reverse micelles |
EP2191001B1 (en) | 2007-04-09 | 2016-06-08 | University of Florida Research Foundation, Inc. | Raav vector compositions having tyrosine-modified capsid proteins and methods for use |
JP5926487B2 (en) | 2007-04-13 | 2016-05-25 | デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド | Method for treating cancer resistant to ErbB therapy |
WO2008127707A1 (en) * | 2007-04-13 | 2008-10-23 | Dana Farber Cancer Institute, Inc. | Receptor tyrosine kinase profiling |
BRPI0810471A2 (en) | 2007-04-16 | 2014-11-11 | Momenta Pharmaceuticals Inc | DEFINED GLYCOPROTEIN PRODUCTS AND RELATED METHODS |
CA2584934A1 (en) | 2007-04-17 | 2008-10-17 | University Of Guelph | Nitrogen-regulated sugar sensing gene and protein and modulation thereof |
ES2558745T3 (en) | 2007-05-03 | 2016-02-08 | Basf Plant Science Company Gmbh | Plants that have enhanced traits related to performance and a production procedure for them |
EP2492346A3 (en) | 2007-05-04 | 2013-03-27 | BASF Plant Science GmbH | Seed enhancement by combinations of pyruvate kinases |
US20100150924A1 (en) * | 2007-05-22 | 2010-06-17 | Elior Peles | Regulation of myelination by nectin-like (necl) molecules |
AR067318A1 (en) | 2007-05-22 | 2009-10-07 | Basf Plant Science Gmbh | PLANTS WITH HIGHER TOLERANCE AND / OR INCREASED RESISTANCE TO ENVIRONMENTAL STRESS AND HIGHER BIOMASS PRODUCTION |
AR066642A1 (en) | 2007-05-22 | 2009-09-02 | Basf Plant Gmbh | VEGETABLE CELLS AND PLANTS WITH HIGHER TOLERANCE AND / OR RESISTANCE TO ENVIRONMENTAL STRESS AND HIGHER PRODUCTION OF BIOMASS PRODUCED BY SILENCING OF GENES |
EP2390335A3 (en) | 2007-05-23 | 2012-03-21 | Syngenta Participations AG | Polynucleotide markers |
EP2426218A1 (en) * | 2007-05-29 | 2012-03-07 | Yale University | Riboswitches and methods and compositions for use of and with riboswitches |
AU2008260089A1 (en) * | 2007-05-29 | 2008-12-11 | Yale University | Methods and compositions related to riboswitches that control alternative splicing and RNA processing |
WO2008153987A2 (en) | 2007-06-08 | 2008-12-18 | The Government Of The United States Of America As Represented By The Secretary Of Department Of Health And Human Services | Methods for determining hepatocellular carcinoma subtype and detecting hepatic cancer stem cells |
WO2008154700A1 (en) | 2007-06-20 | 2008-12-24 | Phylogica Limited | Compositions and uses thereof for the treatment of acute respiratory distress syndrome (ards) and clinical disorders associated with therewith |
US8097422B2 (en) | 2007-06-20 | 2012-01-17 | Salk Institute For Biological Studies | Kir channel modulators |
BRPI0813114A2 (en) | 2007-06-29 | 2014-11-11 | Basf Plant Scinece Gmbh | METHOD FOR IMPROVING YIELD FEATURES IN PLANTS IN RELATION TO CONTROL PLANTS, CONSTRUCTION, USE OF A PLANT CONSTRUCTION, PLANT, PLANT PART OR CELL, METHOD FOR PRODUCTION OF A TRANSGENIC PLANT, HARVEST PARTS, AND, USE OF NUCLEIC ACID |
US20090082217A1 (en) * | 2007-07-16 | 2009-03-26 | California Institute Of Technology | Selection of nucleic acid-based sensor domains within nucleic acid switch platform |
AU2008280152B2 (en) | 2007-07-20 | 2013-11-21 | Basf Plant Science Gmbh | Plants having increased yield-related traits and a method for making the same |
CA2695184A1 (en) | 2007-07-31 | 2009-02-05 | The Ohio State University Research Foundation | Methods for reverting methylation by targeting dnmt3a and dnmt3b |
AR067748A1 (en) | 2007-07-31 | 2009-10-21 | Basf Plant Science Gmbh | PLANTS THAT HAVE IMPROVED FEATURES RELATED TO PERFORMANCE AND A METHOD FOR OBTAINING THEM |
US20110023188A1 (en) | 2007-07-31 | 2011-01-27 | Basf Plant Science Gmbh | Plants having enhanced yield-related traits and a method for making the same |
ES2570359T3 (en) | 2007-08-03 | 2016-05-18 | Univ Ohio State Res Found | Ultraconserved regions encoding RNAnc |
EP2191014B1 (en) | 2007-08-13 | 2013-04-03 | Baxter International Inc. | Ivig modulation of chemokines for treatment of multiple sclerosis, alzheimer's disease, and parkinson's disease |
CA2696887C (en) | 2007-08-22 | 2016-06-28 | The Ohio State University Research Foundation | Methods and compositions for inducing deregulation of epha7 and erk phosphorylation in human acute leukemias |
AU2008296022B2 (en) | 2007-09-06 | 2014-01-23 | The Ohio State University Research Foundation | MicroRNA signatures in human ovarian cancer |
CA2699066A1 (en) | 2007-09-14 | 2009-03-19 | Basf Plant Science Gmbh | Plants having increased yield-related traits and a method for making the same comprising expression of a growth-regulating factor (grf) polypeptide |
DE112008002435T5 (en) | 2007-09-18 | 2010-07-22 | Basf Plant Science Gmbh | Plants with increased yield |
CN101939435A (en) | 2007-09-21 | 2011-01-05 | 巴斯夫植物科学有限公司 | Plants with increased yield |
EP2040075A1 (en) | 2007-09-24 | 2009-03-25 | Julius-Maximilians-Universität Würzburg | Compounds and markers for surface-enhanced raman scattering |
AR068542A1 (en) * | 2007-09-24 | 2009-11-18 | Performance Plants Inc | PLANTS THAT HAVE INCREASED BIOMASS |
US8486680B2 (en) | 2007-10-03 | 2013-07-16 | Bp Corporation North America Inc. | Xylanases, nucleic acids encoding them and methods for making and using them |
US20100285471A1 (en) | 2007-10-11 | 2010-11-11 | The Ohio State University Research Foundation | Methods and Compositions for the Diagnosis and Treatment of Esphageal Adenocarcinomas |
CA2739011A1 (en) * | 2007-10-29 | 2009-05-07 | The Regents Of The University Of California | Osteoarthritis gene therapy |
BRPI0818482A2 (en) | 2007-10-29 | 2014-10-07 | Basf Plant Science Gmbh | METHOD FOR INCREASING CHARACTERISTICS RELATED TO REDUCTION, CONSTRUCTION, USE OF A CONSTRUCTION, PLANT, PART OF PLANT OR PLANT CELL, METHOD FOR PRODUCTION OF A TRANSGENIC PLANT, TRANSGENIC PLANT, HARVEST PRODUCTS, PLANT PRODUCTS, A NUCLEIC ACID |
WO2009064771A2 (en) | 2007-11-12 | 2009-05-22 | North Carolina State University | Alteration of tobacco alkaloid content through modification of specific cytochrome p450 genes |
CN101932712B (en) | 2007-11-20 | 2014-05-14 | 先锋国际良种公司 | Maize ethylene signaling genes and modulation of same for improved stress tolerance in plants |
MX2010005697A (en) | 2007-11-26 | 2010-06-11 | Basf Plant Science Gmbh | Plants having enhanced yield-related traits and a method for making the same. |
CA2708153C (en) | 2007-12-04 | 2017-09-26 | Alnylam Pharmaceuticals, Inc. | Carbohydrate conjugates as delivery agents for oligonucleotides |
BRPI0821231A2 (en) | 2007-12-17 | 2014-12-23 | Basf Plant Science Gmbh | POLYNUCLEOTIDE, VECTOR, HOST STONE CELL, METHOD FOR MANUFACTURING A POLYPEPTIDE, ANTIBODY, ANTIBODY, AND METHODS FOR MANUFACTURING A PLASTIC EIPAID LIPID OR FOR A LIPID FABRICATION |
US20110041215A1 (en) * | 2007-12-17 | 2011-02-17 | Basf Plant Science Gmbh | Lipid Metabolism Protein And Uses Thereof I (BZIP Transcription Factor) |
DE112008003318T5 (en) | 2007-12-19 | 2011-04-21 | Basf Plant Science Gmbh | Plants with increased yield and increased tolerance to environmental stress (IY-B) |
CN101969759A (en) | 2007-12-20 | 2011-02-09 | 巴斯夫植物科学有限公司 | Plants having enhanced yield-related traits and a method for making the same |
US20100293665A1 (en) * | 2007-12-21 | 2010-11-18 | Basf Plant Science Gmbh | Plants With Increased Yield (KO NUE) |
AU2008344053B2 (en) | 2007-12-28 | 2014-03-27 | Swetree Technologies Ab | Woody plants having improved growth charateristics and method for making the same using transcription factors |
US20090226914A1 (en) * | 2007-12-31 | 2009-09-10 | Bates Paula J | Methods and products to target, capture and characterize stem cells |
EP2224912B1 (en) | 2008-01-02 | 2016-05-11 | TEKMIRA Pharmaceuticals Corporation | Improved compositions and methods for the delivery of nucleic acids |
CA2710922A1 (en) | 2008-01-03 | 2009-07-16 | Verenium Corporation | Isomerases, nucleic acids encoding them and methods for making and using them |
US8709772B2 (en) | 2008-01-03 | 2014-04-29 | Verenium Corporation | Transferases and oxidoreductases, nucleic acids encoding them and methods for making and using them |
MX356866B (en) | 2008-01-25 | 2018-06-18 | Multivir Inc | P53 biomarkers. |
EP2599874A3 (en) | 2008-01-25 | 2013-11-13 | BASF Plant Science GmbH | Plants having enhanced yield-related traits and a method for making the same |
EP2245055A2 (en) * | 2008-01-31 | 2010-11-03 | Compugen Ltd. | Polypeptides and polynucleotides, and uses thereof as a drug target for producing drugs and biologics |
EP2247733A2 (en) | 2008-01-31 | 2010-11-10 | National Institute of Biological Sciences | Plants having altered growth and/or development and a method for making the same |
EP2247735A2 (en) | 2008-02-27 | 2010-11-10 | BASF Plant Science GmbH | Plants with increased yield |
US20110020325A1 (en) * | 2008-02-29 | 2011-01-27 | Kwon Eugene D | Methods for reducing granulomatous inflammation |
US8962803B2 (en) | 2008-02-29 | 2015-02-24 | AbbVie Deutschland GmbH & Co. KG | Antibodies against the RGM A protein and uses thereof |
ES2489840T3 (en) | 2008-03-05 | 2014-09-02 | The Regents Of The University Of California | Molecular prognosis and classification of malignant melanoma based on markers selected from the list consisting of RGS1, NCOA3, SPP1, PHIP |
US20090246153A1 (en) * | 2008-03-28 | 2009-10-01 | Nu Skin International, Inc. | Cosmetic compositions for the inhibition of reactive oxygen species |
US20090246152A1 (en) * | 2008-03-28 | 2009-10-01 | Nu Skin International, Inc. | Naractin compositions for the inhibition of reactive oxygen species |
PT2279254T (en) | 2008-04-15 | 2017-09-04 | Protiva Biotherapeutics Inc | Novel lipid formulations for nucleic acid delivery |
US9234205B2 (en) | 2008-04-16 | 2016-01-12 | Basf Plant Science Gmbh | Method for increasing plant yield by expressing a nucleic acid encoding an ornithine decarboxylase polypeptide and plants expressing the same |
WO2009135810A1 (en) | 2008-05-05 | 2009-11-12 | Basf Plant Science Gmbh | Plants having enhanced yield-related traits and a method for making the same |
PL2283034T3 (en) | 2008-05-08 | 2014-05-30 | Monsanto Do Brasil Ltda | Genes and methods for increasing disease resistance in plants |
US20110099669A1 (en) | 2008-06-20 | 2011-04-28 | Basf Plant Science Gmbh | Plants having enhanced yield-related traits and a method for making the same |
EP2304037A1 (en) | 2008-06-26 | 2011-04-06 | BASF Plant Science GmbH | Plants having enhanced yield-related traits and a method for making the same |
EA201100146A1 (en) | 2008-07-04 | 2011-12-30 | Басф Плант Сайенс Гмбх | PLANTS HAVING IMPROVED YIELD CHARACTERISTICS AND METHOD OF OBTAINING THEM |
NZ590605A (en) | 2008-07-09 | 2012-11-30 | Biogen Idec Inc | Compositions comprising antibodies to lingo or fragments thereof |
US9175303B2 (en) | 2008-07-17 | 2015-11-03 | Basf Plant Science Gmbh | Plants having enhanced yield-related traits and a method for making the same |
US8419145B2 (en) * | 2008-07-25 | 2013-04-16 | Eastman Kodak Company | Inkjet printhead and method of printing with multiple drop volumes |
EP2669379A3 (en) | 2008-07-31 | 2014-03-19 | BASF Plant Science GmbH | Plants having modified growth characteristics and a method for making the same |
CA2734347A1 (en) | 2008-08-19 | 2010-02-25 | Basf Plant Science Gmbh | Plants with increased yield by increasing or generating one or more activities in a plant or a part thereof |
WO2010020555A1 (en) | 2008-08-20 | 2010-02-25 | Basf Plant Science Gmbh | Plants having enhanced yield-related traits and a method for making the same |
US8198062B2 (en) | 2008-08-29 | 2012-06-12 | Dsm Ip Assets B.V. | Hydrolases, nucleic acids encoding them and methods for making and using them |
US8153391B2 (en) | 2008-08-29 | 2012-04-10 | Bunge Oils, Inc. | Hydrolases, nucleic acids encoding them and methods for making and using them |
US8357503B2 (en) | 2008-08-29 | 2013-01-22 | Bunge Oils, Inc. | Hydrolases, nucleic acids encoding them and methods for making and using them |
CA2734922C (en) | 2008-09-15 | 2020-01-14 | Laetitia Malphettes | Compositions comprising polynucleotides comprising hybrid osmo-responsive transcriptional regulatory elements and methods for producing a protein under conditions of hyperosmolarity |
EP2719380A3 (en) | 2008-09-16 | 2014-07-30 | University of Maryland, Baltimore | SUR1 inhibitors for therapy |
BRPI0919153A2 (en) | 2008-09-23 | 2019-05-07 | Basf Plant Science Gmbh | method for producing a high yielding plant, nucleic acid molecule, nucleic acid construct, vector, process for producing a polypeptide, polypeptide, antibody, plant cell nucleus, plant cell, plant tissue, propagating material, pollen , progeny, material collected, or a plant, or part of a plant, a transgenic plant, process for identifying a compound, method for producing an agricultural composition, composition, use of nucleic acid, and method for identifying a plant with an increased yield, and to increase the yield of a plant population |
AU2009295991A1 (en) | 2008-09-24 | 2010-04-01 | Basf Plant Science Gmbh | Plants having enhanced yield-related traits and a method for making the same |
US9207242B2 (en) | 2008-10-09 | 2015-12-08 | The University Of Hong Kong | Cadherin-17 as diagnostic marker and therapeutic target for liver cancer |
BRPI0920552A2 (en) | 2008-10-09 | 2019-09-24 | Univ Northeastern | multifunctional self-organizing polymeric nanosystems |
CN104119242B (en) | 2008-10-09 | 2017-07-07 | 泰米拉制药公司 | The amino lipids of improvement and the method for delivering nucleic acid |
US8298794B2 (en) * | 2008-10-09 | 2012-10-30 | Ceres, Inc. | Cinnamyl-alcohol dehydrogenases |
AU2009306369A1 (en) | 2008-10-23 | 2010-04-29 | Basf Plant Science Gmbh | A method for producing a transgenic cell with increased gamma-aminobutyric acid (GABA) content |
EP2350289A1 (en) | 2008-10-23 | 2011-08-03 | BASF Plant Science GmbH | Plants with increased yield (nue) |
US8821880B2 (en) | 2008-10-29 | 2014-09-02 | China Synthetic Rubber Corporation | Methods and agents for the diagnosis and treatment of hepatocellular carcinoma |
WO2010056519A1 (en) | 2008-10-30 | 2010-05-20 | Pioneer Hi-Bred International, Inc. | Manipulation of glutamine synthetases (gs) to improve nitrogen use efficiency and grain yield in higher plants |
EP2184351A1 (en) | 2008-10-30 | 2010-05-12 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Polynucleotides encoding caryophyllene synthase and uses thereof |
UY32220A (en) | 2008-11-03 | 2010-06-30 | Swetree Technologies Ab | VEGETABLE MATERIAL, PLANTS AND METHOD TO PRODUCE THE PLANT CONTAINING ALTERED PROPERTIES OF LIGNINA |
US9289475B2 (en) | 2008-11-06 | 2016-03-22 | The Johns Hopkins University | Treatment of chronic inflammatory respiratory disorders |
WO2010054401A1 (en) | 2008-11-10 | 2010-05-14 | Alnylam Pharmaceuticals, Inc. | Novel lipids and compositions for the delivery of therapeutics |
EP2894166A1 (en) | 2008-11-10 | 2015-07-15 | Alexion Pharmaceuticals, Inc. | Methods and compositions for treating complement-associated disorders |
AU2009315732A1 (en) | 2008-11-12 | 2010-05-20 | Basf Plant Science Gmbh | Plants having enhanced abiotic stress tolerance and/or enhanced yield-related traits and a method for making the same |
MX2011005778A (en) | 2008-12-03 | 2011-07-20 | Basf Plant Science Gmbh | Plants having enhanced abiotic stress tolerance and/or enhanced yield-related traits and a method for making the same. |
US20100183633A1 (en) * | 2008-12-04 | 2010-07-22 | University Of Massachusetts | Interleukin 6 and tumor necrosis factor alpha as biomarkers of jnk inhibition |
CA2743707A1 (en) | 2008-12-04 | 2010-06-10 | Pioneer Hi-Bred International, Inc. | Methods and compositions for enhanced yield by targeted expression of knotted1 |
US20100150949A1 (en) * | 2008-12-16 | 2010-06-17 | Oncopharmacologics, Inc. | Methods and compositions for modulating proline levels |
EP2379582A1 (en) | 2008-12-17 | 2011-10-26 | BASF Plant Science GmbH | Plants having enhanced yield-related traits and/or abiotic stress tolerance and a method for making the same |
CA2750007A1 (en) | 2009-01-28 | 2010-08-05 | Basf Plant Science Company Gmbh | Plants having enhanced yield-related traits and a method for making the same |
EP3243504A1 (en) | 2009-01-29 | 2017-11-15 | Arbutus Biopharma Corporation | Improved lipid formulation |
EP2395996A1 (en) | 2009-02-13 | 2011-12-21 | Indiana University Research and Technology Corporation | Compounds and methods for inhibiting mmp2 and mmp9 |
EP2401291A1 (en) | 2009-02-25 | 2012-01-04 | BASF Plant Science Company GmbH | Plants having enhanced yield-related traits and a method for making the same |
US8716553B2 (en) | 2009-03-02 | 2014-05-06 | Pioneer Hi Bred International Inc | NAC transcriptional activators involved in abiotic stress tolerance |
GB0904904D0 (en) | 2009-03-23 | 2009-05-06 | Univ Leiden Medical Ct | Angiogenesis methods, medicaments and agents |
CN102395674B (en) | 2009-04-14 | 2015-07-29 | 先锋国际良种公司 | Plant biomass under regulating acc synthase to improve low nitrogen condition |
US10519458B2 (en) | 2009-04-22 | 2019-12-31 | Basf Plant Science Company Gmbh | Whole seed specific promoter |
US20120090052A1 (en) | 2009-04-29 | 2012-04-12 | Ana Isabel Sanz Molinero | Plants Having Enhanced Yield-Related Traits And A Method For Making The Same |
AU2010243730B2 (en) | 2009-04-29 | 2016-04-21 | Basf Plant Science Company Gmbh | Plants having enhanced yield-related traits and a method for making the same |
NZ596186A (en) | 2009-05-05 | 2014-03-28 | Alnylam Pharmaceuticals Inc | Lipid compositions |
JP5889783B2 (en) | 2009-05-05 | 2016-03-22 | テクミラ ファーマシューティカルズ コーポレイションTekmira Pharmaceuticals Corporation | Methods for delivering oligonucleotides to immune cells |
CA2760754A1 (en) | 2009-05-06 | 2010-11-11 | Basf Plant Science Company Gmbh | Plants having enhanced yield-related traits and/or enhanced abiotic stress tolerance and a method for making the same |
CA2763283C (en) | 2009-05-21 | 2021-01-12 | Verenium Corporation | Phytases, nucleic acids encoding them and methods for making and using them |
US9187757B2 (en) | 2009-06-05 | 2015-11-17 | University Of Florida Research Foundation, Inc. | Isolation and targeted suppression of lignin biosynthetic genes |
TR201811076T4 (en) | 2009-06-10 | 2018-08-27 | Arbutus Biopharma Corp | Improved lipid formulation. |
CN102656270B (en) | 2009-06-19 | 2015-05-13 | 巴斯夫植物科学有限公司 | Plants having enhanced yield-related traits and a method for making the same |
JP2012532190A (en) | 2009-06-30 | 2012-12-13 | アボット ラボラトリーズ | Markers for XMRV infection and their use |
US20120090043A1 (en) | 2009-06-30 | 2012-04-12 | Universite De Liege | Targets for retrovirus associated diseases |
WO2011000107A1 (en) | 2009-07-01 | 2011-01-06 | Protiva Biotherapeutics, Inc. | Novel lipid formulations for delivery of therapeutic agents to solid tumors |
WO2011011412A2 (en) | 2009-07-20 | 2011-01-27 | Ceres, Inc. | Transgenic plants having increased biomass |
GB0912624D0 (en) | 2009-07-21 | 2009-08-26 | Imp Innovations Ltd | Methods |
EP2456873A1 (en) | 2009-07-23 | 2012-05-30 | BASF Plant Science Company GmbH | Plants with increased yield |
IN2012DN00531A (en) | 2009-07-24 | 2015-08-21 | Pioneer Hi Bred Int | |
EP2462165B1 (en) | 2009-08-03 | 2016-05-11 | University of Miami | Method for in vivo expansion of t regulatory cells |
AU2010282340B2 (en) | 2009-08-13 | 2016-12-22 | The Johns Hopkins University | Methods of modulating immune function |
EP2949661A1 (en) | 2009-08-19 | 2015-12-02 | BASF Plant Science Company GmbH | Plants having enhanced yield-related traits and a method for making the same |
JP2013502906A (en) | 2009-08-31 | 2013-01-31 | アルケド バイオテック ゲゼルシャフト ミット ベシュレンクテル ハフツング | MicroRNA-based methods and compositions for diagnosis, prognosis and treatment of tumors with chromosomal rearrangements |
ES2354922B1 (en) | 2009-09-02 | 2012-02-07 | Fundacion Institut De Recerca De L'hospital Universitari Vall D'hebron | MARKERS FOR THE SELECTION OF PERSONALIZED THERAPIES FOR THE TREATMENT OF THE C�? NCER. |
JP5962996B2 (en) | 2009-09-03 | 2016-08-03 | キャンサー・リサーチ・テクノロジー・リミテッド | CLEC14A inhibitor |
CN104745608A (en) | 2009-09-25 | 2015-07-01 | 巴斯夫植物科学有限公司 | Plants having enhanced yield-related traits and a method for making the same |
US9371537B2 (en) | 2009-09-25 | 2016-06-21 | Basf Plant Science Company Gmbh | Plants having enhanced yield-related traits resulted from modulated expression of a SGT1 polypeptide and a method for making the same |
EP2482837A4 (en) | 2009-09-29 | 2013-05-22 | Joslin Diabetes Center Inc | Use of protein kinase c delta (pkcd) inhibitors to treat diabetes, obesity, and hepatic steatosis |
EP2305285A1 (en) | 2009-09-29 | 2011-04-06 | Julius-Maximilians-Universität Würzburg | Means and methods for treating ischemic conditions |
EP2483404A1 (en) | 2009-10-02 | 2012-08-08 | Pioneer Hi-Bred International Inc. | Down-regulation of acc synthase for improved plant performance |
UA111708C2 (en) | 2009-10-16 | 2016-06-10 | Бандж Ойлз, Інк. | METHOD OF OIL REFINING |
UA109884C2 (en) | 2009-10-16 | 2015-10-26 | A POLYPEPTIDE THAT HAS THE ACTIVITY OF THE PHOSPHATIDYLINOSYTOL-SPECIFIC PHOSPHOLIPASE C, NUCLEIC ACID, AND METHOD OF METHOD | |
CA2777802A1 (en) | 2009-10-22 | 2011-04-28 | Basf Plant Science Company Gmbh | Plants having enhanced yield-related traits and a method for making the same |
CN102812014B (en) | 2009-10-30 | 2016-01-20 | 多美恩医疗公司 | The purposes of novel 9 oxime derivate and the allosteric modulators as metabotropic glutamate receptor thereof |
CA2779988A1 (en) | 2009-11-13 | 2011-05-19 | Basf Plant Science Company Gmbh | Plants having enhanced yield-related traits and a method for making the same |
EP3037435B1 (en) | 2009-11-17 | 2019-08-07 | MUSC Foundation for Research Development | Human monoclonal antibodies to human nucleolin |
WO2011061656A1 (en) | 2009-11-17 | 2011-05-26 | Basf Plant Science Company Gmbh | Plants with increased yield |
ES2365343B1 (en) | 2009-11-19 | 2012-07-10 | Fundación Centro Nacional De Investigaciones Cardiovasculares Carlos Iii | USE OF CD98 AS AN ENDOMETRIAL RECEPTIVITY MARKER. |
US9872905B2 (en) | 2009-12-01 | 2018-01-23 | President And Fellows Of Harvard College | Modulation of NK cell antigen specific effector activity by modulation of CXCR6 (CD186) |
EP3296398A1 (en) | 2009-12-07 | 2018-03-21 | Arbutus Biopharma Corporation | Compositions for nucleic acid delivery |
CN113717286A (en) | 2009-12-08 | 2021-11-30 | Abbvie德国有限责任两合公司 | Monoclonal antibodies against RGM A proteins for use in the treatment of retinal nerve fiber layer degeneration |
WO2011075656A1 (en) | 2009-12-18 | 2011-06-23 | The University Of British Columbia | Methods and compositions for delivery of nucleic acids |
CA2785492C (en) | 2009-12-23 | 2018-07-24 | Novartis Ag | Lipids, lipid compositions, and methods of using them |
AU2010339404B2 (en) | 2009-12-30 | 2016-01-28 | Pioneer Hi-Bred International, Inc. | Methods and compositions for the introduction and regulated expression of genes in plants |
CN102939383B (en) | 2009-12-30 | 2015-04-29 | 先锋国际良种公司 | Methods and compositions for targeted polynucleotide modification |
US20110167517A1 (en) | 2010-01-06 | 2011-07-07 | Pioneer Hi-Bred International, Inc. | Identification of diurnal rhythms in photosynthetic and non-photsynthetic tissues from zea mays and use in improving crop plants |
WO2011088163A1 (en) | 2010-01-14 | 2011-07-21 | President And Fellows Of Harvard College | Methods for modulating skeletal remodeling and patterning by modulating shn2 activity, shn3 activity, or shn2 and shn3 activity in combination |
US9597346B2 (en) | 2010-01-15 | 2017-03-21 | Cornell University | Methods for reducing protein levels in a cell |
WO2011094759A2 (en) | 2010-02-01 | 2011-08-04 | The Regents Of The University Of California | Novel diagnostic and therapeutic targets associated with or regulated by n-cadherin expression and/or epithelial to mesenchymal transition (emt) in prostate cancer and other malignancies |
BR112012021232A2 (en) | 2010-02-24 | 2015-09-08 | Basf Plant Science Co Gmbh | method for accentuating yield traits in plants, plants, buildings, uses of a building. methods of producing a transgenic plant, transgenic plants, harvestable parts of a plant, products derived from a plant, use of a nucleic acid |
CA2788241A1 (en) | 2010-02-24 | 2011-09-01 | Basf Plant Science Company Gmbh | Plants having enhanced yield-related traits and a method for making the same |
EP2361985A1 (en) | 2010-02-26 | 2011-08-31 | BASF Plant Science Company GmbH | Plants having enhanced yield-related traits and a method for making the same |
EP2361927A1 (en) | 2010-02-26 | 2011-08-31 | BASF Plant Science Company GmbH | Plants having enhanced yield-related traits and a method for making the same |
CN103154250A (en) | 2010-03-09 | 2013-06-12 | 耶路撒冷希伯来大学伊森姆研究发展有限公司 | Organism with altered carotenoid content and method of producing same |
DE112011100940T5 (en) | 2010-03-18 | 2013-01-24 | Basf Plant Science Company Gmbh | Plants with enhanced yield-related traits and methods for their production |
BR112012022880A2 (en) | 2010-03-18 | 2015-09-15 | Basf Plant Science Co Gmbh | methods for increasing yield and / or plant yield traits relative to control plants, for the production of a transgenic plant and for the production of a product, plant, construction, use of a construction, transgenic plant, harvestable parts of a plant, products derived from a plant and use of a nucleic acid |
CN102892891A (en) | 2010-03-19 | 2013-01-23 | 巴斯夫植物科学有限公司 | Plants having enhanced yield-related traits and method for making the same |
EP2547774A4 (en) | 2010-03-19 | 2014-01-15 | Basf Plant Science Co Gmbh | Plants having enhanced yield-related traits and method for making same |
EP2371845A1 (en) | 2010-03-22 | 2011-10-05 | BASF Plant Science Company GmbH | Plants having enhanced yield-related traits and a method for making the same |
US20150231215A1 (en) | 2012-06-22 | 2015-08-20 | Randolph J. Noelle | VISTA Antagonist and Methods of Use |
US10745467B2 (en) | 2010-03-26 | 2020-08-18 | The Trustees Of Dartmouth College | VISTA-Ig for treatment of autoimmune, allergic and inflammatory disorders |
CA2794483C (en) | 2010-03-26 | 2020-07-07 | Trustees Of Dartmouth College | Vista regulatory t cell mediator protein, vista binding agents and use thereof |
US20110237513A1 (en) | 2010-03-26 | 2011-09-29 | Pronota N.V. | Ltbp2 as a biomarker for renal dysfunction |
US20130045889A1 (en) | 2010-04-13 | 2013-02-21 | Pronota N.V. | Biomarkers for hypertensive disorders of pregnancy |
GB201105584D0 (en) | 2011-04-01 | 2011-05-18 | Imp Innovations Ltd | Cancer methods |
CN102918152B (en) | 2010-04-23 | 2016-04-13 | 佛罗里达大学研究基金公司 | Be used for the treatment of Lay Bai Shi congenital amaurosis-1(LCA1) RAAV-guanylate enzyme composition and method |
US9441233B2 (en) | 2010-05-06 | 2016-09-13 | Ceres, Inc. | Transgenic plants having increased biomass |
DK2569430T3 (en) | 2010-05-12 | 2019-02-04 | Univ Columbia | PROCEDURES FOR MANUFACTURING ENTEROENDOCRIN CELLS WHICH MANUFACTURE AND SECRET INSULIN |
US8476485B2 (en) | 2010-06-24 | 2013-07-02 | Academia Sinica | Non-human animal model for amyotrophic lateral sclerosis (ALS) with loss-of-TDP-43 function |
DE112011102113T5 (en) | 2010-06-24 | 2013-03-28 | Basf Plant Science Company Gmbh | Plants with enhanced yield-related traits and methods for their production |
CA2801688A1 (en) | 2010-06-25 | 2011-12-29 | Basf Plant Science Company Gmbh | Plants with enhanced yield-related traits and producing method thereof |
WO2012007945A2 (en) | 2010-07-12 | 2012-01-19 | The State Of Israel, Ministry Of Agriculture & Rural Development, Agricultural Research Organization, (A.R.O.), Volcani Center | Isolated polynucleotides and methods and plants using same for regulating plant acidity |
CA2805236A1 (en) | 2010-07-14 | 2012-01-19 | E. I. Du Pont De Nemours And Company | Blended soy protein products with a combined pufa content having altered characteristics |
EP2593555A4 (en) | 2010-07-16 | 2014-02-26 | Basf Plant Science Co Gmbh | Plants having enhanced yield-related traits and a method for making the same |
WO2012016184A2 (en) | 2010-07-30 | 2012-02-02 | Alnylam Pharmaceuticals, Inc. | Methods and compositions for delivery of active agents |
US20130202652A1 (en) | 2010-07-30 | 2013-08-08 | Alnylam Pharmaceuticals, Inc. | Methods and compositions for delivery of active agents |
JP5899213B2 (en) | 2010-08-06 | 2016-04-06 | マイカーティス エヌ.ヴェ.MyCartis NV | Pearlcan as a biomarker for renal dysfunction |
MX2013002137A (en) | 2010-08-24 | 2013-05-17 | Basf Plant Science Co Gmbh | Plants having enhanced yield-related traits and method for making the same. |
ES2377785B2 (en) | 2010-09-08 | 2012-09-26 | Universidad Miguel Hernández De Elche | PHARMACEUTICAL COMPOSITION FOR DRY EYE TREATMENT. |
SG188666A1 (en) | 2010-09-30 | 2013-05-31 | Agency Science Tech & Res | Methods and reagents for detection and treatment of esophageal metaplasia |
EP2622065B1 (en) | 2010-10-01 | 2016-09-07 | The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services | Manipulation of stem cell function by p53 isoforms |
JP6159254B2 (en) | 2010-10-06 | 2017-07-12 | フンダシオ インスティトゥト デ レセルカ ビオメディカ(イエレベ バルセロナ) | Methods for diagnosis, prognosis, and treatment of breast cancer metastasis |
WO2012051055A2 (en) | 2010-10-06 | 2012-04-19 | Bp Corporation North America Inc. | Variant cbh i polypeptides |
BR112013010278B1 (en) | 2010-10-27 | 2020-12-29 | Ceres, Inc | method to produce a plant, method to modulate the biomass composition in a plant, isolated nucleic acid and method to alter the biomass composition in a plant |
WO2012058210A1 (en) | 2010-10-29 | 2012-05-03 | Merck Sharp & Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACIDS (siNA) |
DE112011103723T5 (en) | 2010-11-10 | 2013-08-08 | Basf Plant Science Company Gmbh | Plants with enhanced yield-related traits and methods for their production |
US9072766B2 (en) | 2010-11-18 | 2015-07-07 | Beth Israel Deaconess Medical Center, Inc. | Methods of treating obesity by inhibiting nicotinamide N-methyl transferase (NNMT) |
US9644019B2 (en) | 2010-12-02 | 2017-05-09 | Carlos Zaragoza Sánchez | Compounds for treating cardiac damage after ischaemia/reperfusion |
US9150926B2 (en) | 2010-12-06 | 2015-10-06 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Diagnosis and treatment of adrenocortical tumors using human microRNA-483 |
WO2012093258A2 (en) | 2011-01-05 | 2012-07-12 | Imperial Innovations Limited | Treatment and screening |
CA2824526C (en) | 2011-01-11 | 2020-07-07 | Alnylam Pharmaceuticals, Inc. | Pegylated lipids and their use for drug delivery |
WO2012095843A1 (en) | 2011-01-13 | 2012-07-19 | Yeda Research And Development Co. Ltd. | Organisms with altered steroidal saponin and steroidal alkaloid levels and methods for producing same |
WO2012095548A2 (en) | 2011-01-13 | 2012-07-19 | Centro De Investigación Biomédica En Red De Enfermedades Neurodegenerativas (Ciberned) | Compounds for treating neurodegenerative disorders |
CA2823287A1 (en) | 2011-01-20 | 2012-07-26 | Basf Plant Science Company Gmbh | Plants having enhanced yield-related traits and method for making the same |
US9335289B2 (en) | 2011-02-07 | 2016-05-10 | The Governing Council Of The University Of Toronto | Bioprobes and methods of use thereof |
WO2012109238A2 (en) | 2011-02-07 | 2012-08-16 | President And Fellows Of Harvard College | Methods for increasing immune responses using agents that directly bind to and activate ire-1 |
US20140044644A1 (en) | 2011-02-21 | 2014-02-13 | University Of Zurich | Ankyrin g and modulators thereof for the treatment of neurodegenerative disorders |
CN103492573A (en) | 2011-02-28 | 2014-01-01 | 巴斯夫植物科学有限公司 | Plants having enhanced yield-related traits and producing methods thereof |
CA2826859A1 (en) | 2011-02-28 | 2012-09-07 | Basf Plant Science Company Gmbh | Plants having enhanced yield-related traits and producing methods thereof |
CN103582702A (en) | 2011-03-01 | 2014-02-12 | 巴斯夫植物科学有限公司 | Plants having enhanced yield-related traits and producing methods thereof |
WO2012119129A1 (en) | 2011-03-02 | 2012-09-07 | Berg Biosystems, Llc | Interrogatory cell-based assays and uses thereof |
US10184942B2 (en) | 2011-03-17 | 2019-01-22 | University Of South Florida | Natriuretic peptide receptor as a biomarker for diagnosis and prognosis of cancer |
EP2514831A1 (en) | 2011-04-19 | 2012-10-24 | Pronota NV | New biomarker for measuring beta cell activity |
GB201106845D0 (en) | 2011-04-26 | 2011-06-01 | Vib Vzw | Methods and means to produce abiotic stress tolerant plants |
US9677084B2 (en) | 2011-04-29 | 2017-06-13 | Pioneer Hi-Bred International, Inc. | Down-regulation of a homeodomain-leucine zipper I-class homeobox gene for improved plant performance |
EP2704688B1 (en) | 2011-05-05 | 2019-07-10 | Matinas BioPharma Nanotechnologies, Inc. | Cochleate compositions and methods of making and using same |
WO2012156447A1 (en) | 2011-05-18 | 2012-11-22 | Pronota N.V. | New biomarker for the classification of ovarian tumours |
WO2012160448A2 (en) | 2011-05-25 | 2012-11-29 | Innate Pharma, S.A. | Anti-kir antibodies for the treatment of inflammatory disorders |
US20140134728A1 (en) | 2011-06-01 | 2014-05-15 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Methods for adjusting expression of mitochondrial genome by microrna |
DK3011974T3 (en) | 2011-06-02 | 2018-11-12 | Univ Louisville Res Found Inc | Anti-nucleolin agent-conjugated nanoparticles |
US9920327B2 (en) | 2011-06-02 | 2018-03-20 | The Regents Of The University Of California | Plants with elevated levels of glucan |
CA2838490A1 (en) | 2011-06-10 | 2012-12-13 | Universite Libre De Bruxelles | Targets and agents for the treatment of impaired bone fracture healing |
WO2012174139A2 (en) | 2011-06-14 | 2012-12-20 | Synthon Biopharmaceuticals B.V. | Compositions and methods for making and b ioc ont aining auxotrophic transgenic plants |
CN103608030A (en) | 2011-06-21 | 2014-02-26 | 昂科发克特公司 | Compositions and methods for therapy and diagnosis of cancer |
GB201110546D0 (en) | 2011-06-22 | 2011-08-03 | Imp Innovations Ltd | Compositions |
WO2013011153A2 (en) | 2011-07-21 | 2013-01-24 | Fundació Institut D'investigació Biomèdica De Bellvitge (Idibell) | Method for the prognosis and treatment of metastasis in breast cancer |
WO2013022594A1 (en) | 2011-07-21 | 2013-02-14 | The Regents Of The University Of California | Transcription factors for the production of cellulose degrading enzymes |
WO2013023994A1 (en) | 2011-08-12 | 2013-02-21 | Pronota N.V. | New biomarker for the classification of ovarian tumours |
WO2013024121A2 (en) | 2011-08-18 | 2013-02-21 | Basf Plant Science Company Gmbh | Increase of sucrose transporter activity in the seeds of plants |
SG10201606991RA (en) | 2011-08-23 | 2016-10-28 | Foundation Medicine Inc | Novel kif5b-ret fusion molecules and uses thereof |
GB201115280D0 (en) | 2011-09-05 | 2011-10-19 | Alligator Bioscience Ab | Antibodies, uses and methods |
WO2013039880A1 (en) | 2011-09-12 | 2013-03-21 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Biomarkers and therapeutic targets of hepatocellular cancer |
ES2716723T3 (en) | 2011-09-20 | 2019-06-14 | Univ North Carolina Chapel Hill | Regulation of sodium channels by PLUNC proteins |
JP6250543B2 (en) | 2011-09-27 | 2017-12-20 | アルニラム・ファーマシューティカルズ・インコーポレーテッド | Dialiphatic substituted PEGylated lipids |
WO2013053732A1 (en) | 2011-10-12 | 2013-04-18 | Université Libre de Bruxelles | Bcl6-mediated modulation of cortical differentiation of neuronal progenitor cells |
EP2766734A1 (en) | 2011-10-14 | 2014-08-20 | Pronota NV | Procathepsin l and cathepsin l as biomarkers for ischemia |
CA2850032C (en) | 2011-10-14 | 2022-06-07 | Genentech, Inc. | Anti-htra1 antibodies and methods of use |
US10378060B2 (en) | 2011-10-14 | 2019-08-13 | Dana-Farber Cancer Institute, Inc. | ZNF365/ZFP365 biomarker predictive of anti-cancer response |
AU2012323924A1 (en) | 2011-10-14 | 2014-05-29 | The Ohio State University | Methods and materials related to ovarian cancer |
EP2771482A1 (en) | 2011-10-27 | 2014-09-03 | Institut National de la Sante et de la Recherche Medicale (INSERM) | Methods for the treatment and diagnosis of atherosclerosis |
US20150159166A1 (en) | 2011-10-31 | 2015-06-11 | Pioneer Hi Bred International Inc | Plant drought tolerance and nitrogen use efficiency by reducing plant sensitivity to ethylene |
BR112014010546B1 (en) | 2011-11-02 | 2021-04-13 | Ceres, Inc | METHOD OF INCREASING PLANT Yield IN SOIL CONTAINING HIGH LEVELS OF AL3 +, METHOD OF INCREASING TOLERANCE IN A PLANT |
WO2013083781A2 (en) | 2011-12-08 | 2013-06-13 | Pronota N.V. | Biomarkers and test panels useful in systemic inflammatory conditions |
BR112014013853A2 (en) | 2011-12-09 | 2020-01-14 | Ceres Inc | use of an isolated nucleic acid, method of obtaining a transgenic plant cell, method of obtaining a transgenic plant, method of producing a plant, method of producing biomass, method of biomass processing, method of altering the composition of biomass , biomass composition modulation method, production method of a forage product |
AU2012347263A1 (en) | 2011-12-09 | 2014-07-24 | Mycartis N.V. | LTBP2 as a biomarker for lung injury |
WO2013096455A1 (en) | 2011-12-20 | 2013-06-27 | Dana-Farber Cancer Institute, Inc. | Methods for diagnosing and treating oncogenic kras-associated cancer |
EP2606897A1 (en) | 2011-12-22 | 2013-06-26 | Laboratorios Del. Dr. Esteve, S.A. | Methods and compositions for the treatment of diseases caused by enveloped viruses |
JP6271441B2 (en) | 2012-01-27 | 2018-01-31 | アッヴィ・ドイチュラント・ゲー・エム・ベー・ハー・ウント・コー・カー・ゲー | Compositions and methods for diagnosing and treating diseases associated with neurite degeneration |
EP3456742A1 (en) | 2012-02-15 | 2019-03-20 | Novo Nordisk A/S | Antibodies that bind peptidoglycan recognition protein 1 |
WO2013120553A1 (en) | 2012-02-15 | 2013-08-22 | Novo Nordisk A/S | Antibodies that bind and block triggering receptor expressed on myeloid cells-1 (trem-1) |
US9550830B2 (en) | 2012-02-15 | 2017-01-24 | Novo Nordisk A/S | Antibodies that bind and block triggering receptor expressed on myeloid cells-1 (TREM-1) |
DK2817287T3 (en) | 2012-02-24 | 2019-01-02 | Arbutus Biopharma Corp | TRIALKYL CATIONIC LIPID AND METHODS FOR USING IT |
EP3296320A1 (en) | 2012-03-08 | 2018-03-21 | Halozyme, Inc. | Conditionally active anti-epidermal growth factor receptor antibodies and methods of use thereof |
WO2013138309A1 (en) | 2012-03-13 | 2013-09-19 | Pioneer Hi-Bred International, Inc. | Genetic reduction of male fertility in plants |
WO2013138358A1 (en) | 2012-03-13 | 2013-09-19 | Pioneer Hi-Bred International, Inc. | Genetic reduction of male fertility in plants |
EP2650682A1 (en) | 2012-04-09 | 2013-10-16 | Fundació Privada Institut de Recerca Biomèdica | Method for the prognosis and treatment of cancer metastasis |
EP2836591B1 (en) | 2012-04-09 | 2018-06-06 | The United States of America, as represented by The Secretary, Department of Health and Human Services | Methods for generation of pluripotent and multipotent cells |
WO2013153082A1 (en) | 2012-04-10 | 2013-10-17 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for the treatment of nonalcoholic steatohepatitis |
WO2013153139A1 (en) | 2012-04-11 | 2013-10-17 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for the treatment and diagnosis of acute leukemia |
KR102142161B1 (en) | 2012-05-14 | 2020-08-06 | 바이오젠 엠에이 인코포레이티드 | Lingo-2 antagonists for treatment of conditions involving motor neurons |
EP2666775A1 (en) | 2012-05-21 | 2013-11-27 | Domain Therapeutics | Substituted pyrazoloquinazolinones and pyrroloquinazolinones as allosteric modulators of group II metabotropic glutamate receptors |
CA2874521A1 (en) | 2012-05-24 | 2013-11-28 | Dana-Farber Cancer Institute, Inc. | Targeting the glutamine to pyruvate pathway for treatment of oncogenic kras-associated cancer |
CN104603288B (en) | 2012-06-06 | 2018-12-14 | 生物医学研究机构基金会 | Method for the diagnosis of lung cancer metastasis, prognosis and treatment |
ES2434853B1 (en) | 2012-06-12 | 2014-09-30 | Fundación Centro Nacional De Investigaciones Cardiovasculares Carlos Iii | Molecular marker of therapeutic potency of human mesenchymal stem cells and their uses |
EP2677035A1 (en) | 2012-06-22 | 2013-12-25 | BASF Plant Science Company GmbH | Plants having enhanced yield-related traits and a method for making the same |
CA2877533C (en) | 2012-06-22 | 2022-08-16 | The Trustees Of Dartmouth College | Novel vista-ig constructs and the use of vista-ig for treatment of autoimmune, allergic and inflammatory disorders |
US9890215B2 (en) | 2012-06-22 | 2018-02-13 | King's College London | Vista modulators for diagnosis and treatment of cancer |
WO2014007832A1 (en) | 2012-07-03 | 2014-01-09 | E. I. Du Pont De Nemours And Company | Environmentally sustainable frying oils |
EP2687852A1 (en) | 2012-07-17 | 2014-01-22 | Laboratorios Del. Dr. Esteve, S.A. | Method for diagnosing and treating chronic fatigue syndrome |
US20150285802A1 (en) | 2012-07-18 | 2015-10-08 | Dana-Farber Cancer Institute, Inc. | Methods for treating, preventing and predicting risk of developing breast cancer |
CA3163776A1 (en) | 2012-08-03 | 2014-02-06 | Foundation Medicine, Inc. | Human papilloma virus as predictor of cancer prognosis |
EP2885411B1 (en) | 2012-08-16 | 2018-12-05 | VIB vzw | Means and methods for altering the lignin pathway in plants |
CN105246507B (en) | 2012-09-07 | 2019-01-25 | 达特茅斯大学理事会 | VISTA regulator for diagnosing and treating cancer |
JP6387350B2 (en) | 2012-09-28 | 2018-09-05 | ザ・ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル | Adeno-associated virus vector targeting oligodendrocytes |
KR20210063443A (en) | 2012-10-09 | 2021-06-01 | 바이오젠 엠에이 인코포레이티드 | Combination therapies and uses for treatment of demyelinating disorders |
US10114022B2 (en) | 2012-10-12 | 2018-10-30 | Inbiomotion S.L. | Method for the diagnosis, prognosis and treatment of prostate cancer metastasis |
US10119171B2 (en) | 2012-10-12 | 2018-11-06 | Inbiomotion S.L. | Method for the diagnosis, prognosis and treatment of prostate cancer metastasis |
EP2914621B1 (en) | 2012-11-05 | 2023-06-07 | Foundation Medicine, Inc. | Novel ntrk1 fusion molecules and uses thereof |
AU2013202668B2 (en) | 2012-12-24 | 2014-12-18 | Adelaide Research & Innovation Pty Ltd | Inhibition of cancer growth and metastasis |
KR20210041631A (en) | 2013-01-09 | 2021-04-15 | 유니버시티 오브 마이애미 | Compositions and methods for the regulation of t regulatory cells using tl1a-ig fusion protein |
WO2014113729A2 (en) | 2013-01-18 | 2014-07-24 | Foundation Mecicine, Inc. | Methods of treating cholangiocarcinoma |
AU2014211570A1 (en) | 2013-01-29 | 2015-07-23 | The University Court Of The University Of Glasgow | Methods and means for increasing stress tolerance and biomass in plants |
WO2014127835A1 (en) | 2013-02-22 | 2014-08-28 | Christian-Albrechts-Universität Zu Kiel | Plant-derived resistance gene |
US20160184449A1 (en) | 2013-02-28 | 2016-06-30 | University Of Massachusetts | Peptide-and amine-modified glucan particles for delivery of therapeutic cargoes |
AU2014224205C1 (en) | 2013-03-08 | 2019-04-04 | Novartis Ag | Lipids and lipid compositions for the delivery of active agents |
WO2014164014A1 (en) | 2013-03-11 | 2014-10-09 | Pioneer Hi-Bred International, Inc. | Genes for improving nutrient uptake and abiotic stress tolerance in plants |
US20160017360A1 (en) | 2013-03-13 | 2016-01-21 | Pioneer Hi-Bred International, Inc. | Functional expression of bacterial major facilitator superfamily mfs gene in maize to improve agronomic traits and grain yield |
CA2905418C (en) | 2013-03-13 | 2023-03-28 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods for modulating chemotherapeutic cytotoxicity |
WO2014164074A1 (en) | 2013-03-13 | 2014-10-09 | Pioneer Hi-Bred International, Inc. | Enhanced nitrate uptake and nitrate translocation by over-expressing maize functional low-affinity nitrate transporters in transgenic maize |
EP2970970B1 (en) | 2013-03-14 | 2018-12-12 | Andes Biotechnologies Global, Inc. | Antisense oligonucleotides for treatment of cancer stem cells |
US9302005B2 (en) | 2013-03-14 | 2016-04-05 | Mayo Foundation For Medical Education And Research | Methods and materials for treating cancer |
WO2014153206A2 (en) | 2013-03-14 | 2014-09-25 | Andes Biotechnologies S.A. | Methods for detecting and treating multiple myeloma |
US20140304857A1 (en) | 2013-03-14 | 2014-10-09 | Pioneer Hi Bred International Inc | Maize stress related transcription factor 18 and uses thereof |
CA2899089C (en) | 2013-03-15 | 2021-10-26 | Biogen Ma Inc. | Factor ix polypeptide formulations |
WO2014184679A2 (en) | 2013-03-15 | 2014-11-20 | Inbiomotion S.L. | Method for the prognosis and treatment of renal cell carcinoma metastasis |
CA2906394A1 (en) | 2013-03-15 | 2014-09-18 | Fundacio Institut De Recerca Biomedica (Irb Barcelona) | Method for the prognosis and treatment of cancer metastasis |
SG11201507366RA (en) | 2013-03-15 | 2015-10-29 | Gen Hospital Corp | Glycine, mitochondrial one-carbon metabolism, and cancer |
US20160017350A1 (en) | 2013-03-15 | 2016-01-21 | Pioneer Hi-Bred International, Inc. | Compositions and methods of use of acc oxidase polynucleotides and polypeptides |
EP3272880B1 (en) | 2013-03-15 | 2020-11-25 | Fundació Institut de Recerca Biomèdica (IRB Barcelona) | Method for the diagnosis, prognosis and treatment of metastatic cancer |
US10017778B2 (en) | 2013-03-21 | 2018-07-10 | Vib Vzw | Means and methods for the reduction of photorespiration in crops |
EP3473272A1 (en) | 2013-03-29 | 2019-04-24 | Alexion Pharmaceuticals, Inc. | Compositions and methods for increasing the serum half-life of a therapeutic agent targeting complement c5 |
US10806119B2 (en) | 2013-06-05 | 2020-10-20 | Yeda Research And Development Co. Ltd. | Plant with altered content of steroidal alkaloids |
WO2014195944A1 (en) | 2013-06-05 | 2014-12-11 | Yeda Research And Development Co. Ltd. | Plant with altered content of steroidal glycoalkaloids |
UA122386C2 (en) | 2013-07-01 | 2020-11-10 | Байєр Кропсаєнс Нв | Methods and means for modulating flowering time in monocot plants |
WO2015006543A1 (en) | 2013-07-10 | 2015-01-15 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Method for predicting and detecting tumor metastasis in kidney cancer |
JP6702862B2 (en) | 2013-07-11 | 2020-06-03 | アルニラム ファーマスーティカルズ インコーポレイテッドAlnylam Pharmaceuticals, Inc. | Oligonucleotide-ligand conjugates and methods for their preparation |
ES2964893T3 (en) | 2013-07-17 | 2024-04-10 | Found Medicine Inc | Treatment procedures for urothelial carcinomas |
AU2014318545A1 (en) | 2013-09-12 | 2016-03-24 | Halozyme, Inc. | Modified anti-epidermal growth factor receptor antibodies and methods of use thereof |
US20160223547A1 (en) | 2013-09-13 | 2016-08-04 | Angels SIERRA JIMÉNLEZ | Marker for predicting metastasis of breast cancer |
ES2724300T3 (en) | 2013-09-25 | 2019-09-10 | Univ Cornell | Compounds for inducing antitumor immunity and methods thereof |
EP3049085B9 (en) | 2013-09-26 | 2021-08-18 | Beth Israel Deaconess Medical Center, Inc. | Sgk1 inhibitors in the treatment of long qt syndrome |
US10259875B2 (en) | 2013-10-01 | 2019-04-16 | Mayo Foundation For Medical Education And Research | Methods for treating cancer in patients with elevated levels of BIM |
EP3524698A1 (en) | 2013-10-09 | 2019-08-14 | Fundació Institut de Recerca Biomèdica IRB (Barcelona) | Method for the prognosis and treatment of cancer metastasis |
EP3055426B1 (en) | 2013-10-09 | 2019-06-19 | The United States of America as represented by The Secretary Department of Health and Human Services | Detection of hepatitis delta virus (hdv) for the diagnosis and treatment of sjögren's syndrome and lymphoma |
WO2015066190A1 (en) | 2013-10-29 | 2015-05-07 | President And Fellows Of Harvard College | Methods and compositions for inhibting oxidative stress |
WO2015074057A1 (en) | 2013-11-18 | 2015-05-21 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Microsphere-based delivery and ex vivo manipulation of dendritic cells for autoimmune therapies |
GB201322094D0 (en) | 2013-12-13 | 2014-01-29 | Electrophoretics Ltd | Methods and compositions relating to alzheimers disease |
WO2015095346A1 (en) | 2013-12-19 | 2015-06-25 | Novartis Ag | Lipids and lipid compositions for the delivery of active agents |
PL3083556T3 (en) | 2013-12-19 | 2020-06-29 | Novartis Ag | Lipids and lipid compositions for the delivery of active agents |
RS63295B1 (en) | 2013-12-24 | 2022-06-30 | Janssen Pharmaceutica Nv | Anti-vista antibodies and fragments |
US11014987B2 (en) | 2013-12-24 | 2021-05-25 | Janssen Pharmaceutics Nv | Anti-vista antibodies and fragments, uses thereof, and methods of identifying same |
EP2896698A1 (en) | 2014-01-17 | 2015-07-22 | BASF Plant Science Company GmbH | Plants having one or more enhanced yield-related traits and a method for making the same |
US20170166920A1 (en) | 2014-01-30 | 2017-06-15 | Two Blades Foundation | Plants with enhanced resistance to phytophthora |
WO2015136001A1 (en) | 2014-03-11 | 2015-09-17 | Cellectis | Method for generating t-cells compatible for allogenic transplantation |
WO2015149006A2 (en) | 2014-03-27 | 2015-10-01 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for modulating ncoa4-mediated autophagic targeting of ferritin |
CA2944903A1 (en) | 2014-04-24 | 2015-10-29 | Dana-Farber Cancer Institute, Inc. | Tumor suppressor and oncogene biomarkers predictive of anti-immune checkpoint inhibitor response |
US9101100B1 (en) | 2014-04-30 | 2015-08-11 | Ceres, Inc. | Methods and materials for high throughput testing of transgene combinations |
WO2015171603A1 (en) | 2014-05-06 | 2015-11-12 | Two Blades Foundation | Methods for producing plants with enhanced resistance to oomycete pathogens |
US10302653B2 (en) | 2014-05-22 | 2019-05-28 | Mayo Foundation For Medical Education And Research | Distinguishing antagonistic and agonistic anti B7-H1 antibodies |
US11123426B2 (en) | 2014-06-11 | 2021-09-21 | The Trustees Of Dartmouth College | Use of vista agonists and antagonists to suppress or enhance humoral immunity |
US9458464B2 (en) | 2014-06-23 | 2016-10-04 | The Johns Hopkins University | Treatment of neuropathic pain |
WO2015200281A1 (en) | 2014-06-24 | 2015-12-30 | The Regents Of The University Of California | Methods for production of xylosyl-xylitol oligomers |
EP3160503B1 (en) | 2014-06-26 | 2021-02-17 | The Trustees of Columbia University in the City of New York | Inhibition of serotonin expression in gut enteroendocrine cells results in conversion to insulin-positive cells |
US20170159065A1 (en) | 2014-07-08 | 2017-06-08 | Vib Vzw | Means and methods to increase plant yield |
AU2015289691B2 (en) | 2014-07-15 | 2020-12-24 | Ceres, Inc. | Methods of increasing crop yield under abiotic stress |
US10342761B2 (en) | 2014-07-16 | 2019-07-09 | Novartis Ag | Method of encapsulating a nucleic acid in a lipid nanoparticle host |
LT3172232T (en) | 2014-07-17 | 2024-02-12 | Novo Nordisk A/S | Site directed mutagenesis of trem-1 antibodies for decreasing viscosity. |
WO2016011381A1 (en) | 2014-07-18 | 2016-01-21 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Reducing cxcr4 expression and/or function to enhance engraftment of hematopoietic stem cells |
US10517875B2 (en) | 2014-07-23 | 2019-12-31 | Mayo Foundation for Medical Engineering and Research | Targeting DNA-PKcs and B7-H1 to treat cancer |
JP6731912B2 (en) | 2014-09-05 | 2020-07-29 | ノバルティス アーゲー | Lipids and lipid compositions for delivery of active substances |
EP3000814A1 (en) | 2014-09-26 | 2016-03-30 | Domain Therapeutics | Substituted pyrazoloquinazolinones and pyrroloquinazolinones as allosteric modulators of group II metabotropic glutamate receptors |
WO2016050512A1 (en) | 2014-10-03 | 2016-04-07 | Bayer Cropscience Nv | Methods and means for increasing stress tolerance and biomass in plants |
WO2016057367A1 (en) | 2014-10-06 | 2016-04-14 | Dana-Farber Cancer Institute, Inc. | Angiopoietin-2 biomarkers predictive of anti-immune checkpoint response |
RU2727015C2 (en) | 2014-11-21 | 2020-07-17 | Дзе Юниверсити Оф Норт Каролина Эт Чепел Хилл | Aav vectors aimed at the central nervous system |
AU2015357463B2 (en) | 2014-12-05 | 2021-10-07 | Immunext, Inc. | Identification of VSIG8 as the putative vista receptor and its use thereof to produce vista/VSIG8 modulators |
AU2015358868A1 (en) | 2014-12-11 | 2017-06-01 | Inbiomotion S.L. | Binding members for human C-Maf |
US10435467B2 (en) | 2015-01-08 | 2019-10-08 | Biogen Ma Inc. | LINGO-1 antagonists and uses for treatment of demyelinating disorders |
EP3253786A4 (en) | 2015-02-06 | 2018-10-17 | The University of North Carolina at Chapel Hill | Optimized human clotting factor viii gene expression cassettes and their use |
US10948492B2 (en) | 2015-03-06 | 2021-03-16 | Dana-Farber Cancer Institute, Inc. | PD-L2 biomarkers predictive of PD-1 pathway inhibitor responses in esophagogastric cancers |
EP3268025B1 (en) | 2015-03-10 | 2020-05-06 | University of Massachusetts | Targeting gdf6 and bmp signaling for anti-melanoma therapy |
WO2016168756A1 (en) | 2015-04-15 | 2016-10-20 | Synthetic Genomics, Inc. | Algal chloroplastic srp54 mutants |
US10857237B2 (en) | 2015-05-05 | 2020-12-08 | University Of Louisville Research Foundation, Inc. | Anti-nucleolin agent-conjugated nanoparticles as radio-sensitizers and MRI and/or X-ray contrast agents |
WO2016191734A1 (en) | 2015-05-28 | 2016-12-01 | University Of California Berkeley | Monofunctional aldehyde and alcohol dehydrogenases for production of fuels and commodity chemicals |
CN114805576A (en) | 2015-06-24 | 2022-07-29 | 詹森药业有限公司 | anti-VISTA antibodies and fragments |
CA2997745A1 (en) | 2015-09-14 | 2017-03-23 | Children's Hospital Medical Center | Methods and compositions for treatment of gaucher disease via modulation of c5a receptor |
WO2017062790A1 (en) | 2015-10-09 | 2017-04-13 | Two Blades Foundation | Cold shock protein receptors and methods of use |
US10875923B2 (en) | 2015-10-30 | 2020-12-29 | Mayo Foundation For Medical Education And Research | Antibodies to B7-H1 |
AU2016346630B2 (en) | 2015-10-30 | 2022-02-03 | Pioneer Hi-Bred International, Inc. | Methods and compositions for rapid plant transformation |
SG10202001808VA (en) | 2015-10-30 | 2020-04-29 | Genentech Inc | Anti-htra1 antibodies and methods of use thereof |
EP3371313B1 (en) | 2015-11-06 | 2020-10-14 | Pioneer Hi-Bred International, Inc. | Methods and compositions of improved plant transformation |
EP3173483A1 (en) | 2015-11-27 | 2017-05-31 | Fundació Privada Institut d'Investigació Oncològica de Vall-Hebron | Agents for the treatment of diseases associated with undesired cell proliferation |
TWI756204B (en) | 2016-02-12 | 2022-03-01 | 比利時商楊森製藥公司 | Anti-vista antibodies and fragments, uses thereof, and methods of identifying same |
EP3423488A4 (en) | 2016-02-29 | 2019-11-06 | Foundation Medicine, Inc. | Methods of treating cancer |
WO2017152182A1 (en) | 2016-03-04 | 2017-09-08 | Rhode Island Hospital | Targeting microrna for cancer treatment |
CA3017594A1 (en) | 2016-03-15 | 2017-09-21 | National Research Council Of Canada | Modulating plant abiotic stress responses using the kanghan gene family |
US11859196B2 (en) | 2016-03-15 | 2024-01-02 | National Research Council Of Canada | Modulating drought tolerance in Brassicaceae using the Kanghan gene family |
WO2017161206A1 (en) | 2016-03-16 | 2017-09-21 | Halozyme, Inc. | Conjugates containing conditionally active antibodies or antigen-binding fragments thereof, and methods of use |
WO2017161264A1 (en) | 2016-03-18 | 2017-09-21 | Pioneer Hi-Bred International, Inc. | Methods and compositions for producing clonal, non-reduced, non-recombined gametes |
BR112018071153A2 (en) | 2016-04-15 | 2019-04-16 | Immunext, Inc. | anti-human antibodies and their use |
CA2932910A1 (en) | 2016-06-14 | 2017-12-14 | Entos Pharmaceuticals Inc. | Methods for diagnosing and treating metastatic cancer |
WO2018005553A1 (en) | 2016-06-27 | 2018-01-04 | Intrexon Corporation | Compositions and methods for making benzylisoquinoline alkaloids, morphinan alkaloids, thebaine, and derivatives thereof |
WO2018013714A1 (en) | 2016-07-13 | 2018-01-18 | Biogen Ma Inc. | Dosage regimens of lingo-1 antagonists and uses for treatment of demyelinating disorders |
CA3034739A1 (en) | 2016-08-22 | 2018-03-01 | Biolumic Limited | System, device and methods of seed treatment |
US11136409B2 (en) | 2016-09-20 | 2021-10-05 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for identification, assessment, prevention, and treatment of AML using USP10 biomarkers and modulators |
WO2018112232A1 (en) | 2016-12-14 | 2018-06-21 | Progenity Inc. | Treatment of a disease of the gastrointestinal tract with an il-12/il-23 inhibitor released using an ingestible device |
WO2018112256A1 (en) | 2016-12-14 | 2018-06-21 | Progenity Inc. | Treatment of a disease of the gastrointestinal tract with an il-1 inhibitor |
WO2018112235A1 (en) | 2016-12-14 | 2018-06-21 | Progenity Inc. | Treatment of a disease of the gastrointestinal tract with a smad7 inhibitor |
WO2018112237A1 (en) | 2016-12-14 | 2018-06-21 | Progenity Inc. | Treatment of a disease of the gastrointestinal tract with an il-6r inhibitor |
US20190343425A1 (en) | 2016-12-14 | 2019-11-14 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with a tnf inhibitor |
CN116712540A (en) | 2016-12-14 | 2023-09-08 | 比奥拉治疗股份有限公司 | Treatment of gastrointestinal disorders using integrin inhibitors |
CN116869457A (en) | 2016-12-14 | 2023-10-13 | 比奥拉治疗股份有限公司 | Treatment of gastrointestinal disorders and devices using JAK inhibitors |
IL250538A0 (en) | 2017-02-09 | 2017-03-30 | Yeda Res & Dev | Glycoalkaloid metabolism enyzymes (games) and uses thereof |
CA3054159A1 (en) | 2017-03-30 | 2018-10-04 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with a chst15 inhibitor |
WO2018183932A1 (en) | 2017-03-30 | 2018-10-04 | Progenity Inc. | Treatment of a disease of the gastrointestinal tract with a il-13 inhibitor |
US20210138213A1 (en) | 2017-03-30 | 2021-05-13 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with an immune modulatory agent released using an ingestible device |
WO2018185110A1 (en) | 2017-04-03 | 2018-10-11 | Fit Biotech Oy | Novel expression vectors and uses thereof |
EP3634496A4 (en) | 2017-06-06 | 2021-09-08 | Dana-Farber Cancer Institute, Inc. | Methods for sensitizing cancer cells to t cell-mediated killing by modulating molecular pathways |
WO2019018451A2 (en) | 2017-07-17 | 2019-01-24 | The Regents Of The University Of Colorado | Compositions and methods for preventing and treating radiation-induced bystander effects caused by radiation or radiotherapy |
WO2019038594A2 (en) | 2017-08-21 | 2019-02-28 | Biolumic Limited | High growth and high hardiness transgenic plants |
MX2020005939A (en) | 2017-12-08 | 2020-08-24 | Synthetic Genomics Inc | Improving algal lipid productivity via genetic modification of a tpr domain containing protein. |
MA51184A (en) | 2017-12-15 | 2020-10-21 | Juno Therapeutics Inc | ANTI-CCT5 BINDING MOLECULES AND RELATED METHODS OF USE |
BR112020010329A2 (en) | 2017-12-29 | 2020-11-17 | Synthetic Genomics, Inc. | genetic modulation of photosynthetic organisms for enhanced growth |
WO2019140009A1 (en) | 2018-01-09 | 2019-07-18 | Cibus Us Llc | Shatterproof genes and mutations |
US20210031012A1 (en) | 2018-01-26 | 2021-02-04 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with a pde4 inhibitor |
CN111936520A (en) | 2018-04-02 | 2020-11-13 | 百时美施贵宝公司 | anti-TREM-1 antibodies and uses thereof |
WO2019246317A1 (en) | 2018-06-20 | 2019-12-26 | Progenity, Inc. | Treatment of a disease or condition in a tissue originating from the endoderm |
EP3810085A1 (en) | 2018-06-20 | 2021-04-28 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with an integrin inhibitor |
EP3810095A1 (en) | 2018-06-20 | 2021-04-28 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with a tnf inhibitor |
US20220257600A1 (en) | 2018-06-20 | 2022-08-18 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with a jak or other kinase inhibitor |
US20210363233A1 (en) | 2018-06-20 | 2021-11-25 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with an il-12/il-23 inhibitor |
EP3833747A1 (en) | 2018-06-28 | 2021-06-16 | Pioneer Hi-Bred International, Inc. | Methods for selecting transformed plants |
JP2021529780A (en) | 2018-07-03 | 2021-11-04 | ノバルティス アーゲー | Methods of Treatment or Selection of Treatment for Subjects Resistant to TNF Inhibitors Using NLRP3 Antagonists |
CN112969785A (en) | 2018-09-06 | 2021-06-15 | 耶达研究及发展有限公司 | Cellulose synthase-like enzyme and use thereof |
JP2022500427A (en) | 2018-09-17 | 2022-01-04 | 国立大学法人京都大学 | Administration of anti-C5 agents for the treatment of liver injury or liver failure |
EP3870168A1 (en) | 2018-10-24 | 2021-09-01 | Novartis AG | Compounds and compositions for treating conditions associated with nlrp activity |
AU2019369415A1 (en) | 2018-10-31 | 2021-03-25 | Pioneer Hi-Bred International, Inc. | Compositions and methods for Ochrobactrum-mediated plant transformation |
ES2957692T3 (en) | 2018-11-13 | 2024-01-24 | Novartis Ag | Compounds and compositions for the treatment of conditions associated with NLRP activity |
WO2020102098A1 (en) | 2018-11-13 | 2020-05-22 | Novartis Inflammasome Research, Inc. | Compounds and compositions for treating conditions associated with nlrp activity |
CN116726361A (en) | 2018-11-19 | 2023-09-12 | 比奥拉治疗股份有限公司 | Methods and devices for treating diseases with biologic therapeutic agents |
JP2022533287A (en) | 2019-01-22 | 2022-07-22 | ノバルティス アーゲー | Compounds and compositions for treating conditions associated with NLRP activity |
IL265841A (en) | 2019-04-03 | 2020-10-28 | Yeda Res & Dev | Plant expressing animal milk proteins |
EP3953486A2 (en) | 2019-04-11 | 2022-02-16 | Eleszto Genetika, Inc. | Microorganisms and methods for the fermentation of cannabinoids |
JP2022529917A (en) | 2019-04-18 | 2022-06-27 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | Methods for cancer treatment and prognosis |
US11473086B2 (en) | 2019-06-19 | 2022-10-18 | Ut-Battelle, Llc | Loss of function alleles of PtEPSP-TF and its regulatory targets in rice |
EP3987291A1 (en) | 2019-06-21 | 2022-04-27 | IFM Due, Inc. | Methods of treating cancer |
WO2021002887A1 (en) | 2019-07-02 | 2021-01-07 | Novartis Inflammasome Research, Inc. | Gut-targeted nlrp3 antagonists and their use in therapy |
WO2021019536A1 (en) | 2019-07-30 | 2021-02-04 | The State Of Israel, Ministry Of Agriculture & Rural Development, Agricultural Research Organization (Aro) (Volcani Center) | Methods of controlling cannabinoid synthesis in plants or cells and plants and cells produced thereby |
ES2918001A2 (en) | 2019-08-14 | 2022-07-13 | Acuitas Therapeutics Inc | Improved lipid nanoparticles for delivery of nucleic acids |
CN115666704A (en) | 2019-12-13 | 2023-01-31 | 比奥拉治疗股份有限公司 | Ingestible device for delivery of therapeutic agents to the gastrointestinal tract |
WO2021198534A1 (en) | 2020-04-04 | 2021-10-07 | Oxurion NV | Plasma kallikrein inhibitors for use in the treatment of coronaviral disease |
WO2022140410A1 (en) | 2020-12-22 | 2022-06-30 | Ifm Due, Inc. | Methods of treating cancer |
US20240100017A1 (en) | 2020-12-22 | 2024-03-28 | Ifm Due, Inc. | Methods of treating cancer |
EP4267126A1 (en) | 2020-12-22 | 2023-11-01 | IFM Due, Inc. | Methods of treating cancer |
EP4267127A1 (en) | 2020-12-22 | 2023-11-01 | IFM Due, Inc. | Methods of treating cancer |
WO2022147480A1 (en) | 2020-12-30 | 2022-07-07 | Ansun Biopharma, Inc. | Oncolytic virus encoding sialidase and multispecific immune cell engager |
EP4314016A1 (en) | 2021-03-31 | 2024-02-07 | Entrada Therapeutics, Inc. | Cyclic cell penetrating peptides |
WO2022214632A1 (en) | 2021-04-07 | 2022-10-13 | Neoplants Sas | Compositions and methods for indoor air remediation |
CA3218805A1 (en) | 2021-05-10 | 2022-11-17 | Ziqing QIAN | Compositions and methods for intracellular therapeutics |
EP4337263A1 (en) | 2021-05-10 | 2024-03-20 | Entrada Therapeutics, Inc. | Compositions and methods for modulating interferon regulatory factor-5 (irf-5) activity |
EP4337261A2 (en) | 2021-05-10 | 2024-03-20 | Entrada Therapeutics, Inc. | Compositions and methods for modulating mrna splicing |
WO2022271818A1 (en) | 2021-06-23 | 2022-12-29 | Entrada Therapeutics, Inc. | Antisense compounds and methods for targeting cug repeats |
IL310547A (en) | 2021-08-05 | 2024-03-01 | Sanegene Bio Usa Inc | 1'-alkyl modified ribose derivatives and methods of use |
EP4380352A1 (en) | 2021-08-06 | 2024-06-12 | KWS Vegetables B.V. | Durable downy mildew resistance in spinach |
IT202100023357A1 (en) | 2021-09-09 | 2023-03-09 | Cheirontech S R L | Peptides with anti-angiogenic activity |
AU2022352676A1 (en) | 2021-09-22 | 2024-03-14 | Sanegene Bio Usa Inc. | 2'-alkyl or 3'- alkyl modified ribose derivatives for use in the in-vivo delivery of oligonucleotides |
CA3233097A1 (en) | 2021-09-30 | 2023-04-06 | Katherine Diane GRIBBLE | Compositions and methods for treating kcnq4-associated hearing loss |
WO2023059695A1 (en) | 2021-10-05 | 2023-04-13 | Sanegene Bio Usa Inc. | Polyhydroxylated cyclopentane derivatives and methods of use |
WO2023144792A1 (en) | 2022-01-31 | 2023-08-03 | Genevant Sciences Gmbh | Poly(alkyloxazoline)-lipid conjugates and lipid particles containing same |
WO2023144030A1 (en) | 2022-01-31 | 2023-08-03 | Oxurion NV | Plasma kallikrein inhibitor therapy for anti-vegf sensitization |
WO2023144798A1 (en) | 2022-01-31 | 2023-08-03 | Genevant Sciences Gmbh | Ionizable cationic lipids for lipid nanoparticles |
WO2023148016A1 (en) | 2022-02-04 | 2023-08-10 | Oxurion NV | Biomarker for plasma kallikrein inhibitor therapy response |
US20230346819A1 (en) | 2022-02-22 | 2023-11-02 | Sanegene Bio Usa Inc. | 5'-modified carbocyclic ribonucleotide derivatives and methods of use |
WO2024015796A1 (en) | 2022-07-11 | 2024-01-18 | Sanegene Bio Usa Inc. | Optimized 2'- modified ribose derivatives and methods of use |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4987071A (en) * | 1986-12-03 | 1991-01-22 | University Patents, Inc. | RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods |
-
1986
- 1986-12-03 US US06/937,327 patent/US4987071A/en not_active Expired - Lifetime
-
1987
- 1987-12-02 WO PCT/US1987/003161 patent/WO1988004300A1/en not_active Application Discontinuation
- 1987-12-02 DE DE3751567T patent/DE3751567T2/en not_active Revoked
- 1987-12-02 EP EP88901380A patent/EP0291533B1/en not_active Revoked
- 1987-12-02 AT AT88901380T patent/ATE129251T1/en not_active IP Right Cessation
- 1987-12-02 JP JP63501538A patent/JP2530906B2/en not_active Expired - Lifetime
-
1990
- 1990-08-03 US US07/562,672 patent/US5093246A/en not_active Expired - Lifetime
-
1992
- 1992-02-28 US US07/843,737 patent/US5354855A/en not_active Expired - Lifetime
-
1994
- 1994-07-21 US US08/278,624 patent/US5591610A/en not_active Expired - Lifetime
-
1995
- 1995-12-14 HK HK188395A patent/HK188395A/en not_active IP Right Cessation
-
1996
- 1996-06-05 US US08/671,824 patent/US6025167A/en not_active Expired - Fee Related
-
1998
- 1998-01-09 US US09/005,325 patent/US6180399B1/en not_active Expired - Fee Related
Non-Patent Citations (5)
Title |
---|
Biochemistry, Volume 25, issued 1986, August, (Washington, D.C., U.S.A.), (B. BASS et al) "Ribozyme Inhibitors: Deoxyguanosine and Dideoxyguanosine are Competitive Inhibitors of Self Splicing of the Tetrahymena Ribosomal Ribonucleic Acid Precursor". See pages 4473-4477, see particularly pages 4473 and 4476. * |
Nature, Volume 324 issued 1986 December, (London, U.K.), (A. ZAUG et al), "The Tetrahymena Ribozyme Acts like an RNA restriction Endonuclease". See pages 429-433. * |
Proceedings National Academy of Sciences, Volume 83, issued 1986, June (Washington, D.C., U.S.A.), (T. CECH), "a Model for RNA-catalyzed Replication of RNA". See pages 4360-4363. * |
Science, Volume 224, issued 1984 May, (Washington, D.C., U.S.A.), (A. ZAUG et al), a Labile Phosphodiester Bond at the Ligation Junction in a Circular Intervening Sequence RNA", see pages 574-578, see particularly pages 574, 576, 577 and 578, * |
Science, Volume 321, issued 1986, January, (Washington, D.C., U.S.A.), (A. ZAUG et al), "The Intervening Sequence RNA of Tetrahymena is an Enzyme". See pages 470-475, see particularly pages 470, 471 and 475. * |
Cited By (264)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6025167A (en) * | 1986-12-03 | 2000-02-15 | Competitive Technologies, Inc. | RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods |
US6180399B1 (en) | 1986-12-03 | 2001-01-30 | Competitive Technologies, Inc. | RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods |
US6696250B1 (en) | 1986-12-03 | 2004-02-24 | Competitive Technologies, Inc. | RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods |
EP0321201A2 (en) * | 1987-12-15 | 1989-06-21 | Gene Shears Pty. Limited | Ribozymes |
EP0321201A3 (en) * | 1987-12-15 | 1990-01-10 | Commonwealth Scientific And Industrial Research Organisation | Ribozymes |
EP0334383A2 (en) * | 1988-03-25 | 1989-09-27 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Transgenic plant with modified physiology, morphology and modified hormone metabolism, tissue cultures of this plant and process for its preparation |
WO1989009262A2 (en) * | 1988-03-25 | 1989-10-05 | Max-Planck Gesellschaft Zur Förderung Der Wissensc | Transgenic plant with modified physiology, morphology and modified hormone metabolism, tissue cultures of this plant and process for its preparation |
WO1989009262A3 (en) * | 1988-03-25 | 1989-12-28 | Max Planck Gesellschaft | Transgenic plant with modified physiology, morphology and modified hormone metabolism, tissue cultures of this plant and process for its preparation |
EP0334383A3 (en) * | 1988-03-25 | 1990-01-31 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Transgenic plant with modified physiology, morphology and modified hormone metabolism, tissue cultures of this plant and process for its preparation |
JP2750127B2 (en) * | 1988-07-29 | 1998-05-13 | 三共株式会社 | Method for Cleavage of Specific Site of Polyribonucleotide by Ribozyme |
JPH02195883A (en) * | 1988-07-29 | 1990-08-02 | Sankyo Co Ltd | Cutting method of specific part of polyribonucleotide by ribozyme |
EP0360257A3 (en) * | 1988-09-20 | 1991-04-17 | The Board Of Regents For Northern Illinois University | Rna catalyst for cleaving specific rna sequences |
US5866701A (en) * | 1988-09-20 | 1999-02-02 | The Board Of Regents For Northern Illinois University Of Dekalb | HIV targeted hairpin ribozymes |
US5858785A (en) * | 1988-09-20 | 1999-01-12 | The Board Of Regents For Northern Illinois University Of Dekalb | HIV targeted ribozymes |
US5856188A (en) * | 1988-09-20 | 1999-01-05 | The Board Of Regents For Northern Illinois University Of Dekalb | Hairpin ribozymes |
US5869339A (en) * | 1988-09-20 | 1999-02-09 | The Board Of Regents For Northern Illinois University Of Dekalb | HIV targeted hairpin ribozymes |
EP0360257A2 (en) * | 1988-09-20 | 1990-03-28 | The Board Of Regents For Northern Illinois University | RNA catalyst for cleaving specific RNA sequences |
EP0700996A1 (en) * | 1988-09-20 | 1996-03-13 | The Board Of Regents For Northern Illinois University | RNA catalyst for cleaving specific RNA sequences |
EP0812912A1 (en) * | 1988-09-20 | 1997-12-17 | The Board Of Regents For Northern Illinois University | RNA Catalyst for cleaving specific RNA sequences |
EP0387775A1 (en) * | 1989-03-16 | 1990-09-19 | BOEHRINGER INGELHEIM INTERNATIONAL GmbH | Genetic construct for inhibiting RNA function |
US5728521A (en) * | 1989-03-24 | 1998-03-17 | Yale University | Targeted cleavage of RNA using eukaryotic ribonuclease P and external guide sequence |
US5624824A (en) * | 1989-03-24 | 1997-04-29 | Yale University | Targeted cleavage of RNA using eukaryotic ribonuclease P and external guide sequence |
EP0389299A1 (en) * | 1989-03-24 | 1990-09-26 | University Patents, Inc. | RNA ribozyme restriction endoribonucleases and methods |
US5168053A (en) * | 1989-03-24 | 1992-12-01 | Yale University | Cleavage of targeted RNA by RNAase P |
WO1991004324A1 (en) * | 1989-09-25 | 1991-04-04 | Innovir Laboratories, Inc. | Ribozyme compositions and methods for use |
AU645083B2 (en) * | 1990-03-21 | 1994-01-06 | University Of Colorado Foundation, Inc., The | Site specific cleavage of single-stranded DNA |
US5180818A (en) * | 1990-03-21 | 1993-01-19 | The University Of Colorado Foundation, Inc. | Site specific cleavage of single-stranded dna |
WO1991018913A1 (en) * | 1990-06-07 | 1991-12-12 | City Of Hope | Ribozyme mediated reversal of transformation by cleavage of the hras oncogene rna |
US6258941B1 (en) | 1990-06-14 | 2001-07-10 | Washington University | RNA hydrolysis |
WO1991019789A1 (en) * | 1990-06-19 | 1991-12-26 | Commonwealth Scientific And Industrial Research Organisation | Endonucleases |
WO1992003566A1 (en) * | 1990-08-17 | 1992-03-05 | Yale University | Therapeutic ribozyme compositions |
WO1992007065A1 (en) * | 1990-10-12 | 1992-04-30 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Modified ribozymes |
US5698687A (en) * | 1990-10-12 | 1997-12-16 | Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. | Modified ribozymls |
US5672695A (en) * | 1990-10-12 | 1997-09-30 | Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. | Modified ribozymes |
US6890908B1 (en) | 1990-10-12 | 2005-05-10 | Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. | Modified ribozymes |
US6015794A (en) * | 1991-01-17 | 2000-01-18 | The General Hospital Corporation | Trans-splicing ribozymes |
US5882907A (en) * | 1991-01-17 | 1999-03-16 | The General Hospital Corporation | Cell ablation using trans-splicing ribozymes |
US5874414A (en) * | 1991-01-17 | 1999-02-23 | The General Hospital Corporation | Trans-splicing ribozymes |
US5641673A (en) * | 1991-01-17 | 1997-06-24 | The General Hospital Corporation | Cell ablation using trans-splicing ribozymes |
US5866384A (en) * | 1991-01-17 | 1999-02-02 | The General Hospital Corporation | Cell ablation using trans-splicing ribozymes |
US5849548A (en) * | 1991-01-17 | 1998-12-15 | The General Hospital Corporation | Cell ablation using trans-splicing ribozymes |
US6071730A (en) * | 1991-01-17 | 2000-06-06 | The General Hospital Corporation | Cell ablation using trans-splicing ribozymes |
US5863774A (en) * | 1991-01-17 | 1999-01-26 | The General Hospital Corporation | Cell ablation using trans-splicing ribozymes |
WO1992013070A1 (en) * | 1991-01-25 | 1992-08-06 | United States Biochemical Corporation | Regulation of nucleic acid translation |
US6713456B1 (en) | 1992-01-31 | 2004-03-30 | Massachusetts Institute Of Technology | Nucleozymes |
WO1993015187A1 (en) * | 1992-01-31 | 1993-08-05 | Massachusetts Institute Of Technology | Nucleozymes |
US5652094A (en) * | 1992-01-31 | 1997-07-29 | University Of Montreal | Nucleozymes |
US6140491A (en) * | 1992-01-31 | 2000-10-31 | Ribozyme Pharmaceuticals, Inc. | Nucleozymes |
JPH07507683A (en) * | 1992-04-28 | 1995-08-31 | エール ユニバーシティ | Targeted cleavage of RNA using eukaryotic ribonuclease P and external guide sequences |
US5824542A (en) * | 1992-09-24 | 1998-10-20 | Novartis Finance Corporation | Methods for the production of hybrid seed |
US5409823A (en) * | 1992-09-24 | 1995-04-25 | Ciba-Geigy Corporation | Methods for the production of hybrid seed |
US5659124A (en) * | 1992-09-24 | 1997-08-19 | Novartis Corporation | Transgenic male sterile plants for the production of hybrid seeds |
US6080851A (en) * | 1992-12-04 | 2000-06-27 | American Home Products Corporation | Ribozymes with linked anchor sequences |
US5817635A (en) * | 1993-08-09 | 1998-10-06 | Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. | Modified ribozymes |
US6897016B1 (en) | 1993-11-12 | 2005-05-24 | The Regents Of The University Of Colorado | Alteration of sequence of a target molecule |
US5667969A (en) * | 1993-11-12 | 1997-09-16 | University Research Corporation | Alteration of sequence of a deleterious target molecule by ribozyme catalyzed trans-splicing |
WO1995013379A1 (en) * | 1993-11-12 | 1995-05-18 | Ribozyme Pharmaceuticals, Inc. | Alteration of sequence of a target molecule |
US7045293B2 (en) | 1993-11-12 | 2006-05-16 | The Regents Of The University Of Colorado | Alteration of sequence of a target molecule |
US5869248A (en) * | 1994-03-07 | 1999-02-09 | Yale University | Targeted cleavage of RNA using ribonuclease P targeting and cleavage sequences |
US6518402B1 (en) | 1994-08-23 | 2003-02-11 | Millennium Pharmaceuticals, Inc. | Antibodies to c5 polypeptides |
US6057109A (en) * | 1994-08-23 | 2000-05-02 | Millennium Pharmaceuticals, Inc. | Compositions for the treatment of body weight disorders including obesity |
US6057153A (en) * | 1995-01-13 | 2000-05-02 | Yale University | Stabilized external guide sequences |
US5683873A (en) * | 1995-01-13 | 1997-11-04 | Innovir Laboratories, Inc. | EGS-mediated inactivation of target RNA |
US6277634B1 (en) | 1995-06-07 | 2001-08-21 | Commonwealth Scientific And Industrial Research Organization | Optimized minizymes and miniribozymes and uses thereof |
US6001648A (en) * | 1995-06-07 | 1999-12-14 | Commonwealth Scientific And Industrial Research Organization | Optimized minizymes and miniribozymes and uses thereof |
US6010904A (en) * | 1995-06-07 | 2000-01-04 | The General Hospital Corporation | Cell ablation using trans-splicing ribozymes |
US6004806A (en) * | 1995-06-07 | 1999-12-21 | Commonwealth Scientific And Industrial Research Organization | Optimized minizymes and miniribozymes and uses thereof |
US6620805B1 (en) | 1996-03-14 | 2003-09-16 | Yale University | Delivery of nucleic acids by porphyrins |
US5877162A (en) * | 1996-03-14 | 1999-03-02 | Innovir Laboratories, Inc. | Short external guide sequences |
WO1997047316A1 (en) | 1996-06-10 | 1997-12-18 | Millennium Pharmaceuticals, Inc. | Screening methods for compounds useful in the regulation of body weight |
US5976874A (en) * | 1996-08-16 | 1999-11-02 | Yale University | Phenotypic conversion of drug-resistant bacteria to drug-sensitivity |
US6610478B1 (en) | 1996-08-16 | 2003-08-26 | Yale University | Phenotypic conversion of cells mediated by external guide sequences |
US5830850A (en) * | 1996-08-28 | 1998-11-03 | Mount Sinai School Of Medicine Of The City Of New York | Methods for the treatment of bone resorption disorders, including osteoporosis |
US5866412A (en) * | 1997-03-27 | 1999-02-02 | Millennium Pharmaceuticals, Inc. | Chromosome 18 marker |
US5914394A (en) * | 1997-03-27 | 1999-06-22 | Millenium Pharmaceuticals, Inc. | Methods and compositions for the diagnosis and treatment of neuropsychiatric disorders |
US5939316A (en) * | 1997-03-27 | 1999-08-17 | Millennium Pharmaceuticals, Inc. | Chromosome 18 marker |
US5955355A (en) * | 1997-03-27 | 1999-09-21 | Millennium Pharmaceuticals, Inc. | Chromosome 18 marker |
US7229823B2 (en) | 1997-04-14 | 2007-06-12 | Richard Jude Samulski | Methods for increasing the efficiency of recombinant AAV product |
US6642369B1 (en) | 1997-11-18 | 2003-11-04 | Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E. V. | Nucleic acids involved in the responder phenotype and applications thereof |
US6013447A (en) * | 1997-11-21 | 2000-01-11 | Innovir Laboratories, Inc. | Random intracellular method for obtaining optimally active nucleic acid molecules |
US6399762B1 (en) | 1998-03-16 | 2002-06-04 | The Regents Of The University Of California | Methods and compositions for diagnosing and treating chromosome -18p related disorders |
US6342351B1 (en) | 1998-03-16 | 2002-01-29 | Millennium Pharmaceuticals, Inc. | Methods and compositions for diagnosing and treating chromosome-18p related disorders |
US6248525B1 (en) | 1998-03-30 | 2001-06-19 | Yale University | Method for identifying essential or functional genes |
EP1260596A3 (en) * | 1998-06-17 | 2003-10-29 | Bio Merieux | Process for labeling a ribonucleic acid, including optional signal amplification, and labeled RNA fragments which are obtained by this process |
EP1260597A2 (en) * | 1998-06-17 | 2002-11-27 | Bio Merieux | Process for labeling a nucleic acid, including purification, and labeled RNA fragments obtained by this process |
US6376179B1 (en) | 1998-06-17 | 2002-04-23 | Bio Merieux | Process for labeling a ribonucleic acid, and labeled RNA fragments which are obtained thereby |
EP1260597A3 (en) * | 1998-06-17 | 2003-01-08 | Bio Merieux | Process for labeling a nucleic acid, including purification, and labeled RNA fragments obtained by this process |
US6921640B2 (en) | 1998-06-17 | 2005-07-26 | Bio Merieux | Process for labeling a ribonucleic acid |
WO1999065926A1 (en) * | 1998-06-17 | 1999-12-23 | Bio Merieux | Method for marking a ribonucleic acid and resulting marked rna fragments |
FR2780059A1 (en) * | 1998-06-17 | 1999-12-24 | Bio Merieux | PROCESS FOR MARKING A RIBONUCLEIC ACID AND RNA FRAGMENTS MARKS THUS OBTAINED |
CN1330662C (en) * | 1998-06-17 | 2007-08-08 | 比奥美希奥公司 | Method for marking a ribonucleic acid and resulting marked RNA fragments |
EP1260596A2 (en) * | 1998-06-17 | 2002-11-27 | Bio Merieux | Process for labeling a ribonucleic acid, including optional signal amplification, and labeled RNA fragments which are obtained by this process |
US6322792B1 (en) | 1998-11-19 | 2001-11-27 | Elliott D. Kieff | Rhadino virus LANA acts in trans on a unit of rhadino virus DNA to mediate efficient episome persistance |
US6756203B2 (en) | 1998-11-19 | 2004-06-29 | Elliott D. Kieff | Assays for compounds that modulate rhadino virus LANA action in trans on a unit of rhadino virus DNA to mediate efficient episome persistence |
EP2319939A2 (en) | 1999-10-21 | 2011-05-11 | Case Western Reserve University | Gene expression profiling of inflammatory bowel disease |
JP2003516763A (en) * | 1999-12-17 | 2003-05-20 | ベーイーオー・メリュー | Nucleic acid labeling method |
US6902891B2 (en) | 1999-12-17 | 2005-06-07 | Bio Merieux | Process for labeling a nucleic acid |
WO2001044506A1 (en) * | 1999-12-17 | 2001-06-21 | Bio Merieux | Process for labeling a ribonucleic acid, and labeled rna fragments which are obtained thereby |
US6489114B2 (en) | 1999-12-17 | 2002-12-03 | Bio Merieux | Process for labeling a ribonucleic acid, and labeled RNA fragments which are obtained thereby |
EP2314322A1 (en) | 2000-03-31 | 2011-04-27 | Novarx | Compositions containing genetically modified lung cancer cells expressing a TGF-beta inhibitor |
US7585497B2 (en) | 2000-05-17 | 2009-09-08 | Oregon Health & Science University | Induction of apoptosis and cell growth inhibition by protein 4.33 |
EP2075253A1 (en) | 2000-06-23 | 2009-07-01 | Genentech, Inc. | Compositions and methds for the diagnosis and treatment of disorders involving angiogensis |
EP2042597A1 (en) | 2000-06-23 | 2009-04-01 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis |
EP2275549A1 (en) | 2000-06-23 | 2011-01-19 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis |
EP2168980A1 (en) | 2000-06-23 | 2010-03-31 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of disorders involving angiogensis |
EP2077276A1 (en) | 2000-06-23 | 2009-07-08 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of disorders involving angiogensis |
EP2792747A1 (en) | 2000-06-23 | 2014-10-22 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis |
US6803211B2 (en) | 2000-08-25 | 2004-10-12 | Pfizer Inc. | Methods and compositions for diagnosing and treating disorders involving angiogenesis |
WO2002090558A1 (en) | 2001-05-03 | 2002-11-14 | Fit Biotech Oyj Plc | Novel expression vectors and uses thereof |
US7510718B2 (en) | 2001-05-03 | 2009-03-31 | Fit Biotech Oyj Plc | Expression vectors and uses thereof |
US7498314B2 (en) | 2001-05-03 | 2009-03-03 | Fit Biotech Oyj Plc | Expression vectors and uses thereof |
US9725486B2 (en) | 2001-05-03 | 2017-08-08 | Fit Biotech Oy | Methods of treating HIV diseases using novel expression vectors |
US7319145B2 (en) | 2001-12-03 | 2008-01-15 | Rima Rozen | Methylenetetrahydrofolate reductase inhibitors and use thereof |
EP2002827A2 (en) | 2001-12-05 | 2008-12-17 | The Baylor College Of Medicine | Methods and compositions for control of bone formation via modulation of sympathetic tone |
EP2287192A1 (en) | 2002-11-15 | 2011-02-23 | Novartis Vaccines and Diagnostics, Inc. | Methods for preventing and treating cancer metastasis and bone loss associated with cancer metastasis |
EP2246363A1 (en) | 2002-11-15 | 2010-11-03 | Novartis Vaccines and Diagnostics, Inc. | Methods for preventing and treating cancer metastasis and bone loss associated with cancer metastasis |
US8021833B2 (en) | 2003-02-12 | 2011-09-20 | Functional Genetics, Inc. | Method for reducing HIV viral budding by administering a VPS28-specfic antibody that disrupts Gag-TSG101-VPS28 binding interactions |
EP1980257A1 (en) | 2003-04-07 | 2008-10-15 | Prospect Therapeutics, Inc. | Compositions and uses of galectin antagonists |
US7722886B2 (en) | 2003-05-20 | 2010-05-25 | Wyeth | Compositions and methods for treatment of severe acute respiratory syndrome (SARS) |
US7892563B2 (en) | 2003-05-20 | 2011-02-22 | Wyeth Holdings Corporation | Methods for treatment of severe acute respiratory syndrome (SARS) |
EP3168304A1 (en) | 2003-08-27 | 2017-05-17 | Ophthotech Corporation | Combination therapy for the treatment of ocular neovascular disorders |
EP2281885A1 (en) | 2003-08-27 | 2011-02-09 | Ophthotech Corporation | Combination therapy for the treatment of ocular neovascular disorders |
EP2806036A1 (en) | 2004-05-24 | 2014-11-26 | PTC Therapeutics, Inc. | Methods and agents for screening for compounds capable of modulating VEGF expression |
EP2382991A1 (en) | 2004-06-10 | 2011-11-02 | Omeros Corporation | Methods for treating conditions associated with MASP-2 dependent complement activation |
EP2460537A1 (en) | 2004-06-10 | 2012-06-06 | Omeros Corporation | Methods for treating conditions associated with MASP-2 dependent complement activation |
EP2392350A1 (en) | 2004-06-10 | 2011-12-07 | Omeros Corporation | Methods for treating conditions associated with MASP-2 dependent complement activation |
EP2386315A1 (en) | 2004-06-10 | 2011-11-16 | Omeros Corporation | Methods for treating conditions associated with MASP-2 dependent complement activation |
EP2386317A1 (en) | 2004-06-10 | 2011-11-16 | Omeros Corporation | Methods for treating conditions associated with MASP-2 dependent complement activation |
EP3530288A2 (en) | 2004-06-10 | 2019-08-28 | Omeros Corporation | Methods for treating conditions associated with masp-2 dependent complement activation |
EP3047858A1 (en) | 2004-06-10 | 2016-07-27 | Omeros Corporation | Methods for treating conditions associated with masp-2 dependent complement activation |
EP2386316A1 (en) | 2004-06-10 | 2011-11-16 | Omeros Corporation | Methods for treating conditions associated with MASP-2 dependent complement activation |
EP2465534A1 (en) | 2004-06-10 | 2012-06-20 | Omeros Corporation | Methods for treating conditions associated with MASP-2 dependent complement activation |
EP2446902A1 (en) | 2004-06-10 | 2012-05-02 | Omeros Corporation | Methods for treating conditions associated with MASP-2 dependent complement activation |
EP2465535A1 (en) | 2004-06-10 | 2012-06-20 | Omeros Corporation | Methods for treating conditions associated with MASP-2 dependent complement activation |
EP2446901A1 (en) | 2004-06-10 | 2012-05-02 | Omeros Corporation | Methods for treating conditions associated with MASP-2 dependent complement activation |
EP2446900A1 (en) | 2004-06-10 | 2012-05-02 | Omeros Corporation | Methods for treating conditions associated with MASP-2 dependent complement activation |
EP2457585A1 (en) | 2004-06-10 | 2012-05-30 | Omeros Corporation | Methods for treating conditions associated with MASP-2 dependent complement activation |
US7968762B2 (en) | 2004-07-13 | 2011-06-28 | Van Andel Research Institute | Immune-compromised transgenic mice expressing human hepatocyte growth factor (hHGF) |
EP2359842A1 (en) | 2004-07-14 | 2011-08-24 | University of Utah Research Foundation | Netrin-related compositions and uses |
EP2351859A1 (en) | 2004-07-21 | 2011-08-03 | PTC Therapeutics, Inc. | Methods and agents for screening for compounds capable of modulating gene expression |
US8772464B2 (en) | 2004-10-05 | 2014-07-08 | California Institute Of Technology | Aptamer regulated nucleic acids and uses thereof |
US9315862B2 (en) | 2004-10-05 | 2016-04-19 | California Institute Of Technology | Aptamer regulated nucleic acids and uses thereof |
US9309568B2 (en) | 2004-10-05 | 2016-04-12 | California Institute Of Technology | Aptamer regulated nucleic acids and uses thereof |
US9492400B2 (en) | 2004-11-04 | 2016-11-15 | Massachusetts Institute Of Technology | Coated controlled release polymer particles as efficient oral delivery vehicles for biopharmaceuticals |
EP2123306A1 (en) | 2004-12-03 | 2009-11-25 | Fondazione Telethon | Use of a decoy protein that interferes with the hedgehog signalling pathway for the manufacture of a medicament for preventing, inhibiting, and/or reversing ocular diseases related with ocular neovascularization |
EP2360249A1 (en) | 2005-03-31 | 2011-08-24 | Calando Pharmaceuticals, Inc. | Inhibitors of ribonucleotide reductase subunit 2 and uses thereof |
US10273293B2 (en) | 2005-05-03 | 2019-04-30 | Amgen Inc. | Method for inhibiting bone resorption |
US9089553B2 (en) | 2005-05-03 | 2015-07-28 | Amgen Inc. | Method for inhibiting bone resorption |
EP2287340A2 (en) | 2005-05-11 | 2011-02-23 | Aarhus Universitet | Method for diagnosis and treatment of a mental disease |
EP2305837A1 (en) | 2005-05-11 | 2011-04-06 | Aarhus Universitet | Method for diagnosis and treatment of a mental disease |
US9267937B2 (en) | 2005-12-15 | 2016-02-23 | Massachusetts Institute Of Technology | System for screening particles |
US8014957B2 (en) | 2005-12-15 | 2011-09-06 | Fred Hutchinson Cancer Research Center | Genes associated with progression and response in chronic myeloid leukemia and uses thereof |
EP3034094A1 (en) | 2006-03-08 | 2016-06-22 | Archemix LLC | Complement binding aptamers and anti-c5 agents useful in the treatment of ocular disorders |
EP3360582A1 (en) | 2006-03-08 | 2018-08-15 | Archemix LLC | Complement binding aptamers and anti-c5 agents useful in the treatment of ocular disorders |
EP4159220A1 (en) | 2006-03-08 | 2023-04-05 | Archemix LLC | Complement binding aptamers and anti-c5 agents useful in the treatment of ocular disorders |
EP2596807A1 (en) | 2006-03-08 | 2013-05-29 | Archemix LLC | Complement binding aptamers and anti-C5 agents useful in the treatment of ocular disorders |
WO2007117996A2 (en) | 2006-04-03 | 2007-10-18 | University Of Leicester | Methods for treating conditions associated with masp-2 dependent complement activation |
EP3067067A1 (en) | 2006-04-03 | 2016-09-14 | University Of Leicester | Methods for treating conditions associated with masp-2 dependent complement activation |
US8778633B2 (en) | 2006-04-07 | 2014-07-15 | Molecular Discover Systems | Transcription factor modulator |
US9080014B2 (en) | 2006-05-15 | 2015-07-14 | Massachusetts Institute Of Technology | Polymers for functional particles |
US9688812B2 (en) | 2006-05-15 | 2017-06-27 | Massachusetts Institute Of Technology | Polymers for functional particles |
US9381477B2 (en) | 2006-06-23 | 2016-07-05 | Massachusetts Institute Of Technology | Microfluidic synthesis of organic nanoparticles |
US9279127B2 (en) | 2006-11-01 | 2016-03-08 | The Medical Research Fund At The Tel-Aviv Sourasky Medical Center | Adipocyte-specific constructs and methods for inhibiting platelet-type 12 lipoxygenase expression |
US9663790B2 (en) | 2006-11-01 | 2017-05-30 | The Medical Research, Infrastructure, And Health Services Fund Of The Tel Aviv Medical Center | Adipocyte-specific constructs and methods for inhibiting platelet-type 12 lipoxygenase expression |
US8158595B2 (en) | 2006-11-09 | 2012-04-17 | California Institute Of Technology | Modular aptamer-regulated ribozymes |
US8603996B2 (en) | 2006-11-09 | 2013-12-10 | California Institute Of Technology | Modular aptamer-regulated ribozymes |
WO2008063933A2 (en) | 2006-11-10 | 2008-05-29 | Massachusetts Institute Of Technology | Pak modulators |
US9217129B2 (en) | 2007-02-09 | 2015-12-22 | Massachusetts Institute Of Technology | Oscillating cell culture bioreactor |
WO2008119057A2 (en) | 2007-03-27 | 2008-10-02 | Omeros Corporation | The use of pde7 inhibitors for the treatment of movement disorders |
US9333179B2 (en) | 2007-04-04 | 2016-05-10 | Massachusetts Institute Of Technology | Amphiphilic compound assisted nanoparticles for targeted delivery |
US11965212B2 (en) | 2007-04-27 | 2024-04-23 | Quest Diagnostics Investments Llc | Nucleic acid detection combining amplification with fragmentation |
US9783854B2 (en) | 2007-04-27 | 2017-10-10 | Quest Diagnostics Investments Incorporated | Nucleic acid detection combining amplification with fragmentation |
US11155877B2 (en) | 2007-04-27 | 2021-10-26 | Quest Diagnostics Investments Llc | Nucleic acid detection combining amplification with fragmentation |
US8999634B2 (en) | 2007-04-27 | 2015-04-07 | Quest Diagnostics Investments Incorporated | Nucleic acid detection combining amplification with fragmentation |
US10106857B2 (en) | 2007-04-27 | 2018-10-23 | Quest Diagnostics Investments Incorporated | Nucleic acid detection combining amplification with fragmentation |
EP3486653A1 (en) | 2007-05-24 | 2019-05-22 | The United States Government as represented by The Department of Veterans Affairs | Treatment of skeletal muscle disorder using ent2 |
US8586726B2 (en) | 2007-07-18 | 2013-11-19 | The Trustees Of Columbia University In The City Of New York | Tissue-specific MicroRNAs and compositions and uses thereof |
US8367815B2 (en) | 2007-08-28 | 2013-02-05 | California Institute Of Technology | Modular polynucleotides for ligand-controlled regulatory systems |
US9040495B2 (en) | 2007-08-28 | 2015-05-26 | California Institute Of Technology | General composition framework for ligand-controlled RNA regulatory systems |
US8865667B2 (en) | 2007-09-12 | 2014-10-21 | California Institute Of Technology | Higher-order cellular information processing devices |
EP3085386A1 (en) | 2007-09-17 | 2016-10-26 | Amgen Inc. | Method for inhibiting bone resorption |
EP2556841A1 (en) | 2007-09-17 | 2013-02-13 | Amgen, Inc | Method for inhibiting bone resorption |
WO2009039175A2 (en) | 2007-09-17 | 2009-03-26 | Amgen Inc. | Method for inhibiting bone resorption |
EP3725329A1 (en) | 2007-09-17 | 2020-10-21 | Amgen, Inc | Method for inhibiting bone resorption |
US11091537B2 (en) | 2007-09-17 | 2021-08-17 | Amgen Inc. | Method for inhibiting bone resorption |
EP4335510A2 (en) | 2007-09-17 | 2024-03-13 | Amgen Inc. | Method for inhibiting bone resorption |
US10736848B2 (en) | 2007-10-12 | 2020-08-11 | Massachusetts Institute Of Technology | Vaccine nanotechnology |
US9539210B2 (en) | 2007-10-12 | 2017-01-10 | Massachusetts Institute Of Technology | Vaccine nanotechnology |
US9526702B2 (en) | 2007-10-12 | 2016-12-27 | Massachusetts Institute Of Technology | Vaccine nanotechnology |
US11547667B2 (en) | 2007-10-12 | 2023-01-10 | Massachusetts Institute Of Technology | Vaccine nanotechnology |
US9474717B2 (en) | 2007-10-12 | 2016-10-25 | Massachusetts Institute Of Technology | Vaccine nanotechnology |
US9029524B2 (en) | 2007-12-10 | 2015-05-12 | California Institute Of Technology | Signal activated RNA interference |
EP2628486A2 (en) | 2007-12-14 | 2013-08-21 | Amgen, Inc. | Method for treating bone fracture with anti-sclerostin antibodies |
WO2009123764A2 (en) | 2008-04-04 | 2009-10-08 | Calando Pharmaceuticals, Inc. | Compositions and use of epas1 inhibitors |
WO2010030813A2 (en) | 2008-09-10 | 2010-03-18 | Genentech, Inc. | Methods for inhibiting ocular angiogenesis |
US8906381B2 (en) | 2008-10-12 | 2014-12-09 | Massachusetts Institute Of Technology | Immunonanotherapeutics that provide IGG humoral response without T-cell antigen |
US9233072B2 (en) | 2008-10-12 | 2016-01-12 | Massachusetts Institute Of Technology | Adjuvant incorporation in immunonanotherapeutics |
US9439859B2 (en) | 2008-10-12 | 2016-09-13 | Massachusetts Institute Of Technology | Adjuvant incorporation in immunoanotherapeutics |
US8932595B2 (en) | 2008-10-12 | 2015-01-13 | Massachusetts Institute Of Technology | Nicotine immunonanotherapeutics |
US9308280B2 (en) | 2008-10-12 | 2016-04-12 | Massachusetts Institute Of Technology | Targeting of antigen presenting cells with immunonanotherapeutics |
US8329882B2 (en) | 2009-02-18 | 2012-12-11 | California Institute Of Technology | Genetic control of mammalian cells with synthetic RNA regulatory systems |
US9145555B2 (en) | 2009-04-02 | 2015-09-29 | California Institute Of Technology | Integrated—ligand-responsive microRNAs |
WO2010115868A2 (en) | 2009-04-03 | 2010-10-14 | Fundacio Privada Institucio Catalana De Recerca I Estudis Avancats (Icrea) | Therapeutic agents for the treatment of diseases associated with undesired cell proliferation |
WO2010132609A2 (en) | 2009-05-12 | 2010-11-18 | The Regents Of The University Of California | Methods and compositions for treating neurodegenerative disorders and alzheimer's disease and improving normal memory |
WO2011047346A1 (en) | 2009-10-16 | 2011-04-21 | Omeros Corporation | Methods for treating disseminated intravascular coagulation by inhibiting masp-2 dependent complement activation |
EP3150635A2 (en) | 2009-10-16 | 2017-04-05 | Omeros Corporation | Methods for treating disseminated intravascular coagulation by inhibiting masp-2 dependent complement activation |
EP2322149A1 (en) | 2009-11-03 | 2011-05-18 | Universidad del Pais Vasco | Methods and compositions for the treatment of ischemia |
WO2011054820A1 (en) | 2009-11-03 | 2011-05-12 | Universidad Del País Vasco | Methods and compositions for the treatment of white matter ischemia |
EP3168232A1 (en) | 2009-11-13 | 2017-05-17 | Dana-Farber Cancer Institute, Inc. | Compositions, kits, and methods for the diagnosis, prognosis, monitoring, treatment and modulation of post-transplant lymphoproliferative disorders and hypoxia associated angiogenesis disorders using galectin-1 |
EP2338492A1 (en) | 2009-12-24 | 2011-06-29 | Universidad del Pais Vasco | Methods and compositions for the treatment of alzheimer |
WO2011076946A2 (en) | 2009-12-24 | 2011-06-30 | Universidad Del País Vasco | Methods and compositions for the treatment of alzheimer |
WO2011161295A2 (en) | 2010-06-23 | 2011-12-29 | Fundación Centro Nacional De Investigaciones Cardiovasculares Carlos Iii | Use of anticalcineurin compounds for the treatment of pathologies involving ocular neovascularisation |
EP4275752A2 (en) | 2010-11-08 | 2023-11-15 | Omeros Corporation | Treatment of addiction and impulse-control disorders using pde7 inhibitors |
WO2012064667A2 (en) | 2010-11-08 | 2012-05-18 | Omeros Corporation | Treatment of addiction and impulse-control disorders using pde7 inhibitors |
WO2012100835A1 (en) | 2011-01-28 | 2012-08-02 | Laboratorios Del Dr. Esteve, S.A. | Methods and compositions for the treatment of aids |
WO2012122515A1 (en) | 2011-03-10 | 2012-09-13 | Genentech, Inc. | Treatment of disorders with altered vascular barrier function |
EP3964233A1 (en) | 2011-04-08 | 2022-03-09 | University Of Leicester | Methods for treating conditions associated with masp-2 dependent complement activation |
EP3287142A1 (en) | 2011-04-08 | 2018-02-28 | University Of Leicester | Methods for treating conditions associated with masp-2 dependent complement activation |
US8951522B2 (en) | 2011-04-08 | 2015-02-10 | University Of Leicester | Methods for treating conditions associated with MASP-2 dependent complement activation |
US9644035B2 (en) | 2011-04-08 | 2017-05-09 | Omeros Corporation | Methods for treating conditions associated with MASP-2 dependent complement activation |
US10059776B2 (en) | 2011-04-08 | 2018-08-28 | Omerus Corporation | Methods for treating conditions associated with MASP-2 dependent complement activation |
WO2012139081A2 (en) | 2011-04-08 | 2012-10-11 | University Of Leicester | Methods for treating conditions associated with masp-2 dependent complement activation |
US10202465B2 (en) | 2011-04-08 | 2019-02-12 | Omeros Corporation | Methods for treating conditions associated with MASP-2 dependent complement activation |
WO2013003112A1 (en) | 2011-06-27 | 2013-01-03 | The Jackson Laboratory | Methods and compositions for treatment of cancer and autoimmune disease |
WO2013015152A1 (en) | 2011-07-22 | 2013-01-31 | 公立大学法人横浜市立大学 | TECHNIQUE FOR CLEAVING OUT PART OF poly(A) CHAIN AND/OR 3'-TERMINAL SEQUENCE OF mRNA TO INHIBIT TRANSLATION REACTION |
EP3613765A1 (en) | 2012-08-03 | 2020-02-26 | Dana-Farber Cancer Institute, Inc. | Antibody against repulsive guidance molecule b (rgmb) |
EP3293275A1 (en) | 2013-06-06 | 2018-03-14 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for identification, assessment prevention, and treatment of cancer using pd-l1 isoforms |
US9512430B2 (en) | 2013-07-03 | 2016-12-06 | Wisconsin Alumni Research Foundation | Compositions and methods to promote erythropoiesis |
US9988633B2 (en) | 2013-07-03 | 2018-06-05 | Wisconsin Alumni Research Foundation | Compositions and methods to promote erythropoiesis |
US9771587B2 (en) | 2013-07-03 | 2017-09-26 | Wisconsin Alumni Research Foundation | Compositions and methods to promote erythropoiesis |
WO2015017529A2 (en) | 2013-07-31 | 2015-02-05 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for modulating thermogenesis using pth-related and egf-related molecules |
EP3757130A1 (en) | 2013-09-26 | 2020-12-30 | Costim Pharmaceuticals Inc. | Methods for treating hematologic cancers |
EP3750919A1 (en) | 2013-10-17 | 2020-12-16 | Omeros Corporation | Methods for treating conditions associated with masp-2 dependent complement activation |
WO2015058143A1 (en) | 2013-10-17 | 2015-04-23 | Omeros Corporation | Methods for treating conditions associated with masp-2 dependent complement activation |
US11525011B2 (en) | 2013-10-17 | 2022-12-13 | Omeros Corporation | Methods of inhibiting MASP-2-dependent complement activation in a subject suffering from catastrophic antiphospholipid syndrome |
WO2016061144A1 (en) | 2014-10-14 | 2016-04-21 | The Regents Of The University Of California | Use of cdk9 and brd4 inhibitors to inhibit inflammation |
WO2016094273A1 (en) | 2014-12-08 | 2016-06-16 | Dana-Farber Cancer Institute, Inc. | Methods for upregulating immune responses using combinations of anti-rgmb and anti-pd-1 agents |
WO2016178233A1 (en) | 2015-05-05 | 2016-11-10 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd | Nucleic acid-cationic polymer compositions and methods of making and using the same |
US11053475B2 (en) | 2015-09-24 | 2021-07-06 | Wisconsin Alumni Research Foundation | Methods of expanding hematopoietic stem cells, compositions, and methods of use thereof |
US10584315B2 (en) | 2015-09-24 | 2020-03-10 | Wisconsin Alumni Research Foundation | Methods of expanding hematopoietic stem cells, compositions, and methods of use thereof |
WO2017066561A2 (en) | 2015-10-16 | 2017-04-20 | President And Fellows Of Harvard College | Regulatory t cell pd-1 modulation for regulating t cell effector immune responses |
WO2017075329A2 (en) | 2015-10-29 | 2017-05-04 | Dana-Farber Cancer Institute, Inc. | Methods for identification, assessment, prevention, and treatment of metabolic disorders using pm20d1 and n-lipidated amino acids |
WO2017079227A1 (en) | 2015-11-05 | 2017-05-11 | University Of Connecticut | Compositions and methods for the treatment of liver fibrosis |
US11981749B2 (en) | 2015-11-09 | 2024-05-14 | Omeros Corporation | Methods for treating conditions associated with MASP-2 dependent complement activation |
WO2017083371A1 (en) | 2015-11-09 | 2017-05-18 | Omeros Corporation | Methods for treating conditions associated with masp-2 dependent complement activation |
US12005117B2 (en) | 2016-01-05 | 2024-06-11 | University Of Leicester | Methods for inhibiting fibrosis in a subject in need thereof |
US10736960B2 (en) | 2016-01-05 | 2020-08-11 | Omeros Corporation | Methods for inhibiting fibrosis in a subject in need thereof |
WO2017165412A2 (en) | 2016-03-21 | 2017-09-28 | Dana-Farber Cancer Institute, Inc. | T-cell exhaustion state-specific gene expression regulators and uses thereof |
US10870708B2 (en) | 2016-03-31 | 2020-12-22 | University Of Leicester | Methods for inhibiting angiogenesis in a subject in need thereof |
US11981748B2 (en) | 2016-03-31 | 2024-05-14 | Omeros Corporation | Methods for inhibiting angiogenesis in a subject in need thereof |
WO2019036460A1 (en) | 2017-08-15 | 2019-02-21 | Omeros Corporation | Methods for treating and/or preventing graft-versus-host disease and/or diffuse alveolar hemorrhage and/or veno-occlusive disease associated with hematopoietic stem cell transplant |
US11013772B2 (en) | 2017-08-15 | 2021-05-25 | Omeros Corporation | Methods for treating and/or preventing graft-versus-host disease and/or diffuse alveolar hemorrhage and/or veno-occlusive disease associated with hematopoietic stem cell transplant |
US11896621B2 (en) | 2017-08-15 | 2024-02-13 | Omeros Corporation | Methods for treating and/or preventing graft-versus-host disease and/or diffuse alveolar hemorrhage and/or veno-occlusive disease associated with hematopoietic stem cell transplant |
US11584714B2 (en) | 2018-05-29 | 2023-02-21 | Omeros Corporation | MASP-2 inhibitors and methods of use |
US11325978B2 (en) | 2018-11-06 | 2022-05-10 | The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services | Compositions and methods for treating beta-globinopathies |
WO2020097261A1 (en) | 2018-11-06 | 2020-05-14 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | New compositions and methods for treating beta-globinopathies |
WO2020223121A1 (en) | 2019-04-30 | 2020-11-05 | Dana-Farber Cancer Institute, Inc. | Methods for treating cancer using combinations of anti-cx3cr1 and immune checkpoint blockade agents |
US11807641B2 (en) | 2019-12-04 | 2023-11-07 | Omeros Corporation | MASP-2 inhibitors and methods of use |
WO2022034474A1 (en) | 2020-08-10 | 2022-02-17 | Novartis Ag | Treatments for retinal degenerative diseases |
WO2022240824A1 (en) | 2021-05-13 | 2022-11-17 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Compositions and methods for treating sickle cell diseases |
WO2022261183A2 (en) | 2021-06-08 | 2022-12-15 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for treating and/or identifying an agent for treating intestinal cancers |
WO2023097119A2 (en) | 2021-11-29 | 2023-06-01 | Dana-Farber Cancer Institute, Inc. | Methods and compositions to modulate riok2 |
WO2024038089A1 (en) | 2022-08-18 | 2024-02-22 | Mitodicure Gmbh | Use of a therapeutic agent with phosphodiesterase-7 inhibitory activity for the treatment and prevention of diseases associated with chronic fatigue, exhaustion and/or exertional intolerance |
WO2024042160A1 (en) | 2022-08-26 | 2024-02-29 | Mitodicure Gmbh | Use of a therapeutic agent with sodium-hydrogen antiporter 1 inhibitory activity for the treatment and prevention of diseases associated with chronic fatigue, exhaustion and/or exertional intolerance |
Also Published As
Publication number | Publication date |
---|---|
DE3751567D1 (en) | 1995-11-23 |
EP0291533A1 (en) | 1988-11-23 |
EP0291533B1 (en) | 1995-10-18 |
US6025167A (en) | 2000-02-15 |
ATE129251T1 (en) | 1995-11-15 |
US5591610A (en) | 1997-01-07 |
HK188395A (en) | 1995-12-22 |
US5093246A (en) | 1992-03-03 |
JP2530906B2 (en) | 1996-09-04 |
US6180399B1 (en) | 2001-01-30 |
US5354855A (en) | 1994-10-11 |
US4987071A (en) | 1991-01-22 |
JPH01501445A (en) | 1989-05-25 |
EP0291533A4 (en) | 1989-10-12 |
DE3751567T2 (en) | 1996-05-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US4987071A (en) | RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods | |
US5037746A (en) | RNA ribozyme polymerases, and methods | |
US5116742A (en) | RNA ribozyme restriction endoribonucleases and methods | |
Woodson et al. | Reverse self-splicing of the Tetrahymena group I intron: implication for the directionality of splicing and for intron transposition | |
US6696250B1 (en) | RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods | |
Cech | Structure and mechanism of the large catalytic RNAs: group I and group II introns and ribonuclease P | |
Cech et al. | Group I ribozymes: substrate recognition, catalytic strategies, and comparative mechanistic analysis | |
Koizumi et al. | Design of RNA enzymes distinguishing a single base mutation in RNA | |
CA2093664C (en) | Modified ribozymes | |
US7135312B2 (en) | Circular DNA vectors for synthesis of RNA and DNA | |
Cech | The chemistry of self-splicing RNA and RNA enzymes | |
Carmi et al. | In vitro selection of self-cleaving DNAs | |
US5817635A (en) | Modified ribozymes | |
Williams et al. | Selection of novel Mg (2+)‐dependent self‐cleaving ribozymes. | |
Grosshans et al. | A hammerhead ribozyme allows synthesis of a new form of the Tetrahymena ribozyme homogeneous in length with a 3'end blocked for transesterification | |
Kazakov et al. | A trinucleotide can promote metal ion-dependent specific cleavage of RNA. | |
WO1998038300A1 (en) | Circular dna vectors for synthesis of rna and dna | |
Chowrira et al. | Extensive phosphorothioate substitution yields highly active and nuclease-resistant hairpin ribozymes | |
Campbell et al. | Identification of ribozymes within a ribozyme library that efficiently cleave a long substrate RNA. | |
Szostak | Structure and activity of ribozymes | |
Williams et al. | In vitro selection of catalytic RNA | |
Tocchini-Valentini | Selection of novel Mg2+-dependent self-cleaving | |
Hieronymus | Entwicklung und Charakterisierung Funktioneller Ribonukleinsäuren Mit Präbiotischer Relevanz: Development and Characterisation of Functional Ribonucleic Acids with Prebiotic Relevance | |
Doudna | Towards the design of an RNA replicase | |
Wang | Deoxyribozyme-mediated synthesis of branched and lariat RNAs and their application in studying group II intron's splicing mechanisms |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): JP |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE FR GB IT LU NL SE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1988901380 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1988901380 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 1988901380 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1988901380 Country of ref document: EP |